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The roles of a self-administered symptom questionnaire,
four tumour markers (carcinoembryonic antigen, alpha-l-acid
glycoprotein, C-reactive protein and gamma glutamyl
transpeptidase) and faecal occult blood (FOB) testing were
investigated for their individual and combined ability to detect
colorectal and gastric cancer in both asymptomatic and symptomatic
populations at an early stage.
One thousand and eighty two individuals from six general
practices were invited to participate in cancer screening either
during a consultation with their general practitioner or by letter
of invitation to attend the practice for a screening appointment.
Seven hundred and twenty four subjects accepted and 683 returned
completed FOB's. Twenty asymptonatic subjects (2.9%) had a
positive FOB and on investigation two individuals were found to
have cancers of the colon (1 Dukes' stage A and 1 stage B) and 3
further individuals had adenomatous polyps greater than one
centimetre in diameter detected.
A synptom questionnaire was specifically designed for this
study and a pilot study comprising 144 subjects was performed to
determine the validity of the questions. Three questions were
shown to be ambiguous but the responses obtained for the reminder
were found to conpare favourably with those gained by a consultant
clinician. In the main screening study the prevalence of
gastrointestinal syirptoms was high but on review only 38 of these
individuals were felt to be harbouring previously unsuspected
disease. Upon subsequent investigation although benign pathology
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was identified no neoplastic disease was found. These findings
preclude the use of a sinple syirptom questionnaire in population
screening for colorectal or gastric cancer.
Compliance for FOB screening in this country is on average
33% for a simple postal approach. Compliance was increased to 77%
by direct invitation from the subjects own general practitioners,
as part of their routine consultation, conpared to 50% for a
written invitation. Once enrolled 90% of the study group returned
a completed FOB kit demonstrating that this test can be performed
by the general public if adequately promoted.
The attitudes of the population offered screening were
assessed using a questionnaire. Differences in beliefs concerning
the value of preventive medicine, and attitudes to cancer and
illness were found that significantly distinguished between
conpliers and non-compliers. This could have a bearing on how
medical educationalists and screening organisers should promote
future programmes.
Multivariate analyses were applied to the symptoms and
tumour marker values of a symptomtic population to predict the
risk of cancer in a given individual. The combination of both
approaches gave in a prospective group a sensitivity for cancer of
88.5% and a specificity of 89%. Using log likelihood ratio
analysis for dyspeptic symptoms alone, a scoring index has been
derived that can predict the presence of gastric cancer as
accurately as a clinician. This index has in a prospective study
of 300 consecutive dyspeptic subjects a sensitivity of 93% for
cancer, a specificity of 89% and a positive predictive value of
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33.3%. This approach can readily determine 'risk' of cancer and
therefore priority for investigation in a syirptonatic individual.
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CHAPTER 1
Introduction and Historical Review
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The Problem
In 1979, 124,638 people died of cancer in England and
Wales. Of these, 16,583 were due to cancer of the colon and
rectum and 11,205 deaths due to gastric cancer. Whilst the number
of cancer deaths has shown a slight decline for gastric cancer and
a slight increase for colorectal cancer, the overall death rate of
24 and 35 per 100,000 respectively has altered little over the
past 25 years (OPCS mortality statistics, 1981). The overall
incidence for colorectal cancer in Great Britain is one of the
highest in the world.
The 5 year survival figures for both cancers appears
steady over a similar period. For gastric cancer, the overall
survival rate in the period 1938-1949 was 5.6% in 375 cases
(Swynnerton and Truelove, 1952); in the period 1950-1953, the
crude 5 year survival for 4274 patients was 4.9% (Brookes et al,
1965) and finally in the decade 1960-1969 Fielding et al (1980)
reported a 5 year survival rate in a series of 13,228 patients in
Birmingham of 3.7%. A similar pattern is noted when considering
colorectal cancer, where the Birmingham Cancer Registry reported a
5 year survival of 22% for rectal cancer and 21% for colonic
cancer during the decade 1950-1959 (Slaney, 1971). These survival
figures were unchanged during the subsequent decades (Slaney,
1978) and Clarke et al (1980) reporting their series of 443
patients studied in the 1970's found an overall survival of 27%.
These survival figures for the two comironest gastrointestinal
cancers are extremely disappointing in an era which has seen a
revolution in diagnostic techniques, iirproved radiodiagnosis and
remarkable improvements in operative survival.
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The Solution
Although the overall prognosis for colorectal and gastric
cancer is poor , certain patients do have prolonged survival
following treatment. The clearest prognostic determinant for all
cancers is the pathological stage at the time of therapy. Thus
for colorectal cancer confined to the mucosa and muscularis
propria the 5 year survival may be 65% - 94% (Gilbertsen et al,
1980; Gill and Marris, 1980). Similarly, for gastric cancer
confined to the mucosa and submucosa the 5 year survival nay be
between 57% - 68% (Fielding et al,1980; Green et al, 1981).
Unfortunately in the United Kingdom the number of early gastric
cancers (EGC) confined to the mucosa and submucosa is between 0.7%
- 10% (Fielding et al, 1980; Evans et al, 1978). The number of
Dukes' Stage A cancers (Dukes, 1932) identified in recent series
was 3.7% in the Nottingham hospitals (Holliday and Hardcastle,
1979) and 5.7% in the John Radcliffe Hospital, Oxford (Gill and
IVforris, 1978).
It is clearly desirable that the ratio of early stage
cancers to advanced lesions is increased. This may be achieved by
means of screening programmes or by mare efficient recognition of
these cancers in a symptomatic patient.
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What is Screening
Screening has been defined as "the presunptive
identification of unrecognised disease or defect by the
application of tests, examinations or other procedures which can
be applied rapidly. Screening tests sort out apparently well
persons who probably have a disease from those who probably do
not. A screening test is not intended to be diagnostic. Persons
with positive or suspicious findings must be referred to their
physicians for diagnosis and necessary treatment." (Gnauck 1980).
It should be noted that, by this definition, unrecognised
symptomatic as well as presymptomatic disease is included, and
that the object of screening is "early disease detection" and to
bring these subjects to treatment (Wilson and Jungher 1968).
The success or otherwise of a screening programme is
dependent upon the accuracy of the screening agent itself, the
acceptability of the test to the population to be screened, the
population's participation in screening, the cost of establishing
and maintaining the programme and the success of treatment
available for the disease under investigation when treated early
rather than late.
The cornerstones of screening are clearly the validity of
the agents used and the populations compliance with the screening
invitation. These will be discussed in detail in subsequent
sections. However, to establish a few definitions that will be
raised in the results and discussion the measures of validity for
any test will now be described.
The ideal test will separate those who have the disease in
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question from those Who do not. The ability of the test to detect
the disease is determined as sensitivity i.e. the true positive
rate, whilst any cases missed will be the false negative rate. In
practical terms the actual value of the false negative rate may
not be precisely known since it would be impracticable and
probably unethical to investigate all patients with a negative
test to establish this value. The ability to classify those as
not having the disease is termed specificity. Those subjects
misclassified as harbouring the disease by the test and are
subsequently found on investigation to be free of disease are said
to have had a false positive result. This figure will be known
for all screening programmes and any test with a low specificity
will subject many people to unnecessary investigations which may
have an attached risk e.g. colonoscopy, with time off work for the
subject and an additional running cost for the programme with no
apparent gain.
When coirparing the impact of different screening tests for
the same disease the predictive yield for the tests may be of
value. The predictive yield is that fraction (%) produced by the
number of cases detected divided by the number of subjects
investigated as a result of a positive test. The yield is
dependent on the validity of the test, the pre-existence of the
disease and the quality of the follow-up examinations (vide
infra).
Compliance among asymptomatic patients who are the target
population must be sufficient to justify the cost of the programme
i.e. must be at a level to effectively alter the natural history
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of the disease in question.
There are many pitfalls to the understanding of the biases
associated with and inherent in screening programmes but these are
beyond the scope of this research. To introduce the reader to the
subject of early detection of colorectal and gastric cancer, I
have followed Kipling's exanple of using his "6 wise serving nan,
honest and true, the what, when and where and the how,which and
who" to review the state of the art.
Why screening?
Those who are in favour of screening for cancer and in
particular for colorectal and gastric cancer use survival
statistics such as reported in the section entitled 'The Solution'
to support their argument. They iray also argue that there is no
really viable alternative to screening to reduce the mortality of
these two cancers. Two reasons cited to support the need for
screening or earlier detection are :
A Failure of primary prevention (epidemiology) to
identify the cause of cancer.
B Failure of current therapy to reduce mortality.
Each concept will be discussed in turn.
A. Failure of Primary Prevention (Epidemiological approach)
Epidemiology may be defined as the identification of the
causes of huran cancer with a view to their prevention by
searching for, and studying, groups of individuals with different
incidences of cancer. Much of our knowledge of cancer results
from epidemiological study and over 30 causes, about half
occupational in nature, the remainder being social or iatrogenic,
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have been identified.
Some indication to the aetiology of large bowel cancer and
gastric cancer come from the large geographical variation in
incidences throughout the world. Japan and areas of South America
have the highest incidences of gastric cancer in the world and yet
have relatively low risk for colonic cancer. Conversely in
Western Europe and the USA there is considerably higher risk of
colon cancer than gastric cancer.
Migrant studies have also shown that when families move
from high risk to low risk areas for gastric cancer, then the
incidence of cancer drops to an intermediate level in the first
generation and practically to the local level in the second
generation (Haenszel and Kurihara#1968). In colonic cancer the
fall in risk appears to be more rapid (Buell and Dunn/1965).
These studies favour environmental rather than genetic
factors as being the principal cause of these cancers. Thus many
studies have been undertaken to determine differences in diet,
soil and water as causes of cancer.
The main aetiological factors currently favoured as being
linked to gastric cancer causation are diet related. Lack of fresh
green vegetables, pickling of food, high salt content in the diet
and a deficiency of beef protein and milk products have all been
implicated in the causation of gastric cancer (Hirayaira, 1972).
Unfortunately, no individual dietary item has been totally
incriminated. The bacterial production of nitrosamine substances
from food in the stomach has been raised (Hill et al, 1973)
especially in the hypochlorhydric stomach (Ruddell et al, 1976).
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This certainly has been reproduced in the aniiral models of
Sugimora and Kawachi (1978) and has received support from the
observation of high nitrate levels in the water of high risk
populations in South America (Armijo, 1979).
The carcinogen promoting effect of salt and nitrosamines
can be blocked by fresh vegetables containing Vitamins A, C and E
(Kurechi et al, 1980; Walker et al, 1980).
The debate on large bowel cancer centres round the dietary
contents of fat and fibre in the causation of this cancer. A diet
high in fat increases biliary secretion of acid and neutral
steroids and these steroids exert a promoting or carcinogenic
effect on bowel mucosa (Reddy et al, 1980). The "low fibre
theory" proposes that through a decrease in faecal bulk and
transit time a low fibre diet leads to an increased concentration
in the large bowel of carcinogens and other substances
contributing to the development of a malignant tunour (Burkitt
1969; Modan et al, 1975; Reddy^ 1981).
Unfortunately, when cohort studies have been utilised to
test case - control studies for gastric and colorectal cancer, the
results are often inconclusive or even conflicting in their
support for various agents as being carcinogens. In an excellent
review article Zaridze (1983) reveals how much conflict and
difficulty there has been in the studies of the high fat, low
fibre theories. Alderson (1982) in another review reports on the
role of alcohol in the causation of large bowel cancer and states
that in 13 case cohort studies for colorectal cancer, 3 reported
an association with beer drinking, 4 found no appreciable effect,
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2 found a negative effect and 4 made no comment.
Despite these problems of identifying causation or
association with cancer, and failure to identify truly reversible
causes of colorectal, gastric or even breast cancers, Doll and
Peto (1981) claim that up to 75% of all cancers in subjects under
65 years living in the USA are avoidable.
However, amongst their recommendations lies reduction in
the amount of hamburgers and ice cream eaten, stopping smoking and
drinking and increasing the intake of vegetables containing
Vitamins A,C and E with a large increase in dietary fibre. Such
proposals are firmly shared by Bruce et al (1981), Nigro (1982)
and MoKenna (1983).
There are, however, several drawbacks to this approach.
Firstly, the public has consistently shown its own thoughts on the
merits and demerits of cigarette smoking. There is also the
political delay in banning cigarette smoking when tax revenue and
employment are important factors against too strong action.
Secondly, even in this country, court cases are still ruling
against fluoridation of water to prevent dental caries (Scott v
Strathclyde Region, 1982).
Thus, with no foreseeable breakthrough in the
identification and removal of the cause of colorectal and gastric
cancer, it would seem other alternatives will be required to
improve the fate of Westernized civilisations for some time yet.
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B. Failure of Current Therapy
The failure to achieve 'cure' after apparently curative
resections is a worry to all surgeons. This is further compounded
by the fact that mere than 50% of recurrences experienced in
colorectal and gastric cancer are locoregional i.e. within the
surgical excisional field (Colorectal: Cass, Million and Pfaff,
1976; Whittaker and Goligher, 1976; Gilbert, 1978; Olsen et al,
1980; Ras et al, 1981). Gastric: IVhcNeer et al, 1951; Berne and
Freediran 1951; Iwanaga, Kagoma and Furukowa, 1978; Koga et al,
1978; Pichlmayr and Meyer, 1981; Giles and Donaldson, 1983).
The reasons for such failure of control nay be inadequate
surgery, or micrometastases at the time of surgery, both local and
systemic. This has lead to the concept of adjuvant therapy with
radiotherapy to the local field and/or chemotherapy for the
systemic micrometastases.
Unfortunately radiotherapy, either preoperatively or
postoperatively, has not shown great impact on reducing
recurrences or prolonging survival in colorectal cancer (Hoskins
et al, 1980; Duncan, 1985) unless high doses are used which
inevitably produce considerable toxicity (Hoskins et al, 1980;
Romsdahl and Withers, 1978). Similarly, preoperative (Hoshi,
1968) and peroperative radiotherapy (Abe et al, 1975) has been
shown to be of little value in the management of gastric cancer.
However, postoperative radiotherapy plus chemotherapy nay have
some value in the management of gastric cancer (Goffin and Machin,
1979).
The use of adjuvant chemotherapy has now evolved through
- 15 -
trials of single agents to measure a response, to combination
therapy. Colorectal cancer has relied principally on 5 Fluoro-
uracil (5FU) but experience with 5FU and FUDR in over 2000
patients has shown a less than 10% response (Grage et al, 1979;
Higgins et al, 1976; Dwight et al, 1973; Grassi et al, 1977;
Lawrence, Tery and Horsley 1975). Combinations of 5FU, Methyl
CCNU and oral BCG are now under evaluation with encouraging
results (Killen 1981; Panettiere and Chen 1981).
In the adjuvant setting for gastric cancer, single agents
such as mitomycin C (Goto et al, 1977; Koyama, 1978 and Nakajima
et al, 1978) have shown less than a 10% response. Schein et al
(1982) however feel that gastric cancer is a chenDsensitive tumour
and that combinations of drugs which include Adriamycin may well
be of value in the treatment of advanced gastric cancer and for
the adjuvant setting.
It would seem apparent, however, that the spectacular
successes that have occurred recently in the management of acute
lymphoblastic leukaemia, testicular teratona and Hodgkin's disease
using combination chemotherapy will not be repeated for colorectal
and gastric cancer. Thus whilst intense research is on-going into
biological response modifiers (Carter 1980; Guillou 1987),
radiosensitizers (Carter, 1982) and newer chemotherapeutic
regimens there is little evidence to date of a significant
breakthrough in the management and therefore survival in those
patients whose cancer has breached the serosa or spread to the
lymph nodes and who traditionally have been felt to be surgically
curable.
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Who should be screened?
Where the causative agent of a cancer is known but
cannot be removed from the environment e.g. uranium in nuclear
fuel reactor plants then the 'at risk' population can readily be
identified and be subjected to routine screening. Where the cause
is unknown those at increased risk should possibly be screened.
For colorectal and gastric cancer, the causative agents have not
yet been ascertained, but epidemiological studies have indicated
certain individuals to have a considerably greater risk of
developing these tumours conpared to the remaining population. In
these 'high risk' populations a programme of selective screening
could therefore be effective.
'High risk' individuals for gastric cancer include those
with Menetriers disease ; pernicious anaemia (Elsborg and Mosbech,
1979; Stockbrugger and Cotton, 1981); gastric polyps (Tomasulo,
1971; Niemark and Rogers, 1982; Kamiya et al, 1982); coalminers
(Ames, 1983); chronic atrophic gastritis (Siurala et al, 1966;
Sipponen et al, 1984), intestinal netaplasia (Iida and Kusama,
1982) and previous partial gastrectomy (Eberlein, Lorenzo and
Webster, 1978; Hermanek and Riemann, 1982; Farrands et al, 1983;
Schafer et al, 1983; Pickford et al, 1984). However, in terms of
increased risk of gastric cancer arising in these patients
compared to the general population the ratio is less than 2:1 for
previous gastrectomy, atrophic gastritis and intestinal metaplasia
making these fairly weak indicators of cancer risk for screening
purposes.
For colorectal cancer, the risk groups can be divided into
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those with a genetic predisposition and those associated with
benign inflammatory conditions of the large bowel (ulcerative
colitis and Crohn's disease, Weedon et al, 1973). The hereditary
conditions include familial polyposis coli (Aim and Licznerski
1973), Gardner's syndrome (Gardner and Richards,1953), Cronkite-
Canada syndrome ( Cronkite and Canada, 1955), and the Cancer-
Family syndrome (Lynch et al, 1981). The risk for cancer in these
hereditary conditions appears to be 100% for familial polyposis
coli, (Aim and Licznerski 1973) 66% for Gardner's syndrome, and
unknown for Cronkite-Canada Syndrome. The cancer family syndrome
may be associated with an increased risk of colonic carcinoma and
also endometrial and ovarian carcinoma.
Individuals with the above conditions will be in the main
already under surveillance by the medical profession and any
members of the family of a recently diagnosed familial lesion
should be screened. However, selective screening for these 'at
risk' groups will only account for 10% of the cancer pool
(Schottenfeld, 1975) making little impact on the overall itortality
of these cancers.
There remains however, one condition which appears to be a
high cancer risk lesion said to be present in nearly all patients
with colorectal cancer i.e. the colorectal adenoma (Grinnel and
Lane, 1958; Kalus, 1972; Morson, 1974; Mito et al, 1975;
Enterline, 1976). The risk of malignancy is directly related to
the size, histological type and number of adenomata present.
Approximately 1% of all adenomas under 1 cm in size undergo
malignant change (Welch 1979; Morson 1974). Morson (1974)
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further noted that with an increase in size the malignant
potential rose; 50% of polyps over 2 cm in size showed
histological evidence of carcinoma. Shinya and Wolff (1979) also
found in a study of endoscopically removed polyps that 21% of
polyps greater than 2 cm showed evidence of malignancy compared to
5% in those less than 1 cm.
Adenomas are histologically described as being tubular,
villous or tubulo-villous (Morson, 1974). Muto et al (1975)
described a 40% cancer presence in villous adenoita compared to 5%
for tubular polyps, a finding also confirmed by Gillespie (1979)
and Shinya and Wolff (1979).
Unfortunately, polyps tend to be relatively asynptomatic
and therefore difficult to detect. Clearly any screening agent to
detect colorectal cancer should also identify those larger polyps
with a villous pattern to interrupt the polyp-cancer sequence
(Morson, 1974; Gilbertsen and Nelms, 1977).
When do you screen?
The cancer mortality statistics show that colorectal
cancers are relatively uncommon below 40 and rise dramatically in
incidence from age 50 years. A similar pattern is seen for
gastric cancer with a rapid rise in incidence from age 55 years
(Mortality statistics, 1979).
It is reported that polyps tend to appear 5-10 years prior
to cancers (Brahne et al, 1974) and that screening should
therefore start 5-10 years before this rise in the incidence of
colorectal cancers i.e. 40-45 years. The American Cancer Society
has therefore proposed age 45 years as the time to initiate
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screening. In this country Hardcastle (1980; 1983) has taken age
45 years as the cut-off age for screening. Lallemand et al (1984)
have started screening at age 40 years and it may be that this
early entry to screening was responsible for the poor yield of
neoplasia in their large study.
For the purpose of this study age 50 years has been taken
to indicate the lower age limit for screening in an attempt to
raise the potential for detection of disease since the
anticipated numbers entering the study will be small.
Which test?
Screening for colorectal cancer now principally relies on
the faecal occult blood (FOB) test with the aid of sigmoidoscopy
in riany Alterican centres but alone in the United Kingdom (Fig 1).
Other methods including digital rectal examination, and rigid and
flexible sigmoidoscopy have also been investigated but have not
been adopted with the same enthusiasm as FOB testing.
Population screening for gastric cancer has received scant
attention in Europe and North America due to the relatively low
prevalence and falling incidence of this disease. Furthermore the
only apparently reliable screening technique according to the
Japanese experience appears to be endoscopy preceded by a 6 film
barium meal study. The barium study identifies 85% individuals as
requiring endoscopy and so a lengthy and expensive screening
procedure is necessary (Micha et al,1985). Few Western countries
wculd contemplate this approach so selective screening of at risk
populations has been advocated including post-ulcer surgery
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Fig 1 Screening for colorectal cancer using
faecal occult blood tests and fibreoptic
sigmoidoscopy.
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patients. Even then there is controversy over this approach with
Professor Langlands stating that in the United Kingdom there is
little to be gained from it (Roberts and Langlands, 1983). One
alternative approach has been suggested by Hakkinen et al
(1980,1981), where population screening using gastric juice
analysis was adopted with some success in the detection of EGC and
advanced gastric cancer.
Tumour markers and symptom analysis have also been used to
aid the earlier detection of these two cancers and will be
reviewed now along with the above methods.
Faecal Occult Blood Testing
The concept of occult blood detection in the stool is
generally credited to Von Deen, who in 1864 used gum guaiac as an
indicator reagent ( Irons and Kirsner, 1965).
Some 90 years later it has been appreciated that occult
blood detection is dependent on the oxidation of a phenolic
compound to a quinone structure, which in turn changes colour by
an intermolecular reaction (Harvey, 1956). Hydrogen peroxide
facilitates the oxidation process, which is catalyzed by the
haematin component of haemoglobin or by naturally occurring
peroxides and catalases in food. The resultant phenolic oxidation
in the presence of a chromogenic indicator, e.g. guaiac, results
in a blue colour (Fig 2). Benzidine and orthotolidine have also
been used as colour indicators.
Commercial FOB Tests
The faecal occult blood test that is most frequently used
in early detection of colorectal cancer is the Haemoccult test
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Fig 2 Positive reaction to occult blood test.
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(Norwich Eaton; Smith Kline Laboratories). This in common with
Fecatest (Finpipette) uses guaiac as its chromogenic indicator.
This review will concern itself principally with Haemoccult and
Fecatest as they are to be used in the study.
Other commercially available tests use benzidine or
orthotolidine as their indicators (Hemofec, Med-Kjemi A/S, HON,
Norway; Hemotest, Miles Laboratories) but have fallen into
disrepute for being too sensitive with high false positive rates
(Morris et al, 1976; Irons and Kirschner, 1965; Cameron 1960).
Furthermore, several chemical tests utilising benzidine and
orthotolidine have been withdrawn because of their carcinogenic
potential (Chester Beatty, 1966).
Immunological FOB tests
At the beginning of this study immunochemical detection of
occult bleeding had been investigated by Barrows et al (1978) and
Songster et al (1980), in the United States, by Vellacott,
Baldwin and Hardcastle (1981), in this country and Williams et al
(1982), in Australia.
Barrows and Songster with their team developed a radial
immunodiffusion technique (Barrows et al, 1978) and applied this
to 150 patients with diagnosed colorectal cancer (Songster et al,
1980). They found that the immunodiffusion technique was more
sensitive than the guaiac test Haemoccult for all cases and for
all anatomical sites. Thus overall the radial immunodiffusion
technique detected 65% cancers compared to 40% cancers detected by
Haemoccult. Haemoccult detected 50% right colon lesions, 34% left
colon lesions and 29% rectal lesions, whilst the immunodiffusion
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test detected 63%, 72% and 50% respectively. However, 29% cancers
were missed by both Haerroccult and the radial immunodiffusion
test. The restriction to the routine use of this test is the
preparation tine of 24-48 hours before reading the result.
Vellacott, Baldwin and Hardcastle (1981) developed a
modified immunodiffusion technique using fluorescein-labelled
anti-humn haemoglobin binding antibody. Whilst the sensitivity
of the test proved superior to Haemoccult it is not commercially
available precluding any further investigation in this study.
Williams et al (1982) also modified Barrows' technique
(1978) and found that the immunological technique was more
sensitive in the detection of colorectal cancers and polyps (89% v
65% for Haemoccult) but that the immunochemical test was also
subject to more false positives than Haemoccult.
Whilst this immunological approach will prove the most
technically satisfactory FOB test no commercially available test
that has been fully assessed, is yet available. Turunen et al
(1984) however feel that they may have developed a much improved
and easily performed immunochemical test.
"Normal" Gastrointestinal Blood Loss
The accuracy or 'sensitivity' of a chemical method for the
detection of faecal occult blood can be compared with a "gold
s tandard'' method.
The development of radiochromium red cell labelling has
produced such a 'standard'. It is a highly accurate and
reproducible method of detecting occult blood loss. There is
general agreement that 'normal' occult blood loss is in the order
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of 0.5 - 2 ml blood per day (Roche et al, 1957; Ebaugh et al,
1958; Cameron 1960). Morris et al (1976) have used the convention
of describing blood loss as mg haemoglobin per gram of stool and
suggest an upper limit of 2 mg haemoglobin per gram stool per day
as being normal.
An efficient FOB test should therefore detect blood only
above these levels and when screening for colorectal neoplasia
should not detect bleeding from upper GI disease (vide infra).
Ability of Haemoccult and Fecatest to detect blood in faeces
Ostrow et al (1973) were the first group to conpare the
sensitivity of chemical occult blood tests and the radiochromium
red cell labelling irethod. This group found that where the stool
under examination contained 5-10 mg Hb/gram stool then Haemoccult
was positive in 50% of cases and where the stool contained mare
than 10 mg Hb/g stool uniformly positive results were obtained.
Similarly Marris et al (1976) investigated 39 patients
51
with both Haemoccult and Cr red cell labelled assay. Taking 2
mg Hb/g stool as the upper limit of normal they found that
Haemaccult was positive in only 12% stools tested below this
level. Stroenhlein et al (1976) also noted that Haemoccult was
positive in 7.4% of 338 specimens where the level of blood loss
detected by ~^Cr labelling was between 0.2 mg/day, rising to 67%
with blood losses greater than 10 ml/day and 93% with blood losses
of mare than 30 ml/day.
Adlercreutz, Liewendahl and Virkola (1978) found that
Fecatest could detect mean occult blood excretion of 2.5-3.0 ml or
/ SI
mare /24 hour as determined by Cr labelling techniques, using 24
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hour homogenized faecal sairples. Single homogenized faecal
sanples were positive to Fecatest only at levels of 4.8 ml
blood/24 hours. Haemoccult was not positive until the blood
loss/24 hours approached 10 ml.
The amount of bleeding from the upper gastrointestinal
tract required to give a positive Haeiroccult is much larger than -
from the colon. Subjects given labelled blood orally had only one
positive reaction when 30ml were ingested (Ransom et al, 1980).
Fecatest may be more susceptible however to upper GI bleeding
giving a positive result. Parkins and Barrison (1981) detected
positive Fecatest sairples with as little as 5-10 ml of blood
ingested.
In summary, Haemoccult will readily detect blood in faeces
at a level of 10 mg Hb/g stool whereas Fecatest is mare sensitive
and will detect levels of loss of as low as 2.5-5 ml blood in 24
hr.
The sensitivity of Haenoccult and Fecatest in the detection of
diagnosed Colorectal Neoplasia
In the previous section it has been shown that Haemoccult
and Fecatest can detect occult bleeding above a 1 norital' level.
However, can these tests detect bleeding from a colorectal
neoplasm and if so what is their sensitivity? Unfortunately many
uncontrolled screening studies have been performed since Greegor
(1971) first described the detection of asymptonatic cancers with
Haemoccult without the true validity of the test being determined
in established disease. Furthermore it would clearly not be
practicable to endoscope or perform barium enemas on all those
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participating in screening programmes to determine the false
negative rate for the test. The true sensitivity can only be
anticipated therefore by reviewing the literature for FOB testing
in diagnosed colorectal neoplasia.
A number of these studies are now available to us (Table
1.1) and show a false negative rate for cancer ranging from 18-
60%. However, in Songster's study ( Songster et al, 1980) stool
testing was only performed for one day, and since most authors
follow Greegor's original suggestion of stool testing for 3
consecutive days one might anticipate that this high false
negative rate could have been reduced by serial stool collection
and testing.
Griffiths et al (1981) noted that 21 of 23 patients with a
positive result had ulcerating lesions whereas all 5 cancers not
detected by Haemoccult were not ulcerated. Leicester et al (1983)
found that 22 of 25 (85%) patients with colonic cancer were
detected by Haenoccult but that only 50% rectal cancers were thus
detected. They suggested that there had been insufficient time
for contact and mixing with stool for the rectal cancers to become
Haemoccult positive.
It is also apparent that there is a low sensitivity (high
false negative rate) for Haemoccult detection of adenoiras of the
large bowel. Ihcrae et al (1982) observed that only adenomas
greater than 1 cm bleed and even then the false negative rate for
polyps greater than 2 cm was 25%. Herzog et al (1982) studied 44
patients with colorectal polyps (34 polyps in the descending colon
and rectosigiroid, 10 in the right colon) and noted that 25 (57%)
- 28 -
Table 1.1



















































overall were detected by Haemoccult. However, by considering site
alone 86% of the left colon polyps were detected.
One British study reports the use of Fecatest in a
symptomatic population. Farrands and Hardcastle (1983) noted that
in 61 patients with proven colorectal cancer Fecatest was positive
on 3 day testing in 55 patients (90.2%) that is a false negative
rate of 9.8%. Haemoccult was also given to all these patients and
on similar 3 day testing the false negative rate was 17 (27.9%) of
61 but fell to 9.7% on 6 day testing.
Causes of False Negative Responses to FOB testing in diagnosed
Colorectal Neoplasia
Reduced to the sinplest options the reasons for failure of
Haemoccult to detect symptomatic diagnosed cancer may be either
the cancer is not bleeding or the FOB test is not sensitive enough
to detect the blood that is being lost.
As mentioned above Griffiths et al (1981) would favour the
fact that non-ulcerating lesions are unlikely to be detected and
the second option my be supported by Farrands and Hardcastle
(1983) where Fecatest is more sensitive than Haemoccult in the
ranges of 5-10 mg Hb/g stool lost. This lack of sensitivity for
Haemoccult has already been reviewed (Ostrow et al, 1973; Morris
et al, 1976).
The more scientific approach of Doran and Hardcastle
(1982), Macrae et al (1982) and Herzog et al (1982), however,
reveals the answer. These 3 groups investigated patients with
SI
known colorectal neoplasia, performed Cr red cell labelling
studies and analysed the Haemoccult findings with the blood loss
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calculated by the radiochromium studies.
Doran and Hardcastle (1982) found large variations in the
daily blood loss ranging from 0.00 - 74.7 ml/day, and that
bleeding from individual tumours was found to be intermittent. In
only 36 of 150 daily stool saitples was the blood loss greater than
10 ml. Thus 15 of 50 (30%) cancers were undetected in 3 day
testing with Haemoccult.
IVhcrae et al (1982) found that in a study of 46 cancers,
bleeding was highest in ascending colon lesions, 9.3 ml/day, with
losses of 1.5 ml/day for transverse colon, 1.9 ml/day for sigmoid
colon lesions and 1.8 ml/day for rectal tumours. These patients
collected sairples on average for 5.8 days and for 11 patients at
no tine was Haemoccult positive.
Herzog and colleagues (1982) showed that polyps apparently
bleed less vigorously, the mean blood loss per day for 34 left
colonic polyps being 1.36+0.14 (sd) ml/day and for right colonic
polyps 1.28 + 0.31 ml/day. They noted that in patients with left
colon polyps whose faecal specimens contained 2.0 - 3.99 ml
blood/day Haemoccult was positive in 86%, whereas right-sided
lesions with equal loss yielded a positive test in only 26%. Thus
in this study Haemoccult was able to detect low levels of
bleeding, polyps were found to bleed little, and that detection of
occult colorectal neoplasia was affected by anatomic site.
Other factors affecting the false negative rate apart from
the low and intermittent nature of neoplastic bleeding include
ingestion of Vitamin C (Jaffe, Kasten and Young, 1975; Garrick,
Close, McMurray 1977) and dehydration (Macrae et al, 1982).
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Whilst Macrae et al (1982) have noted improved sensitivity for
rehydration of the Haemoccult slide, this whole question has been
vexed with arguments in favour (Wells and Pagano, 1977) and
against (Winawer et al, 1980). As the manufacturers do not
recommend rehydration for the purposes of this study it has been
deemed unnecessary.
Causes of False Positive Results on FOB Testing
Positive reactions to FOB testing in screening programmes
range from 0.5-14% (Table 1.2) although the majority of workers
have experienced positive rates between 2% - 5%. The false
positive rates vary from 50% - 85% in these investigated cases.
The occult blood reaction is not specific for human
haemoglobin but is affected by peroxidases and catalases in
various foodstuffs e.g. fish, fresh fruits and uncooked vegetables
(iVbcrae et al, 1982). The ingestion of these foodstuffs may
therefore produce false positive results and so many investigators
recommend dietary restrictions for the screened individual whilst
the stool specimens are being collected.
The rehydration of the Haemoccult slide may increase the
sensitivity of the test but may well lead to a fall in specificity
(Wells and Pagano, 1977). ffecrae et al (1982) have suggested that
a strict diet excluding red meat may enhance the sensitivity of
the test without increasing the false positive rate. As mentioned
above this issue is contentious and the iranufacturer' s advice of
no rehydration for Haemoccult will be adhered to.
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Screening for Colorectal Neoplasia with Haemoccult and Fecatest
Boas is reported in 1901 to have emphasised the role of
occult bleeding into the stool as indicating the existence of a
gastrointestinal tumour (Irons and Kirschner, 1965), however, it
took nearly 70 years before occult blood testing was deemed
feasible following the efforts of Dr. David Greegor in Ohio.
The Breakthrough
Disenchanted with the unpredictability of guaiac,
benzidine and orthotolidine testing (Hoerr et al, 1949; Mason and
Belfus, 1952; Camsron, 1960; Irons and Kirschner, 1965) Greegor
developed a stable guaiac preparation impregnated on
electrophoresis filter paper, Hemoccult, (Greegor, 1967). By
1971, 900 asynptonatic patients had undergone occult blood
testing, following dietary restriction, for 3 days. In these
subjects, 5% had a positive Hemoccult slide and on subsequent
investigation with sigmoidoscopy and barium enema, one per hundred
screened had a colonic cancer detected (Greegor 1971). In 1972 he
further reported the detection of 47 asymptomatic cancers detected
as a routine office testing using Hemoccult.
As will be shown below, great interest was placed in
Haemoccult testing and soon other guaiac impregnated paper FOB
tests became commercially available (Fecatest, Hema-chek). By
varying the concentration of guaiac peroxide then the sensitivity
of the test can be varied thus explaining the difference in
sensitivity between Haemoccult and Fecatest shown by Aldercreutz,
Liewendahl and Virkola (1978).
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Verification
Over the following decade many investigators have taken up
with enthusiasm the Haemoccult test as a means of screening for
colorectal neoplasia, and attempted to verify Greegor's findings.
The majority of these studies are uncontrolled, varying in
size, population selection and dietary restriction, whilst only 3
large studies have been developed in a proper controlled fashion
(Gilbertsen et al, 1980; Winawer et al, 1980; Hardcastle et al,
1983).
Uncontrolled Studies
lVfeny studies have been performad throughout the world
using Haemoccult to detect asymptomatic colorectal cancer. Table
1.2 lists the najority of large populations studied, along with
the test positive rate, the number of cancers and polyps found,
and the yield per 1000 screened.
Such studies have indeed detected asymptomatic colorectal
cancers and polyps, and show earlier stage cancers than might be
expected in routine practice (Goodman, 1977; Bralow and Kopel,
1979; Winchester et al, 1980; Larkin 1980; Sontag, Durczak and
Arariha, 1983; Habba and Doyle, 1983). Where the data has been
recorded it is clear that the ratio of early stage to advanced
colorectal cancers is reversed with 143 of 194 (73%) of these
cancers being either Dukes' stage A or stage B.
The positivity of Haemocult slides however ranges from 2%
- 6% and of those the predictive yield of cancers for a positive
test on subsequent investigation ranges between 2% - 14% (Miller
and Knight 1977; Habba and Doyle 1983; Gnauck 1980). The yield of
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polyps is higher in these studies than for cancer but the
predictive value is only 20% maximum (vide infra).
The British experience of Haemoccult testing is very
similar (Table 1.3). Professor Hardcastle in Nottingham pioneered
Haeiroccult screening in this country, selecting a snail country
town for his study. 1638 invitations were sent by post with an
enclosed HaeiiDccult test to perform stool testing. 742 (45%)
returned the FOB with 2 cancers and 4 polyps being subsequently
detected.
Once again there is a range of positive responses from
1.5% - 5% for Haemoccult with both cancers and polyps being
detected on subsequent investigation (Table 1.3). The cancers
thus detected were 1 Dukes' Stage B and 3 C (Farrands et al,
1981), 2 Dukes' Stage A (Million et al, 1982), 1 Dukes' Stage B
(Lallemand et al, 1984). Colonic polyps of greater than 1 cm in
size were found in all studies and are included in the
calculations of predictive yield of neoplasia.
Lee in 1983 has so far reported the only United Kingdom
screening programme using Fecatest and had previously reported a
comparison of Fecatest and Haemoccult in a mixed screening and
symptomatic population study (Lee and Costello, 1982). In his
occupation based screening study Lee (1983) recorded an overall
positivity rate of 5.8% (140) of 2420 men and on subsequent
investigation 5 cancers (2 Dukes' A; 1 Dukes' B; 2 Dukes' C) and
17 polyps were identified with 52 individuals having no lesion to
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In their hospital based and occupational screening study,
Lee and Costello (1982) observed that Fecatest detected 6 cancers
and 4 polyps whilst Haemoccult was positive in only 3 individuals
with cancer and 3 with a polyp. The authors claim that Fecatest
is itore sensitive than Haemoccult in this study (5.5% v 2%
positivity) yet does not produce unmanageably high numbers of
false positive cases. However, the predictive yield for a
positive Fecatest is 14% for neoplasia compared to 26.9% for
Haemoccult.
Although Lee (1983) has felt that Fecatest can be used
cost effectively for population screening, Berretta et al (1978)
have shown that the positivity for Fecatest in 150 unselected
patients was 50% and that in their opinion Fecatest most certainly
was not suitable as a screening agent.
Controlled Screening Studies with Haemoccult
Despite the multitude of screening studies only 4
controlled studies are in progress (Gilbertsen et al, 1977; 1980;
Winawer et al, 1977, 1980; Hardcastle et al, 1983; Kewenter et al,
1984). Whilst these studies are as yet incomplete and therefore
the inpact on survival and mortality of FOB testing not known some
lessons have been learned from interim reports.
Hardcastle et al (1983) have established a controlled
study of 20,525 patients taken from general practitioners lists
and offered half the opportunity of repeated FOB screening with
Haemoccult. Their reported findings include a FOB positivity rate
of 2.1%, a 50% predictive yield for neoplasia with 9 of 12 cancers
being Dukes' Stage A lesions, and an overall compliance rate of
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36.8%. In the control group 10 cancers (4 Dukes B, 4 Dukes C and
2 Dukes D) were detected at one year i.e. one per 1000 controls
compared to 3.6 per 1000 in the screened group. In a further 27
FOB +ve subjects 40 polyps were detected. Fibreoptic
sigmoidoscopy detected 10 of 12 cancers within its range and 39
adenonas. Double contrast radiology identified only 9 of the 12
cancers and 24 (62%) of the polyps. Colonoscopy was performed in
all cases thus allowing comparison with radiology.
In their latest report Hardcastle et al (1985) have found
4 further cancers on rescreening with Haemoccult and one cancer
has come to light having been missed by FOB testing. In the
control group in the second year of follow-up a further 7 cancers
have presented (4 Dukes' B and 3 Dukes1 C).
Kerwenter et al (1984) have initiated a controlled study
of 21,700 individuals aged 60-64 years in Gotheriberg using
Hemoccult II. They have compared rehydration with non-rehydration
in this study also.
In the non-rehydration group they found 1.9% positive
FOB's and on investigation 4 cancers and 19 patients with polyps
(predictive yield 27%). However, over the following 18 norths 14
patients have presented with colorectal cancer giving an 'at best'
sensitivity for non-rehydrated Hemoccult II as 22%. For the
rehydration group 5.8% had a positive FOB, 12 patients were found
to have cancer and 37 to have adenomas upon examination
(predictive yield 18.4%). No subjects in the second group have
presented with cancer subsequently. In the control group of
13,700 subjects, colorectal cancer was diagnosed in 12 individuals
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(0.88 per 1000). The Dukes1 staging for all three groups,
however, was not shown to be different. This group stressed the
value of rehydration of Hemoccult II and only with rehydration
would screening with Hemoccult II become viable.
From the American centres it has become clear that
flexible sigmoidoscopy is superior to rigid sigmoidoscopy even in
the range of the rigid instrument (Winawer et al, 1980), that 44%
of cancers detected on FOB testing are beyond the range of the
flexible sigmoidoscopy (Nivathongs et al, 1983) and that
colonoscopy is superior to double contrast barium studies for the
detection of colorectal neoplasia (Gilbertsen et al, 1980; Winawer
et al, 1980). Further that by using flexible sigmoidoscopy
routinely in all patients, Winawer et al (1980) have shown a false
negativity for polyps on FOB testing to be as great as 76% when
present in the recto-sigmoid region.
Tumour l^farkers
In this thesis only four of the many possible substances
that have been investigated as potential biochemical rtarkers of
cancer have been assessed; they are carcinoeiribryonic antigen
(CEA), alpha-l-acid glycoprotein (AGP), C-reactive protein (CRP),
and gamma glutarryl transpeptidase (GGT).
Berlin (1981) has proposed that the successful cancer
diagnostic test is one which will detect 75% of all cancers when
90% of these cancers have not metastasised. The test should also
indicate the organ where the cancer resides since this information
is essential if curative treatment is to be instituted.
Unfortunately, no such irarker exists as will be highlighted by the
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review of the best known agent CEA. However recent developments in
the preoperative asssessment of cancer of the large bowel and the
stomach have precipitated the re-examination of the value of the
combination of these four tumour narkers to predict the presence
of cancer in a symptomatic patient.
Carcinoembryonic Antigen (CEA)-Biochemical Review
Carcinoembryonic antigen (CEA) was discovered in 1965 and
defined as a tunour-specific antigen of the digestive system (Gold
and Freedman, 1965). The fact that CEA was absent from
corresponding normal adult tissues, but was present in human
embryonic digestive organs by the immunological techniques
employed in the initial observations, accounts for the designation
given the molecule. It has been proposed that the reinitiation of
its synthesis by bowel cancer cells in the adult is the result of
a process variously known as derepressive dedifferentiation,
retrodifferentiation or antigenic reversion.
The CEA molecule was characterized as a glycoprotein with
a molecular weight of approximately 200,000 daltons, sedimentation
coefficient of 7-8s and possessing negative electrophoretic
mobility (Gold 1967; Gold et al, 1968; Krupey et al, 1967, 1972;
Coligan et al, 1972; Newman et al, 1974; Banjo et al, 1974), and
possesses 50-60% carbohydrate (Banjo et al, 1972,74; Terry et al,
1972, 1974; Coligan et al, 1975; Slayter and Coligan, 1976).
Electronmicroscopy studies reveal that CEA consists of twisted
rod-shaped particles, measuring 9 x 40 nm (Slayter and Coligan,
1975; Egan et al, 1976).
Studies with immunofluorescence (Gold et al, 1968; Von
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Kleist et al, 1969; Burtin et al, 1972; Denk et al, 1972, 1973;
Burtin et al, 1973; O'Brien et al, 1979; Potomski et al, 1979;
Pihl et al, 1980) and electron microscopy (Gold et al, 1970;
Huitric, 1973; Heberman et al, 1975) in tissue sections of
adenocarcinomas of the digestive system, revealed that CEA is
situated to a large extent in the glycocalyx on the luminal
surface of the membranes and in the cytoplasm. These findings lead
to the conclusion that CEA is a secretion product (Denk et al,
1972; Rogalsky, 1975) rather than a cell constituent (Gold et al,
1970). From this site CEA can be released into the circulation of
the cancer-bearing host. This has enabled the development of
radioimmunoassays to detect the presence of the irolecule in blood
(Thomson et al,1969; Hansen et al,1974) and has resulted in a
proliferation of reported studies on the levels of CEA in the
clinical setting.
CARCINOEMBRYONIC ANTIGEN (CEA) - CLINICAL REVIEW
CEA levels in colorectal neoplastic and premalignant conditions,
Thomson et al (1969) described a radioimmunoassay for CEA
in serum. Thirty-five out of 36 patients (97%) who were known to
have cancer of the large bowel, presented with raised levels in
their sera but the antigen could not be demonstrated in patients
with cancerous and non-cancerous conditions of the non-digestive
organs nor in benign gastrointestinal disorders. This high
positivity of CEA for colorectal cancer was subsequently confirmed
in other publications ranging from 81% to 95% (Lo Gerfo et al,
1971; Reynoso et al, 1972; Meeker et al, 1973; Gold et al, 1973;
Khoo, 1974; Martin et al, 1976; Alsabati and Kamel, 1979). However
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several reports have not reproduced these optimistic results and a
fall below 70% in the pre-operative CEA positivity rate has been
observed (Dhar et al, 1972; Laurence et al, 1972; IVhch et al,
1974a; Nugent and Hansen, 1974; Booth et al, 1974a; Onizawa et al,
1976; IVbr et al, 1977; Jubert et al, 1978; Slater et al, 1979a;
Beatty et al, 1979).
The relationship between CEA levels and histopathological
examination of colorectal cancer
1. Staging
The Joint National Cancer Insitute of Canada/American
Cancer Society reported that 62% of 147 patients with large bowel
cancer had raised CEA pre-operatively; 28% Dukes' A, Bl; 58% B2,
Cl; 83% C2 (Miller et al, 1974). The incidence of a positive CEA
has also been observed to vary with the stage of the cancer in
other studies ranging from 14 to 44% in patients with Dukes' A, 45
to 76% with Dukes1 B and 60 to 100% in individuals with metastatic
disease (Dhar et al, 1972; Lo Gerfo et al, 1972; Laurence et al,
1972; Shuster et al, 1974; Livingstone et al, 1974;Booth et al,
1974a; Luporini et al, 1976; Beatty et al, 1979).
2. Vascular invasion
Necrosis and vascular invasion seems also to correlate
with CEA level and it was suggested that CEA being a cell surface
antigen may be washed off by exposure to the bloodstream (Bivins
et al, 1975).
3. Site of primary tumcur
Right-sided colon tumours have been described as having a
lower incidence of raised CEA than left-sided neoplasms (Shuster
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et al, 1974; Livingstone et al, 1974; Nhrtin et al, 1976; Slater
et al, 1979). 40% of neoplasms of the caecum show increased CEA
levels, with potentially curable lesions (Dukes' A, B and C) being
positive in only 33% of the cases. Similarly, CEA in cancer of the
rectum was elevated in only 52% of patients, most of them with
distant spread, termed Dukes' stage D ( Turnbull et al, 1974), and
who therefore had a poor prognosis. On the other hand 76% of all
sigmoid tumours had positive titres, 73% of these patients having
potentially curable lesions. Neoplasms in the right colon were
positive in 54%. However the highest positivity was observed in
tunours of the splenic flexure to sigmoid colon with an incidence
of 77% (Shuster et al, 1974).
Correlation have also been observed between tumour size
(Nakamura et al, 1978; Arnaud et al, 1980) and degree of tumour
cell differentiation (Sugarbaker, 1976; IVfertin et al 1976; Arnaud
et al, 1980) with the CEA values. The poorer the differentiation
of the tumour, the lower is the CEA level. It must be stated
however that these strong correlations noted above are not borne
out by the following reports: the location of the tumour
(Sugarbaker, 1976; Jubert et al, 1978; Miwa et al, 1980; Arnaud et
al, 1980); the size of the primary lesion (Shuster et al, 1974;
Livingstone et al, 1974); the pathological stage (Bivins et al,
1975; Boyd et al, 1976) and the tumour grade (Inaeda et al, 1976;
Boyd et al, 1976; Cooper et al, 1979; Chapuis et al, 1980).
Two proper screening studies and several case finding
studies termed "screening" have been reported in the literature.
Stevens et al (1975) screened the elderly population of the town
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of Busselton, Australia. Their study of 956 unselected persons
over the age of 60 years revealed 44 (4.5%) had a CEA level
greater than 5 ng/ml at the beginning of the study. During a four
year follow-up, 6 of these 44 had died of CEA-associated cancers,
15 were heavy smokers, 2 had colonic diverticula and one a peptic
ulcer. By contrast, 18 (2%) of the original 912 CEA negative
group had developed CEA associated cancers during the sane period.
20 subjects who were CEA positive when re-examined 4 years later,
revealed 2 occult cancers, one of the lung and one of the colon.
It was concluded that the specificity of the CEA and the high
levels in smokers detract from its usefulness as a population
screen.
Holyoke et al (1982) performed CEA estiirations in a group
of 1800 older aged businessmen and two unsuspected cancers were
discovered, one in the pancreas, one in the colon: both were
incurable. The authors felt this approach was unreasonably
expensive for the yield it provided.
Constanza et al (1974) assessed the value of CEA
measurements in a population of 205 mixed cancer patients and 553
non-cancer but symptomatic patients. 15 of 23 (65%) colon cancer
subjects had raised CEA levels and 9 of 13 early lesions were
positive. However, 98 (18%) of the non-cancer group had a raised
CEA and of these one developed a carcinoma over 5 year follow up.
El Roubi and Lasne (1978) "screened" 786 subjects for CEA
levels. They reported that 37% colorectal cancers were detected
with a false positive rate of 33% for the benign GI disease group.
Finally, Klein (1978) performed a comprehensive
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investigation of 500 subjects reviewed for proctoscopy, flexible
sigmoidoscopy, FOB testing, colonic lavage for CEA and plasma CEA
levels, plus barium enema. 7 cancers, 9 villous adenomas and 22
adenomatous polyps were found but the faecal and plasma CEA levels
were entirely non-contributory.
CEA and High Risk Groups for Colonic Cancer
(a) Colorectal polyps
Isaacson and Le Vann (1976) have shown CEA to be present
in colorectal polyp tissue. The literature gives conflicting
evidence as to the levels of circulating CEA in the serum and the
value of CEA in this situation. El Roubi and Lasne (1978)
reported that 7 of 21 polyps had very high levels of CEA and
Ziegenbein et al (1980) noted 52% polyps to have elevated CEA
levels which fell on polypectomy to normal. However, Constanza et
al (1974) and Miller et al (1974) found the test to be totally
insensitive to the presence of colonic polyps.
The risk of patients with colorectal adenomata possessing
elevated CEA levels and subsequently developing carcinona was
discussed by Doos et al, (1975). Fourteen of 93 patients had CEA
levels greater than 2.5 ng/ml and 7 of them had malignant (2) or
pre-malignant (5) changes within one year of follow-up. CEA
titres were associated with the increasing age of patients,
villous type histologically and cumulative adenoma volume over 6
cm . No significant association was observed between the antigen
values and dysplastic changes or carcinoma-in-situ.
(b) Inflammatory bowel disease
The presence of augmented concentrations of CEA in
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inflammatory bowel disease was first reported by Lo Gerfo et al,
in 1971 and further confirmed by Kleinman and Turner (1972) in
patients with Crohn's disease. Although variable results have
been obtained, it is generally accepted that approximately 10% of
these individuals have raised CEA titres which appear related to
symptomatic disease (Moore et al, 1972a; Turner et al, 1973;
Hansen et al, 1974; INfertin et al, 1976). However, Rule et al
(1973) reported a higher proportion of positive values with the
incidence of an elevated CEA being 36.6% in 30 patients with
granulomatous colitis and 27% in 26 patients with ulcerative
colitis.
The CEA level has also been associated with the extent
(Gardner et al, 1978) and degree of disease activity (Moore et al,
1972a; Wight and Gazet, 1972; Rule et al, 1973; Booth et al,
1974; Hansen et al, 1974; Mitchell et al, 1975; Martin et al,
1976), generally returning to normal levels following remission or
total colectomy (Rule et al, 1973). Furthermore persistent
elevation has been found in patients with longstanding Crohn's
disease (Booth et al, 1974). Dilawari et al (1975) tried to
predict the presence of severe dysplasia or cancer in a group of
long-standing colitis. The levels of 6 of 7 patients with cancer
and 6 of 7 with severe dysplasia were no different from those
obtained in a control group of uncomplicated colitis patients.
CEA levels in gastric cancer
The measurement of plasma CEA to indicate gastric cancer
suffers from the sane drawbacks as for colorectal cancer - low
sensitivity particularly for early stage I & II cancers and low
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specificity. The following table (1.4) indicates the %
sensitivity of CEA by stage for the principal reported series of
gastric cancer.
CEA levels seem to depend on the degree of tuirour cell
differentiation (Chatal et alf 1976; Dedieu et al, 1977), with
lower titres present in the itore poorly differentiated lesions.
The prognostic value of preoperative CEA in stomach cancer
patients has not been yet confirmed (Ellis et al, 1978) although a
raised value after resection has been associated with residual
tunnur or metastases (Chatal et al, 1976; Dedieu et al, 1977).
As seen in the above table (Table 1.4), the extremely low
levels of CEA in early gastric carcinoma have discouraged the use
of plasm CEA levels as a method of screening. However, there has
been considerable interest in analysis of gastric juice for CEA
and associated CEA-like proteins.
4 groups of workers (Fujimoto et al, 1979; Bunn et al,
1979; Satake et al, 1980 and Tatsuta et al, 1980) have
investigated the activity of gastric juice CEA in patients with
benign gastric disease and patients with gastric cancer. In these
studies elevated gastric CEA levels were found to be consistently
more accurate than plasm CEA levels ranging from 54.5-75%
elevation - for early gastric cancer and 52-100% for advanced
cases (see Table 1.5).
These reports were preliminary studies and supported the
potential of gastric juice over plasm CEA to identify early and
advanced gastric cancers but the specificity of the test does seem
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Sensitivity and specificity of gastric
Author Early Gastric Cancer
Bunn et al uncertain data
(1979)
Fujiiroto et al 6/8 75
(1979)
Tatsuta et al 12/22 54.5
(1980)
Satake et al 13/16 81.3
(1980)
juice CEA for cancer








to fall in the presence of active peptic disease. The authors
have therefore suggested that rather than general screening,
surveillance of "at risk" populations e.g. Pernicious Anaemia
patients (persistently elevated in the study of Bunn et al, 1979)
would he more valid.
True population screening for gastric cancer has been
performed using gastric juice analysis. Hakkinnen (1980) has used
not CEA but fetal sulphoglycoprotein antigen (FSA) to screen
40,000 individuals in a rural Finnish community. The coitpliance
rate was 75% and a positive rate on testing of 8.8%. Endosopy was
performed on nearly all FSA positive subjects (92.5%) and 35
cancers were identified plus one gastric carcinoid, 10 adenomas
and 45 peptic ulcers. In only 6 subjects with cancer were
symptoms present and subsequent surgical resection showed the
stages of the 35 cancers as follows: 19 Stage I; 6 Stage III; 10
Stage IV.
In the United Kingdom gastric juice analyses to detect
gastric cancer has been reported using a ratio of lactate
dehydrogenase and B-glucoronidase (Rogers et al, 1981). In this
study, 113 patients with dyspepsia were investigated fully
including gastric juice analysis. By mathematical manipulation an
index dependent on the ratio of LDH:B-glucuronidase could identify
41/42 cancers whilst maintaining a specificity of 89%. 2 of 3
early gastric cases were identified in this way. The authors
proposed this may be a suitable screening agent for high risk
populations such as the coal miners in the high incidence area of
South Wales.
No follow up data is available from these authors so one
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must conclude that this approach to screening for gastric cancer
has fallen from favour.
Non-specificity of the CEA Radioimmunoassay
Despite early support for the concept of CEA being colon
cancer specific (Thomson et al,1969; LoGerfo et al,1971) it soon
became clear that not only did other digestive and non-digestive
tract tumours exhibit elevated levels of CEA. but so did patients
with benign conditions of the liver, lungs and the gut.
Cross-reactivity of the CEA radioimmmunoassay with other tumours
LoGerfo et al (1971) demonstrated elevated CEA levels, not
only in the sera of patients with GI tract cancers but also in
tunours affecting lung, breast and prostate. The presence of CEA
titres in cancers other than the GI tract has since been widely
confirmed (Booth et al,1973; Meeker et al,1973; Hansen et
al,1974). Reynoso et al (1972) found an overall CEA positivity in
31% and 28% of patients with cancer of the male and female
genito-urinary tract respectively. Abnormal elevations of CEA were
also found in patients with lung cancer (70%) and breast cancer
(15.7%).
CEA levels in normal subjects and patients with benign conditions
A multi-institutional collaborative study on CEA in 10,000
patients in the United States, Canada and the United Kingdom using
the Z-Gel method of Hansen has been performed ( Hansen et al,
1974). Titres greater than 2.5 ng/ml (accepted normal level) were
observed in 8.3% of healthy individuals, while only 1.6% were
above 5 ng/ml. In this group the smoking history appeared to
interfere with the CEA titre, since 19% of the smokers had CEA
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levels above the normal range, while only 3% of non-smokers had
elevated levels. In those patients with benign disorders 34% had
levels of 2.6% or greater with the highest positive titres
observed in those patients with alcoholic cirrhosis, pulmonary
emphysema, pancreatitis, kidney transplant, granulomatous colitis
and alcohol addiction. The high false positive rate could be
reduced to 7.6% by considering titres above 5 ng/ml at the expense
of increasing the proportion of false negative results to 52.5% in
the group of patients with cancer (Hansen et al, 1974).
CEA has since been noted to be elevated in a considerable
number of benign conditions ranging from peptic ulceration,
pancreatitis, diverticulitis to benign liver diseases (Beatty et
al, 1979; Hansen et al, 1974; Miller et al, 1974; Moore et al,
1971, 1972b).
National Institute of Health consensus statement on CEA.
The extensive investigations of the role of CEA as a
single agent in the management of gastrointestinal cancer has
revealed that this irarker is insensitive, has a low specificity
and cross-reacts with other tumours. In the consensus view of the
NIH (1981) CEA is not suitable for screening an asymptoiratic
group, is unreliable in the detection of syirptomatic cancer and
has limited value in the monitoring of the postoperative patient.
Current use of CEA
CEA has been used in the postoperative surveillance of
cancer patients, and the response to chemotherapy ( Steele et al,
1980). New emphasis is now being placed on the potential for
immunoscintigraphy to detect tumours secreting CEA and also for
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targeting chemotherapeutic agents bound to anti-CEA monoclonal
antibodies at tumour deposits ( Britten and Granowska, 1985).
Combination of carcinoembryonic antigen with other tumour markers:
its role in the clinical diagnosis and assessment of patients
with digestive tract cancer
The measurement of different tumour-related substances in
conjunction with the CEA assay has been attempted in order to
iirprove the detection rate of gastrointestinal cancer. The
simultaneous assay of plasma CEA and serum enzymes such as gamma
glutamyl transpeptidase (GGT), (Steele et al, 1974); Munjal et al,
1976a; Miron et al, 1979) or phosphohexose isomerase (PHI),
(Munjal et al, 1976a-78) may be useful in the differentiation
between hepatomegaly due to metastatic cancer and benign hepatic
disorders. Furthermore, serial concomitant estimations of these
"markers" might predict liver recurrence weeks before clinical
confirmation (Cooper et al, 1975; 1976a; Cooper 1978a; Munjal et
al 1976a; Neville et al, 1978).
Ward et al (1977) applied a discriminant function for 70
preoperative patients with cancer of the colon with CEA and acute
phase reactant proteins (APRP's) measurements to predict those
patients who would develop metastases after 'curative' resection.
The combination proved significantly better as a prognostic
indicator than when using CEA levels alone. Rashid et al (1982)
similarly found that a combination of CEA + APRP's could identify
those patients with irresectible lesions and whose survival was
limited to a mean of 5 weeks. The differences in survival when
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both CEA and an APRP were raised were significantly lower p <
0.002 than when one or other marker was raised. The value of this
preoperative prognostic information is not clear other than
perhaps for future stratification of chemotherapy trials or
avoidance of surgery when palliation is not needed for symptoms.
The most interesting use of combinations of CEA and other
markers is in the preoperative diagnosis of gastrointestinal
malignancy with 3 groups of workers reporting stimulating
findings. Chu et al (1982) evaluated 72 subjects with colorectal
cancer preoperatively. Using CEA alone only 28.6% of Dukes' A,B
and C cases were identified, whilst AGP identified 43%
corresponding stages. Overall CEA detected 58% cancers with a 79%
specificity and AGP detected 57% cancers with an 81% specificity.
The combination of CEA + AGP increased the sensitivity for cancer
to 79% (p < 0.01) whilst the specificity becaire 67% (p > 0.10).
Further the detection of the Dukes' A, B & C cases rose from 29-
57% (p < 0.046). Walker and Gray (1983) reported similar findings
for the combination of CEA and the acute phase reactant, serum
protein hexase. In this study, CEA alone detected 29% Dukes' B
patients and 32% Dukes' C patients (28% overall). Protein hexose
was elevated in 71% Dukes B cases and 91% Dukes C cases (75%
overall). The addition of CEA and the APRP increased the overall
sensitivity to 79% (2 additional Dukes' B identified).
Unfortunately the authors have failed to indicate whether there
was any significant alteration in the specificity of the
combination of tumour markers for the 33 control subjects.
Finally, de Mello et al (1983) investigated the value of a
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battery of 6 non-specific tumour markers to determine the
preoperative diagnosis of cancer in 200 patients with gastric or
colorectal cancer. Using multivariate analysis the group was able
to predict 84% patients with cancer with only a 16% false positive
rate for the 73 controls studied. Furthermore the group
identified 85% Dukes' A & B colorectal lesions and 63% Stage I &
II gastric lesions.
From these three studies, there appears to be a pattern
emerging that the combination of 2 or more non-specific markers
will not only increase the identification of advanced cancers but
also will significantly increase the detection of early 'curable'
colorectal and gastric cancers. Furthermore, in these small
studies where recorded the increase in sensitivity does not
apparently lead to an undesirable fall in specificity.
It was these reports which raised the question of whether
a re-evaluation of the value of tumour markers in the detection of
early gastrointestinal cancer was feasible when used in
coirbination since one would rarely diagnose cancer on the basis
of a single symptom.
Acute Phase Reactant Proteins (APRP* s)
General Aspects
There are a great many proteins which fall into this group
e.g. caeruloplasmin, haptoglobin, fibrinogen and serum Amyloid A
but the commonest proteins investigated in relation to human
malignancies are alpha-l-acid glycoprotein (AGP) C-reactive
protein (CRP) and alpha-1-antithymotrypsin (ACT). Only AGP and CRP
will be discussed further.
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C-reactive protein comprises five identical covalent bound
units each of approxiirately 21,000 daltons molecular weight and
they join to form a pentagonal shape (Kushner et al, 1981).
Alpha-l-acid glycoprotein has a molecular weight of approximately
40,000 daltons, containing 45% carbohydrate in the moiety
(Schmidt, 1975). AGP does ejdiibit some microheterogeneity
especially related to glycosylation (Wells et al, 1981) and thus
appears to be influenced by endogenous oestrogens. CRP is a pure
peptide and is not altered by hormones.
The biological function of these proteins is not clear but
they derive this name of acute phase reactant proteins as part of
the host's response to injury. In addition to the containment and
removal of the injurious agent, removal of any damaged tissue and
repair and restoration of function, the inflamnatory response
stimulates an increase in the hepatic synthesis of proteins - the
acute phase reactants. Koj (1974) suggests that a humoral factor
is responsible for eliciting the acute phase phenomena through the
continuance of tissue necrosis and inflammation. Raised levels of
these proteins are therefore found in a multitude of illnesses
including cancer and are therefore a reflection of a non-specific
response to "injury".
Both CRP and AGP have been found in tissues in relation to
acute inflammatory change in arthritis and myocardial infarction
(Kushner et al, 1963; Kushner et al, 1980). Conflicting reports
appear in the literature as to whether APRP's can be localised to
tumour tissues. Twining and Brecher (1977) identified AGP in
breast, colon and stoirach cancers; however Uete et al (1970) were
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unable to localise CRP in gastric cancer tissue.
During tissue destruction, CRP and AGP nay reirain elevated
and at levels corresponding to the severity of tissue damage
(Fisher and Gill, 1975). Experiments in vitro have shown that CRP
(JVbrtensen et al, 1975, 1976) and AGP (Chiu et al, 1977) may
inhibit some immunological responses, such as lynphoblastogenesis
and mixed lymphocyte reactions. The suppressive effect was
predominantly directed upon T-cell mediated functions.
Furthermare, Kushner et al (1981) have shown that CRP will
activate complement and initiate phagocytosis by macrophages.
APRP's and cancer
Shetlar et al (1955) have proposed that raised circulating
levels of glycoproteins occur in carcinomata as a result of
cellular proliferation and inflamnation. Cooper and Stone (1979)
reported that a continuous rise in APRP's was associated with a
rapid course of a tumour and similarly Rashid et al (1982) have
reported a sudden and maintained elevation of APRP's immediately
prior to death.
Since the APRP's are a non-specific marker for tissue
injury they have not been used as a screening study to elicit
cancer. However, they have been shown to be present to high
levels in advanced tumours (Ward et al, 1977; Kelly et al, 1978).
Recent reports are available in the literature concerning
the sensitivity of AGP and CRP in the detection of colorectal and
gastric carcinomata. W&lker et al (1981) examined 104 patients
with a preoperative diagnosis of colorectal cancer and found 78
(75%) to have elevated AGP levels compared to only 33% with raised
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CEA levels. Cooper and 0'Quigley (1982) noted that 45% Dukes1 A +
B, 67% Dukes' C and 84.6% Dukes' D patients had raised APRP's
whilst Raynes and Cooper 1983 reported only 24.3% Dukes' A+B had
raised CRP, 47% Dukes' C and 90% Dukes' D patients were found to
have elevated preoperative CRP levels in this study.
'When they investigated 75 gastric cancer subjects, Raynes
and Cooper (1983) found that 8/50 patients with stage I-III had an
elevated CRP but 24 (96%) with advanced gastric cancer had CRP
level > 10 mg/l. Grindulis et al, (1981) reported 12/17 gastric
cancers had elevated CRP levels (70%) but that 22/52 subjects with
benign inflammatory conditions of the stomach also had elevated
CRP levels which were statistically indistinguishable from the
cancer range. This precluded their routine investigation in the
opinion of the authors as the overall specificity of the CRP was
75%.
Finally, in parallel with studies of gastric juice for CEA
levels, Rapp et al (1972) measured AGP levels in gastric juice and
found an elevation in 89% of 34 individuals with gastric cancer
and only in 12% with peptic disorders.
In summary, the APRP's are even less specific than CEA and
as with that marker elevated levels when present in cancer tend to
be associated with advanced disease.
Gamma-Glutamyl Transpeptidase
Gamma-glutamyl transpeptidase (EC 2.3.2.2) is a membrane
bound glycoprotein which catalyses the transfer of gamma-glutamyl
groups between peptides or amino acids (Rosalki 1975; Tate and
Rose 1977). The physiological function of GGT is thought to
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involve the mediation of amino acid translocation across cell
membranes (Griffiths et al, 1979). Although the highest
concentration of GGT is found in the brush border lining the
luminal surface of the cells of the proximal convoluted tubules of
the kidney, the enzyme has been demonstrated in a variety of other
hunan tissues and body fluids (Rosalki, 1975).
The major role of the enzyme is as an indicator of
hepatobiliary dysfunction and has been used to screen for alcohol
abuse (Rosalki and Ray 1972; Rolleson et al, 1972). However, in
a major review of the clinical value of GGT as an indicator of
hepatobiliary disease of benign origin, Penn and Worthington
(1983) have seriously questioned the need for the test to be
performed in a clinical laboratory in preference to the standard
liver function tests.
In the diagnosis of gastrointestinal cancer an elevated
GGT is taken to indicate the possible presence of hepatic
metastases. Preliminary studies revealed that approximately 90%
of anicteric patients with liver replacement by tumour presented
with abnormal levels in their blood (Ruteriburg et al, 1963; Kokot
et al, 1965; Aronsen et al, 1970). However, further reports have
not confirmed these initial findings and a fall in the sensitivity
of the assay was noted with a significant increase in the number
of false positive results (Baden et al, 1971; Irvin et al, 1973;
Aimersjo et al, 1976; Beck et al, 1979). Furthermore, its
measurement was not superior in this context to conventional liver
function tests (Baden et al, 1971; Irvin et al, 1973). Moreover,
transient elevations have been observed in the immediate
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postoperative period after curative resection of colorectal
carcinoma (Steele et al, 1974; Beck et al, 1979).
Thus in isolation, gamma-glutamyl transpeptidase has
little in the way of sensitivity or specificity to indicate liver
dysfunction secondary to metastases. However, in the following
section the interaction of GGT and other "tumour markers" can
indicate a role for GGT in cancer patients.
Questionnaire
General
The use of questionnaires is now commonplace in medical
research. The range of practice is broad, varying from defining
risk of heart disease in civil servants (Rose et al, 1977)
adjuncts to medical history taking (Brodnan et al, 1951; Pecaroro
et al, 1979; Guitpel and IVhson, 1974) to highly sophisticated
psychology research (Becker 1976). It is not surprising,
therefore, that there should be interest in the use of
questionnaires to screen for colorectal neoplasia (Siliran et al,
1983; Farrands and Hardcastle, 1984) or to predict risk of
gastric disease, including gastric cancer, on the basis of a
questionnaire response (f^hnn et al 1983).
The value of self-administered questionnaires used for
whichever purpose, is that they are generally quick to complete,
cheap to use and readily acceptable to the population. Providing
that the basic principles of questionnaire design are followed
(Opperiheim, 1978; Pecaroro et al, 1979) the data so collected will
also be reproducible, consistent and not subject to the bias that
can occur from visual and voice clues given in an informal
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interview (Collen et al, 1969).
Questionnaire and Colorectal Cancer Screening
Schewe et al (1979) suggested that a symptom questionnaire
may identify those individuals with cancer of the large bowel who
were FOB negative. Whilst this was based on a hospital population
it was felt that there nay be some value for symptoms as markers
of colonic cancer in general screening.
Until recently, there has been little evidence to support
symptom screening for colorectal neoplasia. Most studies of
symptomatic cancer patients have shown that there is no
relationship between length of symptoms and stage of cancer at
diagnosis. Whilst Keddie and Hargreaves (1968), Irwin & Greaney
(1977) and Holliday and Hardcastle (1979) showed no correlation at
all between duration of symptoms and stage IVfcDermott et al (1981)
have shown that the longer the symptoms were present the better
was the prognosis. Further Welch and Donaldson (1974) reported
their experience at the ffessachusetts General Hospital, Boston
where they reduced the delay in patient presentation from 7 months
to 2 months before treatment but found no alteration in the number
of localised and advanced lesions at laparotoiry.
Another fundamental obstacle to the use of a questionnaire
to screen for colorectal neoplasia is the prevalence of synptoms
normally taken to indicate significant pathology of the colon and
rectum within the population at large. Thus Thomson and Heaton
(1980) in a study of 301 apparently healthy individuals found that
62 regularly experienced abdominal pain and in 41 of these the
pain was relieved by defaecation. 31 further individuals were
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regularly constipated and 14 experienced episodic diarrhoea.
Jones (1976) also noted 36 of 112 normal adults had rectal
bleeding at some time and 72% were prone to episodic diarrhoea.
Thus any questionnaire to detect just such symptoms at a given
moment in tine might select a large proportion of the general
public for further investigation.
Similarly, the symptoms of large bowel dysfunction nay
well be secondary to benign pathology and not just malignancy.
Tada et al (1978) used a questionnaire in 304 patients, who were a
mixture of referred and screening individuals and found that the
analysis of symptoms could not distinguish early colon cancer or
colonic polyps from normal individuals who showed similar synptom
distributions. Clanp and Wenham (1984) have shown that in
"symptomatic" individuals the use of a structured questionnaire,
whose data can be analysed by miroconputer, can accurately predict
the presence of colorectal cancer (83%) and that this prediction
would be enhanced by the use of FOB testing (93% sensitivity).
Despite the theoretical and practical considerations
above, two groups of workers have explored the value of self-
coirpleted synptom questionnaires as part of a colorectal neoplasia
screening study (Silman et al 1983; Farrands and Hardcastle 1984).
Silnan and his colleagues investigated 1195 individuals
aged over 40 years from a working population. A 9 item
questionnaire to elicit bowel synptoms was used in conjunction
with FOB testing to screen for colorectal neoplasia. 28 (3.1%)
individuals were Haenoccult positive and 114 (12.4%) had one or
more synptoms. All positives (129 persons) were examined by
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flexible sigmoidoscopy and barium enema. No cancer was found but
7 subjects with adenomas greater than 1 cm were discovered. Each
of the 7 patients reported at least one symptom (dark red bleeding
in 4, bright red bleeding in 2 and diarrhoea in 1) and 6 were
Haemoccult positive. There was no individual with a Haemoccult
positive adenoma without symptoms. Predictive values for these
adenomas for Haemoccult positive tests (21%) self-reported dark
bleeding (15%) and diarrhoea (17%) were significantly higher than
for other symptoms. As with Clamp and Wenham (1984) it was found
that the predictive value rose significantly to 46% for Haemoccult
positive individuals who had at least one symptom (p < 0.05) and
to 57% when a positive FOB was associated with dark red bleeding.
Siliman and his colleagues drew up three conclusions
regarding their study: (a) FOB testing nay not be identifying
"asymptomatic" patients as often as had been previously thought;
(b) the addition of self-reported large bowel symptoms improves
the performance of Haemoccult as a screening test and (c) the
presence of dark red bleeding, which can be ascertained using a
symptom questionaire, has a predictive value for adenomas over 1
cm, comparable with Haemoccult and thus may have a separate role
in screening.
By contrast Farrands and Hardcastle (1984) concluded that
self-reported symptom questionnaires were of little value in the
early detection of colorectal neoplasia. In their study, using a
very simple 5 item questionnaire plus FOB's to screen, 527
questionnaires and 483 FOB's were available for analysis.
Colonoscopy revealed 6 of the 12 individuals positive for one or
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more Haemoccult slide had significant colorectal neoplasia (2
cancers; 4 polyps). This represents a predictive yield of 50%.
The responses to the questionnaire revealed 128 (24.4%) had one or
more positive synptoms. On full investigation of these
individuals only one was found to harbour any neoplastic lesion,
revealing an 85% false negative rate and a positive predictive
yield of 0.78%. The authors' conclusions were that symptom
questionnaires were of little value in colorectal cancer screening
compared to FOB testing.
Questionnaires and Gastric cancer
Early gastric cancer (EGG) has been reported by several
workers to be symptomatic (Table 1.6) and that these symptoms may
be present for nany months prior to diagnosis (Fielding et al
1980; Green et al 1981; Correia et al 1981; Rosch 1981).
The commonest symptom is that of upper abdominal pain or
discomfort ranging from 28.9% cases in the Birmingham study
(Fielding et al 1980) to 92% in the Portugese study (Correia et
al, 1981), whilst an unexpectedly high incidence of
gastrointestinal haemorrhage 24-32% was noted by Rosch (1981),
Green et al (1981) and Correia et al (1981).
The duration of symptoms in these patients with EGC ranged
widely between the studies. The Birmingham study (Fielding et al
1980) revealed that only 15.6% patients had experienced synptoms
for more than one year, whilst Green and his colleagues (1981)
noted that the mean duration of symptoms for EGC was 36 months
compared to 6 months for advanced cancer. Correia et al (1981)
found that 50% patients had experienced synptoms related to EGC




Incidence (%) of synptoms in Early Gastric Cancer
Abdo Pain Weight loss Vomiting GI haemorrhage
Fielding et al
(1980) 28.9 18.9 23.3 6.6
Green et al
(1981) 82 'low' - 32.1
Correia et al
(1981) 92 62.5 68.4 31.6
Rosch
(1981) 74 41 32 24
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These features would suggest that there nay be a potential
role for a symptom questionnaire to screen for EGC. Unfortunately
there are a great many factors that have conspired against
previous attempts to identify cancer or peptic ulcer on the basis
of synptoms.
One such factor is the prevalence of symptoms within the
population at large. Whilst the true prevalence of "dyspeptic"
symptoms within the population is unknown, audit of GP referral
patterns have shown that 1% of all visits to the GP relate to
upper GI, "dyspeptic" symptoms (Gear and Barnes, 1980). A postal
survey of a North East Scotland practice revealed 29% had
experienced symptoms suggestive of peptic ulceration at some time
(Weir et al, 1967).
If we consider the incidence of symptoms commonly seen in
EGC with that found in patients presenting with benign disease it
is also difficult to discriminate between the two. Horrocks et al
(1978) reported an analysis of 360 patients carefully assessed and
followed through surgery. The incidence of upper GI pain was
clearly high in both groups with little to distinguish between
cancer pain (except the degree of periodicity) from duodenal or
gastric ulcer pain. Similarly, it was noted that weight loss of
more than 4 kg in the weeks preceding diagnosis was noted in 85%
of patients subsequently found to harbour gastric cancer, but also
a similar degree of weight loss was found in patients with gastric
ulcer (62%), duodenal ulcer (44%), non-ulcer dyspepsia (32%) and
finally in cholecystitis (23%). This group concluded that the
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symptoms of gastric cancer were vague and difficult to distinguish
from those of other gastroduodenal diseases.
Thus in clinical practice if an audit is performed of
those patients investigated by either barium meal examination or
upper gastrointestinal endoscopy, it is not uncommon to find that
only 20% of those examined will exhibit pathological abnormalities
(Table 1.7). The principal diagnoses as shown in the table are
duodenal ulcer, gastric ulcer, with gastric cancer accounting for
only 1% of all cases except in highly select studies.
Read et al (1982) reviewed 1286 cases investigated for
'dyspeptic' symptoms in the literature and found that only 1.4%
cases revealed a gastric nalignancy.
It is little wonder therefore that many workers have felt
that symptom analysis has little in the way of predictive value
when considering the aetiology of upper gastrointestinal synptoms
(Mead et al 1977, Horrocks et al, 1978; Marton et al, 1980; Ross
and Dutton 1972; Scheinok and Rinaldo 1967, Editorial BMJ 1978,
and Mallnan et al, 1975). However a recent report from IVhnn et al
(1983) has again raised the possible value of symptom analysis to
determine risk of an individual's symptoms representing
'significant' gastroduodenal disease and therefore determining
priority for investigation.
In this study, a multivariate analysis of the symptoms
elicited by a questionnaire of 235 individuals referred for upper
gastrointestinal endoscopy was performed. The analysis was
designed to identify those patients with either peptic ulcer
gastric cancer or peptic stricture and a predictive equation of
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Table 1.7
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the 6 discriminatory factors was found. This equation was then
applied prospectively to 356 patients similarly referred for
endoscopy. The system was able to accurately identify 587
patients with the above three conditions whilst reducing the
number of investigations (in theory by 30%). In the study, all 52
cancers were recognised by the scoring index devised.
The application of this multivariate approach to the
analysis of gastrointestinal symptoms seemed an appropriate
pathway to follow in the search for a simple and cheap screening
filter for gastric cancer, with implications also for colorectal
screening.
What factors affect compliance?
General Review
Compliance is defined as "Action in accordance with a
request or command" (Oxford English Dictionary, 1979) and
compliance for medical advice or treatment is low generally
(Eraker et al, 1984). Compliance for screening tests is a
critical factor in the potential cost effectiveness of such
programmes and as such is worthy of considerable attention, yet
few factors are appreciated which will influence response or non-
response to screening opportunities. The largest experience in
screening for cancer is in cervical and breast cancer where
compliance rates range from 5%-65% for breast cancer (Chamberlain,
1975; Shapiro, 1978) and l7%-95% for cervical cancer (Sansom,
1972; Cardiff Cervical Cytology Study, 1980).
Certain general factors which influence response to
screening have been elicited from screening for cervical and
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breast cancer. Age and social class are factors one would
consider as being important determinates of screening activity.
Wakefield and Sansom (1966) have shown that increasing age and
lower social class were associated with low compliance for
cervical cancer. Similarly, the Cardiff Cervical Cytology Study
(1980) found the largest compliance group to be aged 25-29 years
were also members of social class I (95% conpliance), coirpared
with the lowest coirpliance group social class V (20%), who were
older than 60 years.
It has also been shown that the method of pronntion and
the person promoting screening influences compliance for breast
and cervical cancer. Thus when a general practitioner extends a
written invitation to attend a screening clinic for breast cancer,
the response ranges from 57% (Hobbs et al, 1980) to 82% (Edinburgh
Breast Screening Clinic, 1978) and compares favourably with the
open access approach to a clinic experienced by Chamberlain et al
1975. Cullum and Savory (1983) have investigated the question of
who should perform cervical screening and found that the practice
nurse or midwife is likely to be most successful in screening
young women than the GP or Family Planning Clinics.
Factors Affecting Conpliance in Colorectal Cancer Screening with
Faecal Occult Blood Testing
Several factors affect conpliance for screening for all
cancers including age, sex and social class. However, the method
of promotion of faecal occult blood testing appears also to be
iirportant. These factors will now be reviewed.
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Age, Sex and Social Class
Hardcastle et al (1983), Farrands et al (1981) and Million
et al (1982) have all reported a falling compliance rate with
increasing age. In these three studies conpliance for individuals
over 70 years was between 17%-27%, whilst in those subjects aged
65 years or less, the range of compliance was 30%-40%.
Hardcastle et al (1983) also revealed a significant
difference in compliance between the sexes where 1940 ( 38.4%)
women complied with FOB testing, compared to 1673 (35.1%) men.
Both Farrands et al (1981) and Million et al (1982)
suggest that social class affects compliance and that the low
compliance they experienced in their studies, 27% and 32.4%
respectively, was due to the preponderance of lower social class
members in their studies, compared to that of Hardcastle et al
(1980) where the return of completed FOB's was 45%. However,
social class is not necessarily the sole determinant of screening
for colorectal cancer using POB's, since Dent et al (1980) have
shown that in a study of over 300 hospital workers it was the
"blue collar" workers and not the doctors or nurses who were more
likely to comply.
Promotion of Faecal Occult Blood Testing for Colorectal Cancer
Screening
When the FOB test was introduced as part of a regular
health check-up facility, it was found to be accepted by the
motivated group of volunteers. For example, Fruhmorgen and
Demling (1978) found that 83.5% of 6,007 individuals attending the
Erlangen clinic completed the FOB test when first introduced. In
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the United States, Winawer et al (1977) reported that in addition
to signoidoscopic examination, 85% of 6597 individuals accepted
FOB as part of their screening routine. Furthermore, Gilbertsen
et al (1980) have reported that 85% of 48,000 individuals
attending the University of Minnesota Medical Centre accepted the
addition of FOB's to their usual examination.
When the FOB test is introduced de novo to an unselected
population, then a markedly lowered compliance rate can be
expected (Table 1.8). In the United Kingdom, where 3 studies have
employed postal delivery of the FOB test, the return rates of
completed FOB were 27%, 36.9% and 45% (Farrands et al 1981;
Hardcastle et al 1983; Hardcastle et al, 1980). In further
studies, following a letter of invitation to screen from the GP,
those willing to participate either collected the FOB personally
from the GP surgery (Lallemand et al, 1984) or contacted the GP
and were visited and counselled by a State Registered Nurse
(Million et al, 1982). In these studies the response rates were
42% (after 2nd letter, Lallemand et al 1984) and 32.4% (Million et
al, 1982).
In all these studies, personalized letters from the
subject's own GP, were sent as experience in breast cancer
screening had suggested this to be the mast favourable input
(Hobbs et al, 1980; Edinburgh Breast Screening Clinic 1978).
Similar experiences have been reported in West Germany and
the United States where Durst, Newmann and Schmidt (1976) found
only 28% persons accepted screening and Helfrick Petrucci and Webb
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programme in Washington DC.
These unacceptably low levels of compliance have led to an
exploration of alternative approaches to the public for the
promotion of FOB testing. Elwocd, Erikson and Liebermann (1978)
examined 5 methods of promotion varying in the extent of personal
or impersonal contact. In this study, 11,115 members of the
American Association of Retired Persons were either sent a letter
of explanation and asked to reply if they wished to complete an
FOB test to conplete, or they were simply sent the FOB pack
direct. The third approach was to attend a hospital clinic and
the fourth and fifth approaches were either as a part of a group
meeting or a direct consultation at hone. The response rates were
from 8.6% for the clinic attendance approach, 13.6% for those
writing to request an FOB, 15.4% coirpleted the test when sent
direct, 28.7% responded to the group meeting and 20.4% to the home
visit.
Hoogewerf et al (1981) have further investigated the value
of the home visit. Their study comprised 152 patients and those
who failed to return an FOB within a week were visited at home by
a district nurse up to 3 times per individual. Compliance rose to
74%, but clearly is not practicable in mass population screening.
Further support for the role of personal contact, as a means for
promotiig FOB testing, is found in Hardcastle et al's study (1983)
where prior interview during which colorectal cancer and the test
were discussed, raised compliance to 51.6% compared to an overall
36.9% (P < 0.0001). Hastings (1974) found increased compliance for
POB's following rectal examination.
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Several workers "have evaluated the workplace as a site for
the promotion of the FOB test. Silman et al (1983) approached two
large industrial organisations to perform FOB testing on their
errployees. 1806 eirployers were approached by letter inviting them
to participate. 1195 responded and were sent FOB tests. A
follow-up letter was sent if an FOB was not returned complete.
During the promotion period lectures, leaflets and group
discussions were arranged for the employees. 916 subjects (50.7%)
returned a conpleted FOB.
Lee (1983), similarly, performed screening in 2 factory
based populations. In one factory, where the workforce was used
to an annual physical examination, 45% (989) men conpleted the FOB
test, whereas in those who received the invitation to screen in
their pay packet and who did not receive annual physical
examinations, only 22% (1431) men participated.
Miller and Knight (1977) had a 94% return in their study,
offering POB's to military personnel at the Mather Air Force Base.
Unfortunately, the true compliance for the study is not known
since there was extensive publicity aimed at both active and
retired personnel. However, it would seem that the armed forces
are used to physical examination and subject to certain discipline
which would explain the high return rate seen.
One obvious approach for the promotion of nass screening
with FOB testing is the use of the media. In the United States, 3
large studies have been performed utilising extensive TV and
newspaper coverage. Whilst Richardson (1977) and Bralow and Kopel
(1979) experienced high compliance rates (85% and 79%
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respectively), Winchester et al (1980) in Chicago, despite 5
promotions on the TV news, radio and newspaper coverage despatched
54,101 FOB's and received only 14,074 ( 26%) completed FOB's.
Similarly, in the "Frome experiment" Farrands et al (1981) found
in the UK despite extensive advertising, the response rate for FOB
testing was only 27%.
Compliance for Gastric Cancer Screening
The main thrust of gastric cancer screening is in Japan.
Unfortunately, there is no fixed policy for screening which varies
from self-presentation to a clinic to attending a mobile screening
clinic which attends the workplace. Also patients who are
symptomatic and who may also be referred by their GP1s are
included in the data. The information that is published in the
English literature is therefore confusing and limited in volume.
Hirayama (1978) shows that screening however does vary by
age and sex. In 1975, of the total adult population of Japan,
3.4% males and 2.3% females were screened. The peak age for
screening was 45-55 years, where 7.5% men and 5.4% women underwent
screening. However, selection bias may be strong since a great
deal of screening appears to be aimed at factory workers (Kaneko
et al, 1977).
Hakkinen (1980), in Finland, found a surprisingly high
compliance of 74% of a rural population invited to provide gastric
aspirates for fetal sulphaglycoprotein. Such high compliance rates
are also found for cervical and breast cancer screening in
Scandinavian countries (Lundgren, 1979; Hakama et al, 1979).
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In the United Kingdom, where screening has focused on
endoscopy to the post-gastric surgery group, less than 50% have
attended for gastroscopy despite the majority being under regular
hospital follow-up (Savage and Jones, 1979; Farrands et al, 1983;
Pickford et al 1984).
Attitudes to Cancer and Cancer Screening
For many years it has been apparent behavioural scientists
that health activity is not due to one or two sociodenographic
factors, but to the sum of the interaction of many perceptive
factors and past experiences. Becker (1974) and Cummins et al
(1977) have extensively investigated mothers who failed to have
their children immunised and developed a model to explain their
response or non-response to the preventive approach.
He has termed this model "the health belief model" (HBM)
and it takes into account 6 broad factors which determine any
health action. These factors are:
1. Readiness to be concerned about health matters.
2. Perception of vulnerability to the illness concerned.
3. Belief about the severity of the illness.
4. Belief about the effectiveness of the treatment.
5. Belief about possible harm or cost.
6. Reaction to cues (e.g. invitations) which might
trigger a response.
Only 2 groups have previously examined the role of the HBM
in colorectal screening. Dent and Goulston (1980) performed a
small study and showed some iterit to this approach. Halper et al
(1980) examined 1143 subjects at first presentation to the Strang
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Clinic, Sloan Kettering Hospital, New York using the HBM
questionnaire. They found three basic differences between
compilers and non-compliers for the FOB test. Firstly, non-
compliers seemed reluctant to see doctors, reported less illness
and were less likely to have had a recent medical than compilers.
Secondly, non-cornpliers viewed cancer as mare disruptive and life-
threatening than compilers and may have been fearful to complete
the FOB test whose aim is to detect cancer. Finally, the
alteration in diet required for the FOB test was seen as an
intrusion into the lives of the non-compliers.
The Strang group are cautious as to the interpretation of
their data, but clearly there are different psychological concepts
interacting here to determine health activity and that simple
concepts of age and sex alone will not readily identify reasons
for compliance and non-compliance for screening activities.
However, this study has only looked at a very select population
who for whatever reasons have still volunteered for a health
check-up and do not represent the population as a whole. There is
a need, therefore, to in6estigate a itore representative group
approached during a mass screening programme, using the health
belief nodel, to identify those factors which lead to non-
conpliance. In this way, new strategies could be devised to make
colorectal screening itore acceptable to the population at large.
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Summary and State of the Art
To date there is no single biochemical marker available to
identify pre-operatively an early, curable gastric or colorectal
cancer.
Faecal occult blood testing (table 1.9) is plagued by
problems including a high false negative rate for colorectal
cancers and adenomas with associated variations in false
positivity depending on rehydration and dietary factors.
There is conflict as to whether syirptom questionnaires
have a role to play in the earlier detection of colorectal
neoplasia or in the preliminary assessment of patients with
dyspepsia to determine priority of investigation to exclude
gastric cancer.
Screening for gastric cancer in the Western world is not
feasable due to a low prevalence and a falling incidence. Case-
finding studies in 'high risk' groups are complicated by such
groups being poor indicants of gastric cancer.
Compliance for screening programmes for any common cancer
in the UK is low and particularly for FOB testing. The factors
affecting the individual's decision to respond to a screening
invitation are also poorly understood and researched.
In the following chapters, these areas will be pursued
with particular reference to:
(1) the interaction of several biochemical markers to the
preoperative detection of gastric and colorectal cancer.
(2) the sensitivity and predictive yields of three guaiac
based FOB tests in screening for colorectal neoplasia
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Table 1.9
State of the Art in Screening for Colorectal and Gastric Cancer
COLORECTAL CANCER
Haemoccult testing
Rate of Positive slides 1-5%
Predictive Value 18-50%
False positive rate 2-20%
False negative for cancer 9-31%





Low Prevalence and falling incidence in UK
No simple non-invasive screening agent
"High risk" groups are poor indicators of cancer
Low compliance for endoscopic screening in "risk" groups
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(3) the development and applicability of a symptom
questionnaire to detect gastric and colorectal cancer in
the community and 'at risk' groups.
(4) to investigate the factors affecting compliance for
cancer screening in the community.
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CHAPTER 2
Screening for colorectal cancer and gastric cancer
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Introduction
Colorectal cancer screening with Haemoccult as indicated
in the introduction has the shortcomings of a high false negative
rate, a moderate false positive rate and a low compliance rate.
In order to reduce the false negative detection of cancer
with FOB testing two approaches have been proposed; the first to
use a questionnaire to detect any symptomtic cancers not
producing positive faecal occult blood tests and secondly, to use
a more sensitive FOB test.
Schewe et al (1979) proposed the use of a questionnaire to
elicit symptomatic cancers and this challenge has been taken up
with conflicting results in the United Kingdom. On the positive
side, Silman and colleagues (1983) noted that all seven polyps
detected in their screening study were symptomatic and that the
predictive yield for investigation of an individual with a
positive response to one of their nine bowel syiptoms (dark red
bleeding) was equivalent to that of a positive FOB. Contradicting
these results, Farrands et al (1984) found a false negative rate
for the questionnaire compared to FOB testing was 83% and the
yield of investigation of a positive response to their five item
questionnaire was 1.8%, corrpared with 50% for the Haemoccult test.
Lee and Costello (1982) have advocated the use of a more
sensitive guaiac test Fecatest to reduce the false negative rate.
In their comparative study of FOB testing with Haemoccult and
Fecatest they found that the lesions missed by Haemoccult were
indeed detected by Fecatest. However, the positive rate for the
Fecatest also rose to 5.8% conpared to 2.5% for Haemoccult. They
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felt, however, that the positive rate was within manageable
limits.
Both these approaches are worthy of further investigation
in a screening study and the following account reveals an
examination of the value of a self-administered synptom
questionnaire on screening for colorectal cancer and also the
value of using three guaiac based FOB's of different sensitivities
to detect colorectal neoplasia.
Gastric cancer screening in this country does not exist as
an entity although studies of post-gastrectomy patients using
endoscopy as the screening agent have been performed. Since it is
known that early gastric cancer is symptomatic (Fielding et
al,1980; Rosch,198i) a survey of upper gastrointestinal symptoms
using the questionnaire will also be performed. The data derived
from this pilot study will be assessed to determine the possible
value of investigating individual 'dyspeptic' symptoms in a




(1) To produce a valid questionnaire for use in the screening
study.
(2) To assess the ability of the questionnaire to detect
colorectal neoplasia in the community.
3) To compare the sensitivity and predictive yield of three
commercially available FOB tests.
(4) To compare the predictive yield for colorectal neoplasia of
the questionnaire and the FOB tests.




One thousand and eighty three individuals from 6 urban
practices in Leeds were invited over a 15 month period to take
part in the study. The subjects were enrolled into the study by
one of two methods which will be fully discussed in the compliance
section.
Each practice was a group practice with 4-6 partners and
together they represent a wide cross-section of the population of
Leeds.
(i) Street Lane Practice
This is a 5 man practice serving 11,000 patients in an
expensive suburb of Leeds. The majority of the housing is
privately owned, with the residents being mainly professional
people.
(ii) Slaid Hill Practice
Four GP's serve 4,000 patients. The majority of these
subjects are business owners or professional people, who own their
houses.
(iii) Burmantofts Health Centre
This practice coirprises 4,500 patients served by the same
4 GP's as the Slaid Hill practice. The patients are minly housed
in high-rise flats which are rented from Leeds Corporation. There
is a high level of unemployment in this practice.
(iv) Shaftesbury Health Centre
Six GP's serve 13,000 patients. There is a high level of
unemployment within this practice, which covers a corporation
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housing estate that has the third highest crime rate in the United
Kingdom.
(v) Chapeltown Health Centre
This practice of 9,000 patients is served by 5 GP's. A
high proportion of the patients are Asian or West Indian.
Uneirployment is high and few individuals own their houses.
(vi) Meanwood Health Centre
Six GP's serve 13,000 patients. There is a very broad mix
of social class groups in this practice.
Criteria for entry to study
Each subject was required to fulfil four requirements to
enter the study. He/she should be aged between 50-70 years, not
have any previous history of gastrointestinal malignancy or be on
any medication for GI disease and finally, at the time of
presentation to have had no recent consultation with his/her GP
with GI syirptoms.
Detection of Neoplastic Disease
(1) Agents
(a) Faecal Occult Blood Testing
3 commercially available guaiac based FOB tests,
Haemoccult, Fecatest and Hema-chek, were used in this study.
The Haemoccult (Eaton Laboratories) package contains 3
cardboard test envelopes with 6 applicators for taking sairples of
stool. On three consecutive days the patient takes a pea-size
sample from two parts of the stool and spreads them onto the two
red-framed openings inside the test envelope. If the patient
misses a day he is requested to take samples from his next stool.
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The three envelopes are then returned for testing.
No dietary restriction, other than reduction of Vitamin C
intake is required when using Haemoccult. No rehydration prior to
testing is required. A positve test is defined as the presence of
a blue colour within 30 seconds (Fig 2). Cost;- £1.50
Hema-chek is similar to Haemoccult in that two separate
sanples from three motions are required for testing. However
dietary restriction is recommended for two days prior to testing
and also during the collection of the samples. The subject should
not eat meat, turnips, horseradish or medicines containing aspirin
or Vitamin C. He my eat snail amounts of chicken, tuna fish,
peanuts and bran cereal and is permitted lots of vegetables and
fruit. Rehydration with one drop of water immediately prior to
testing is also recommended. A positive test is the appearance of
a blue colour on the slide within 30 seconds. Cost:- £ 1.25
Fecatest is supplied as a well designed package containing
three robust plastic containers for the sarrple collection (Fig 1).
Only one sanple per day on three days is required. Due to the
extreme sensitivity of the test strong emphasis is placed on the
dietary restrictions listed above being adhered to in order to
reduce any false positive tests. No rehydration is required
unless the specimen is dry and the guaiac paper is unmarked when
one drop of water should be applied to the sample before testing.
Cost:- £1.75
Each individual received one of the packages and was given
counselling on diet and instructions for conpletion of the test.
Haemoccult was available at the commencement of the study and was
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extensively used. When Fecatest and Herra-chek became available
then each agent was used for a 4 week period in rotation.
On coupletion of the package the patient returned the
POB's in the prepaid envelope to St. James's University Hospital
for testing. The author performed all the tests. Any blue
discoloration on the addition of the hydrogen peroxide within the
30 second period constituted a positive test (Fig 2) requiring
full assessment by digital examination of the rectum, proctoscopy,
fibreoptic sigmoidoscopy and double contrast barium enema.
(b) Symptom Questionnaire
The questionnaire consisted of 41 questions. These dealt
with 18 specific gastrointestinal symptoms as well as 8 genito¬
urinary and cardio-respiratory questions. Past medical history,
drug history, family history of stomach and bowel disease were
also included as any symptom responses gained may be influenced by
these factors or their interpretation altered. Specific questions
relating to smoking, alcohol and arthritis were included as they
not only have an aetiological impact on GI disease but can also
produce variations in the levels of tumour markers.
The final choice of questions was derived from a number of
sources. Other questionnaires in observed use were reviewed in
particular the Cornell Medical Index (Brodman, 1951), the Strang
Clinic questionnaire (courtesy of Dr. Helen Miller) in the United
States and the questionnaires used by Grumpel and Mason (1974) and
by Silrnan et al (1983) in this country. A number of questions
were derived and modified from these. Following discussions with
colleagues in the Department of Surgery at St. James's University
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Hospital several new questions were devised for final inclusion.
The format selected was a deliberately simple one. Each
question was followed by two boxes in which according to the
answer reqired a tick is placed to indicate yes or no. This
closed format of question only allowing one or other response was
felt to be the simplest available and therefore most valid for
general use. It would be possible to answer only 36 questions as
a negative response to certain questions lead to missing out the
next question.
Methodology
The general scheme is shown in the flow diagram opposite
(fig 3). Each subject completed the questionnaire to the best of
their ability at the time of consultation. Any person unable or
unwilling to complete the form was then asked the questions by the
investigator but a note was made that this was a failure of the
method.
Any symptoms elicited by the questionnaire were expanded
upon at this time. A record was then made in a logbook as to
whether in the investigator's opinion the patient would require
further assessment of these syirptoms. These individuals would be
reviewed in a further 4 weeks and if still symptomatic were
offered appropriate investigation.
Instructions for the completion of the FOB tests were also
given at this time plus appropriate dietary advice. The specimens
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No action was taken where the results were considered
normal. For patients with positive results, further consultation
was arranged in the GP's surgery to review any symptoms and to
discuss the need for further investigations.
Suspected bowel disease was assessed by digital
examination of the rectum, proctoscopy and fibreoptic
sigmoidoscopy. All patients with a positive FOB also underwent
double contrast barium enema. Those with upper GI symptoms either
were subjected to gastroscopy or appropriate radiological studies.
All endoscopies were performed by the author.
Diagnosis and Treatment of Neoplastic Disease
All biopsy specimens were reported by the Pathology
Department at St. James's Hospital. Any patient found to have an
adenomatous polyp was referred for colonoscopic poylpectomy and
italignancy was dealt with as indicated by routine clinical
criteria.
Follow-up of screened individuals
Each subject was flagged for instant notification to the
investigator of the diagnosis of cancer via the Regional Cancer
Registry. Regular review of the pathology reports of newly
diagnosed GI cancers was undertaken to identify any false negative
cases for the study and all the GP records have been personally
reviewed by the investigator at one year.
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Validation of the questionnaire to elicit symptoms.
The questionnaire underwent a pilot study to determine its
validity before general use in the screening situation. Validity
in this context was felt to encoitpass five aspects: (i) to be
acceptable to the population under study; (ii) to be easily
conpleted; (iii) to be consistent i.e. responses are similar to
those gained in a conventional doctor-patient interview; (iv) to
be reproducible when elicited on two separate occasions; (v) to be
of value or use when complete. The steps taken to validate this
questionnaire are now described. A copy of the questionnaire is
printed opposite and in Appendix A.
Patients
144 subjects were enrolled and divided into 3 groups: 69
were 'normal' individuals who were not attending hospital clinics
and who were aged over 50 years; 40 subjects were inpatients with
proven benign gastrointestinal conditions and 35 individuals had
proven GI cancer.
Questionnaire
As indicated above the format of the questionnaire was a
series of closed questions followed by two boxes. A tick in the
appropriate box indicated either a positive or negative response.
Methods
All 144 subjects were required to complete the
questionnaire unaided to assess its acceptability and feasability
of completion. A test-retest system was used to assess the
reproducibility of the responses, 20 subjects being required to
coirplete a second questionnaire after a 2 week interval.
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THE DEPARTMENT OF SURGERY AT ST. JAMES'S HOSPITAL IN CONJUNCTION WITH LOCAL
G.P.'S IS TRYING TO COMPOSE A SIMPLE FORM OF QUESTIONNAIRE VHICH WILL LEAD TO
EARLIER DETECTION OF VARIOUS DISEASES
COULD YOU PLEASE FILL IN THE QUESTIONNAIRE AS BEST YOU CAN, TAKING YOUR TIME AS
THERE IS NO HURRY. IF YOU ARE NOT SURE OF ANYTHING OR THE QUESTIONS ARE NOT
CLEAR, DO NOT ANSWER THAT QUESTION '
PLEASE FILL IN A FEW PERSONAL DETAILS. ALL ANSWERS WILL BE ENTIRELY
CONFIDENTIAL
NAME AGE SEX M/F
(FORENAME) (SURNAME)




THE FOLLOWING QUESTIONS PROVIDE USEFUL BACKGROUND KNOWLEDGE ON THE STATE OF YOUR
PAST HEALTH AND YOUR FAMILY'S HEALTH
MOST QUESTIONS REQUIRE YOU TO PLACE A TICK IN THE CORRECT BOX OPPOSITE THE QUESTION
PAST HEALTH YES NO
HAVE YOU EVER ATTENDED A HOSPITAL OUTPATIENT CLINIC? [ ] [ ]
HAVE YOU EVER BEEN A PATIENT IN HOSPITAL? [ ] [ ]
If YES to either question, please give a few details
HAVE YOU EVER HAD AN OPERATION ON YOUR STOMACH, BOWEL OR
GALLBLADDER? [ ] [ ]
DO YOU HAVE SUGAR DIABETES? [ ] [ ]
DO TOU SUFFER FROM ARTHRITIS? [ ] [ ]
DO YOU SUFFER FROM ASTHMA? [ ] [ ]
ARE YOU BEING TREATED FOR RAISED BLOOD PRESSURE? [ ] [ ]
TREATMENT
DO YOU TAKE ANY MEDICINES/TABLETS REGULARLY? [ ] [ ]
ARE THESE FOR STOMACH OR BOWEL PROBLEMS? [ ] [ ]
If YES, please name them
SMOKING AND DRINKING
Both smoking and drinking can affect your health. Please answer the following
questions
DO YOU SMOKE? [ ] [ ]
HAVE YOU EVER SMOKED, BUT HAVE SINCE STOPPED [ ] [ ]
PLEASE STATE AVERAGE AMOUNT SMOKED
(If you have given up, state average amount before stopping)
PLEASE RECORD AVERAGE ALCOHOL INTAKE
(e.g. 3 pints/night, 2 glasses wine/week)
FAMILY HISTORY
Some diseases run in the Family, e.g. Asthma, sugar diabetes
ARE THERE ANY DISEASES THAT RUN IN YOUR FAMILY? [ ] [ ]
If YES, please give details
HAVE EITHER OF YOUR PARENTS OR BROTHERS OR SISTERS HAD AN OPERATION CM THEIR
STOMACH, BOWEL, BREAST?
If YES, please give details as best you can [ ] [ ]
Please turn over
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THE FOLLOWING SECTIONS ARE RELATED TO YOUR HEALTH AT PRESENT
PLEASE TICK THE BOX THAT SEEMS MOST SUITED TO YOU
IF YOU ARE ASKED TO GIVE DETAILS, TRY TO BE BRIEF
SECTION A YES NO
HAS YOUR APPETITE CHANGED RECENTLY? [ ] [
If YES, has it DECREASED? [ ] [
HAVE YOU LOST WEIGHT RECENTLY? [ ] [
ARE YOU ON A DIET? [ ] [
DO YOU HAVE DIFFICULTY SWALLOWING FOOD? [ ] [
DO YOU FEEL THAT POOD STICKS BEFORE REACHING YOUR STOMACH? [ ] [
ARE YOU TROUBLED BY BURNING OR DISCOMFORT BEHIND THE BREAST BONE? [ ] [
HAVE YOU EXPERIENCED ANY NAUSEA (feeling sick) OR VOMITING
(being sick) RECENTLY? [ ] [
DO YOU HAVE ANY PAIN OR DISCOMFORT IN THE ABDOMEN (Tunny)? [ ] [
IF YES, IS THIS DIFFERENT FROM PREVIOUS TUMMY UPSETS? [ ] [
Please give details
SECTION B
A FEW QUESTIONS RELATED TO YOUR BOWEL HABIT NOW FOLLOW
HOW OFTEN DO YOU OPEN YOUR BOWEIS (e.g. once alternate days)
AFTER YOU HAVE EMPTIED YOUR BOWELS DO YOU FEEL YOU STILL NEED TO GO?[ ] [ ]
HAS THERE BEEN A RECENT CHANGE IN THE FREQUENCY OF YOUR MOTIONS? [ ] [ ]
HAS THERE BEEN A CHANGE IN THE APPEARANCE OF YOUR MOTIONS? [ ] [ ]
DO YOU HAVE EPISODES OF YOUR MOTIONS BEING LOOSE THEN BECOMING
NORMAL AGAIN? [ ] [ ]
HAVE YOUR MOTIONS BECOME MORE CONSTIPATED? [ ] [ ]
HAVE YOU NOTICED ANY BLOOD IN YOUR MOTIONS? [ ] [ ]




THIS IS THE LAST SECTION TO EE COMPLETED. AS BEFORE PLACE A TICK IN THE
APPROPRIATE BOX
YES NO
DO YOU HAVE A COUGH MOST DAYS? [ ] [
HAVE YOU EVER COUGHED UP BIOOD? [ ] [
DO YOU SUFFER FROM PAIN OR DISCOMFORT IN YOUR CHEST? [ ] [
DO YOU HAVE TO GET UP AT NIGHT TO PASS VCYTER? [ ] [
IF YES, IS THIS MORE OFTEN IN THE LAST SIX MONTHS? [ ] [
DO YOU HAVE ANY DIFFICULTY PASSING WATER? [ ] [
HAVE YOU EVER NOTICED BLOOD IN YOUR WATER? [ ] [
HAS THERE BEEN ANY CHANGE IN COLOUR OF YOUR WATER RECENTLY? [ ] [
If YES, please give details
TO EE COMPLETED BY WOMEN ONLY
DO YOU STILL HAVE YOUR PERIODS? [ ] [ 3
IF NO, HAVE YOU NOTICED ANY BLOOD OR BROW DISCHARGE
FROM FRONT PASSAGE? [ ] [ ]
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Twenty three syrrptomatic patients completed a questionnaire before
being interviewed in the routine manner by a consultant clinician.
To determine the consistency of the responses on the patient's
questionnaire, the clinician then conpleted an identical
questionnaire on the basis of the interview without reference to
the patient's form. The two forms were then compared using Kappa
statistics.
Statistical Method
Since the possibility of chance agreement between two
series of replies to the same set of questions varies according to
the incidence of positive and negative replies to the individual
questions, the Kappa (K) statistic was calculated to adjust for
the contribution of chance agreements. Kappa is calculated
according to the formula, K =(Po-Pe)/(1-Pe), where Po is the
observed proportion of agreement and Pe is the proportion of
expected agreement from chance and calculated from the marginals
in a two by two table. The values for Kappa vary from +1.0 where
there is total agreement to -1.0 where there is total
disagreement. A value of 0 corresponds to chance agreement alone.
Results
Acceptabi1ity
One subject refused to complete the questionnaire.
Feasability
Three subjects failed complete the questionnaire due to
poor eyesight or dyslexia. The average time to completion was 7
minutes (range 4-10 minutes). The completion rate for the
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questionnaire was 96% of all questions.
Reproducibi1ity
In all three groups the test-retest study showed only one
answer was altered in one questionnaire and this related to family
history. Thus only one response was changed out of a possible
1,440 answers.
Consistency
In the study which compared responses obtained on the
questionnaire with those obtained by the consultant clinician,
Kappa statistics were applied to the 18 GI symptoms. In 15
questions there was a close correlation of answers and the K
values all exceeded +0.85. However with three questions, namely
those designed to elicit responses concerning tenesmus, early
satiety for food and new episodes of abdominal pain, the K values
were +0.2, +0.125 and +0.3 respectively. The remaining general
questions all had K values =+1.0.
Applicabi1ity
When the responses to the gastrointestinal questions were
compared between the three groups of subjects, the number of
positive responses was naturally greater in the hospital referred
groups. Fifty four of 65 subjects (82%) in the 1 normal' group had
zero or one positive response, with seven having three or mere
positive responses. In the group with cancer 33 of 35 (94%) had
three or more positive responses, as did 33 of 40 (82%)
individuals in the benign disease group (table 2.1).
Follow-up assessment of the seven 'normal' subjects
revealed that one had a confirmed diagnosis of ulcerative colitis
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Table 2.1
The distribution of positive gastrointestinal responses by group
+ve responses "Normal" Benign Cancer
(n = 65) "9 ii o (n = 35)
0 39 0 0
1 15 3 0
2 4 4 2
> 3 7 33 33
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and was experiencing a relapse of synptoms, two were treated with
H2 blockers for dyspeptic synptoms when reviewed by their GP and
three were referred for investigation of rectal bleeding and were
found to have haemorrhoids. The remaining individual, who had
right-sided pain, loose altered stools, nausea and change in the
colour of his urine was diagnosed as having choledocholithiasis on
ultrasound examination.
The results of the pilot study produced the conclusion
that three questions in the GI section needed re-wording and re-
piloting. However the questionnaire was relatively easy to
complete, could elicit GI synptoms consistent with a clinician,
could accurately identify subjects with established GI disease and
finally, as was desired for the main screening study, the
questionnaire could highlight normal subjects with synptoms as yet
unreported to a doctor, which merited further investigation. In
particular, any subject with three or more positive responses to
the GI questions in the main study would appear to be at risk of
harbouring gastrointestinal disease. Equally iiportant is the
value of a negative response which on the reproducibility study
showed one alteration in 1,440 possible responses, inplying a low
risk of sypmtonatic false negative disease in the screening study.
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Results of Mhin Study
Questionnaire Results
724 questionnaires were available for analysis from the
main GP group. The questionnaire was conpleted unaided by 609
individuals; a further 63 attempted the questionnaire but had
difficulty completing the form due to poor eyesight (lack of
reading glasses). Only 52 subjects made no attempt to complete
the questionnaire, the majority being elderly women from the inner
city practices. In these cases the investigator completed the
questionnaire for the individual.
The rate of completion for the questionnaire in the 609
cases was greater than 90% of all items. 95% of the
gastrointestinal symptoms were completed, maintaining the high
levels found in the pilot study.
The most common symptom elicited in the GP group was that
of episodic looseness of the bowel motion (26%) followed by
heartburn (23.8%). The least common symptom elicited was
difficulty in swallowing food (2.45%) and that was most commonly
seen in patients presenting with sore throats (Table 2.2). The
frequency of the remaining symptoms in the population is shown in
table 2.2.
Although 74 subjects had noticed blood in their motion,
only 10 had noticed this within the past 6 months. Four of these
had not reported this to their GP and were subsequently
investigated. One subject of the 74 noted dark red 'blood' in the
motion and was also investigated.
It was found that overall 238 (27%) of the group had three
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Table 2.2
Frequency of positive responses per question in
the general practice group
No. %
Reduced Appetite 55 6.75
Wt loss, no diet 35 4.3
Difficulty swallowing 20 2.45




New pain 61 10.34
Bowel habit 32 4.03
Incomplete emptying 66 8.12
Altered stool frequency 50 6.17






or more positive GI responses, and that 5% had 6 or more symptoms
present. Since it would be clearly impossible to investigate all
subjects with three or mure positive responses, all such
individuals were interviewed by the investigator and a decision
reached on the basis of his clinical judgement. In this way 38
individuals were investigated for upper or lower G.I. symptoms to
exclude malignancy. 9 subjects underwent upper GI endoscopy and
29 fibreoptic endoscopy (9 also had a positive faecatest) and
barium enema.
Three patients undergoing gastroscopy had no lesion
detected in the oesophagus, stonach or duodenum. Random biopsies
were also normal in these individuals. 2 duodenal ulcers, 1
gastric ulcer and 2 hiatus herniae with oesophagitis and one bile
gastritis were found in the remaining 6 subjects.
During the investigation of the individuals with large
bowel symptoms diverticular disease was found most commonly (13
cases). In 2 further cases haemorrhoids were discovered, drug
induced colonic inertia in one and in 3 no lesion was detected,
although spasm of the bowel during endoscopy reproduced their
symptoms. These patients were subsequently labelled as having the
irritable bowel syndrome following normal barium enemas. In 6
subjects no explanation was found for their synptoms.
Whilst two hyperplastic polyps and one adenomatous polyp
(4 mm dia) were found coincidentally at fibreoptic sigmoidoscopy
no significant neoplastic disease was found giving an overall
4.12% investigation rate with a predictive yield for neoplasia
using the questionnaire of zero. Only one person to date has
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presented with a GI malignancy (pancreatic cancer) but she had no
symptoms of gastrointestinal dysfunction for 15 months following
screening.
F.0.B. 1 s
Six hundred and eighty three fully completed FOB packages,
460 Haemoccult, 127 Fecatest and 96 Heira-check, were returned out
of a total of 724 (94.6%). The number of positive packages is
tabulated below along with the percentage positivity rate,
findings on investigation and the predictive yield per type of FOB
for neoplasia (Table 2.3).
Haemoccult testing revealed one carcinoma arising in an
adenomatous polyp of the sigmoid colon and this had breeched the
muscularis mucosa. Colonoscopic snare of the polyp had been
performed and as there was no evidence of lymphatic or venous
invasion and the cells were well-differentiated no further
treatment was given except routine follow-up by endoscopy. In two
further subjects adenomatous polyps were detected. One subject
had a sigmoid polyp 1 x 1.5 cm and a caecal polyp 1.5 cm x 1.5 cm
removed by snare polypectomy and in the remaining subject a 2 cm
adenomatous polyp was removed endoscopically from the descending
colon. All 3 individuals were FOB positive on one day only.
Unfortunately, 3 individuals refused to have any
investigation for positive Haemoccult findings, despite being nade
fully aware of the risks of neoplastic disease being present. To
date no patient has presented during the follow-up period with
synptoms or signs of bowel disease. In the remaining 6 cases







Results of Faecal Occult Blood Tests
No. Positive % +ve Neoplastic Yield
12 2.6 1 polyp cancer,3 polyps 33%
16 12.6 No Neoplasia 0%
1 1.04 1 Dukes'B cancer 100%
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noted and 1 case of haemhorroids was found with no radiological or
endoscopic abnormality. Repeat FOB's in these patients at 6 weeks
were all negative.
None of the 12 subjects positive on Haemoccult testing had
a positive symptom response on the questionnaire, nor did they on
subsequent review own up to any syirptoms.
As shown in table (2.3) Fecatest proved to have the
highest positive rate almost 5 times that of Haemoccult. Whilst
the positive rate was recorded as 12.6% (16 subjects) in fact six
other subjects had initially had positive Fecatest slides but they
had not adhered to the dietary advice. On retesting with dietary
restriction, they were all negative for both Fecatest and
Haemoocult and so not investigated. To date none of these six
have presented with gastrointestinal disease. Nine of these 16
Fecatest positive individuals were also symptomatic for colonic
disease (8) or for upper GI disease.
No neoplastic disease was detected by Fecatest. In 11
subjects diverticular disease was found, 2 subjects had
haemorrhoids, one a duodenal ulcer and in two remining subjects
no disease was detected at endoscopy or on barium enema.
Hema-chek revealed one asymptomatic Dukes' B cancer of the
signoid colon. 2 of the six slides, both on the same day, were
positive. This lesion was polypoidal in appearance on endoscopy,




The faecal occult blood tests have again shown their
ability to detect early colorectal cancers and significant sized
colorectal polyps. However, it is clearly seen that the
differences in sensitivities of the three guaiac based kits are
quite different. The positivity for Haemoccult in this series
(2.6%) is comparable with other screening studies (Hardcastle et
al 1983; Silman et al 1983) and the positive rate for Hema-chek
(1.04%) is encouraging although the number investigated with this
test is extremely small. Fecatest, however, has shown itself in
this study to be quite unsuitable for screening with a positive
rate of 12.6% (after 6 had repeated the test with proper dietary
restrictions). This rate lies between that experienced by
Berretta et al (1980) and Feneyrou et al (1982) ( 50% and 30%
respectively), and that of Lee and Costello (1982; 1983) where a
5%-8% positivity rate was encountered.
Furthermore the predictive yield for Fecatest was 0%
compared with 33% for Haemoccult. Clearly random chance will
affect the yield of tumours and the detection of 2 cancers in 683
patients equates with Hardcastle's rate of 3.3 per 1000 screened
aged over 45 years (Hardcastle et al, 1983). Whilst any of the
neoplasms could have just as easily fallen in the Fecatest group,
by comparing the predictive yield it is further apparent that the
relative superiority of Fecatest in conparative studies of
diagnosed cancers (Farrands and Hardcastle 1984; Turunen et
al,1984) bear little relation to the screening situation. Indeed
Armitage et al,(1985) found that screening using Fecatest and a
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special FOB kit with Fecatwin S and FECA-EIA (an immunological
test to reduce the false positive cases) had a prohibitively high
positive rate. No direct comparison can be made between the FOB
kits since it was felt that the compliance for stool testing would
be reduced if double the amount of stool samples would have to be
taken by completing two tests at the same time.
In view of the small numbers of individuals involved, no
comment can be made as to the potential of FOB tests for reducing
mortality from colorectal cancer but the diagnosis of a Dukes' A
and B cancer is in line with most screening studies where a
predominance of early stage cancers has been found.
The questionnaire has provided interesting data on the
prevalence of gastrointestinal symptoms experienced by the general
population. To ensure the validity of the responses the pilot
study was performed and proved a valuable exercise. As indicated
three questions, whilst used in other questionnaires, were found
to be invalid in our screening questionnaire. This supports
Opperiheim's (1978) point that all questions should be piloted
before general use.
As with the pilot study, the questionnaire was acceptable
to the public who expected to be asked health and symptom related
questions as part of a screening programme. The pilot study had
indicated that some would be unable to complete the questionnaire
due to visual problems but few refused to attempt to complete the
questionnaire (3.2%) and the general rate of completion was
staggering with over 90% of the questions being answered.
Unfortunately, in the main study the number of positive
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responses to the GI questions was considerably higher than in the
pilot study. Even using the arbitrarily contrived cut-off point
from the pilot study more than 27% had three or more positive
responses. It became rapidly clear in the study that not all
these individuals could be investigated nor did they merit
investigation for colorectal symptoms where the FOB's were usually
negative. Thus, remembering that a screening test is not
diagnostic in itself but an indicator of potential risk and that
some form of further assessment is required, the author opted to
accept the questionnaire as a filter to draw attention to
possible symptomatic cancers. Using a standard clinical history
and examination a clinical decision was made to investigate or not
on this basis. As shown in the results no colorectal neoplasm was
identified in this way, although benign conditions were found. No
new case of colorectal cancer has come to light from either the
regional cancer registry or from surveillance of the pathology
reports in St James's University Hospital to date.
The incidence of lower GI symtoms in the study is very
similar to that seen by Farrands and Hardcastle (1984) and
reflects the work of Jones (1976) and Thomson and Heaton (1980)
and so it is not surprising that 29 individuals were investigated
with no benefit. In only one subject was the symptom of dark red
blood encountered and on full colonoscopy no lesion was found.
This is in direct contrast with Silman et al (1983) who had found
this synptom to be common and to have a predictive yield for
neoplasia equal to Haemoccult. However Chapuis et al (1985) found
a predictive yield on investigation of rectal bleeding as a first
- Ill -
presentation in middle age was 8% for sigmoid and rectal
neoplasms.
The final problem in this study was that all the
neoplastic lesions detected on occult blood testing were
asyirptomatic on two occasions during the assessment period. This
also confirms the 83% false negative rate for the symptom
questionnaire of Farrands and Hardcastle (1984) where the
predictive yield for a symptom in that study was 0.78%.
The prevalence of upper GI symptoms within the population
must also be high with the incidence of heartburn in this study
alone being 24%. The potential of a sinple synptom questionnaire
to detect gastric cancer would therefore seem limited in the
extreme. In the period of this study only nine individuals were
investigated for worrying symptoms and whilst new peptic
ulceration was detected the whole tine pursuit and investigation
of upper GI symptomatic individuals with minimal symptoms in a
screening setting does not seem feasible from the pilot study.
This is in conflict with arguments proposed by Gear and Barnes
(1980) and Allum et al (1986) and will be examined in greater
detail in the chapter on symptomatic detection of colorectal and
gastric cancer.
The principal conclusion of this study is that the
addition of a symptom questionnaire to elicit lower GI symptoms in
combination with FOB testing confers no advantage to screening for
colorectal cancer. On the contrary, its use does in fact reduce
the cost effectiveness of any potential screening programme by
increasing the investigation rate for no additional neoplastic
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yield.
It is further noted that Fecatest was too sensitive in
this study to be of value in any future colorectal cancer
screening programme.
Finally, the existence of considerable upper GI symptoms
precludes any attempt at repeating the approach of Silman et al
(1983) and Farrands and Hardcastle (1984) using a single syirptom
to indicate potential risk for the presence of early gastric
cancer as opposed to colorectal cancer.
Looking to the future, any major developments in the
performance of the screening agent for colorectal cancer must lie
with the production of a more reliable FOB test. The most likely
source of success would seem to lie with the immunological
differences between human haematin and the presence in food of
cross-reactive substances rather than with more sensitive guaiac
tests (Armitage et al,1985). Attention to simpler aspects of FOB
testing may favourably influence the false positive rate of
Haemoccult. Elliott et al (1984) invited any subjects with a
positive FOB to complete a second FOB test under strict dietary
restriction. Investigation of only those positive on a second
occasion were investigated. In his study Elliott and his
colleagues (1984) had an initial positive reaction in 99 cases
which then fell to 32 on strict dietary control second tine round.
Twelve cancers were found, 9 Dukes' stage A. The predictive yield
was increased by this approach and there were no false negative
cancers on review in this study. Six day testing may also reduce
the false negative cases missed by Haemoccult and deserves further
- 113 -
prospective evaluation. There appears to be little to offer in the
way of screening for gastric cancer other than surveillance of
high risk groups (Cuschieri, 1986) or the earlier investigation of




Factors affecting screening coitpliance
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Introduction
The cost-effectiveness of any screening agent is dependent
upon two variables - the validity of the agent itself and the
acceptability of the agent to the target population. In the
previous chapter the value or otherwise of screening agents for
colorectal cancer principally was considered and in this chapter
factors affecting cortpliance for a screening invitation including
FOB testing will be studied.
Jocelyn Chamberlain (1982) has stated that a compliance
rate of 80 - 85% for faecal occult blood testing would be required
to make colorectal cancer population screening viable. However as
shown in Table (3.1) that goal has never been attained in randomly
selected groups in the United Kingdom. As shown in the table
where some input has been given by the screening promoters (Siliran
et al 1983; Lee 1983) compliance can be raised above the average
response to a sirtple postal invitation to screen. However the
workplace is not the ideal situation for population screening in
terms of the distribution of the workforce in too many outlets.
An appraisal of the factors producing conpliance and non-
conpliance is clearly necessary to seriously consider FOB
screening in the United Kingdom. If one was to sinply list the
likely causes of failure to comply with screening three reasons
might suggest themselves. Firstly, the test is unacceptable to
the target population, secondly the way screening is promoted by
the iredical profession is poor and insufficient to overcome the
final factor, a resistance on the part of the public to preventive
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unquantified, factor to which failures of compliance for the
common cancers and immunisation programmes have been ascribed.
In the following studies, the role of the G.P. in
promoting screening and the acceptability of several screening
tests will be assessed. Whilst designing such variations in
screening packaging may be relatively straightforward, measuring
the attitudes of the population to preventive health measures
requires the expertise of the behavioural psychology approach.
Becker (1974) and his associates (Cummins et al,1978), have
recorded the mothers' responses to immunisation therapy and as a
result formulated a model of behaviour, the Health Belief Model,
to explain coirpliant and non-compliant behaviour.
Tliis model formulates that health behaviour is dependent
on the sum of the interaction of six variables or scales in the
model described as the following
i. Readiness to be concerned about health matters
ii. Perception of vulnerability to illness
iii. Perception of the benefits/barriers to health action
iv. Knowledge of the illness concerned
v. Perceived severity of illness
vi. Reaction to cues (e.g. invitations).
At the outset of this research, only two limited studies
(Halper et al 1980, Dent and Goulston 1980) have been reported
using this approach. It was therefore felt that an assessment of
the populations attitudes to health, illness and screening for




To assess the influence of the General Practitioner in the
promotion of FOB testing.
To record the attitudes of the population to health,
illness and cancer prevention by use of the Health Belief Model.
To determine if there are consistent differences in the





Individuals aged between 50 and 70 years old and not
currently complaining of or on medication for GI synptoms were
eligible for study. They were recruited by two methods discussed
below from the six general practices in the Leeds East Area, as
described in chapter 2.
Agents
Each individual was required to coirplete a 41 item self-
administered symptom questionnaire (see chapter 2), give blood for
tumour marker estimation and return by post a three day faecal
occult blood test.
To assess the population's attitudes to health, illness
and preventive medicine a 71 item self-completed questionaire was
developed and modified following a pilot study based on the Health
Belief Model (Cummins et al 1978). This questionnaire shown in
full in subsequent pages conprised six scales to measure general
health belief, perceived vulnerability to illness, benefits and
barriers to health activity, attitudes to medical services,
knowledge of cancer and perceived severity of illness. Basic
demographic data inluding age, level of education and smoking was
also recorded.
Enrollment
Two methods were used to assess the role of the G.P. in
promoting FOB testing, a direct 'case-finding' exercise and a
second indirect 'screening' approach.
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In the following sections we would like you to read some statements about
health problems, and indicate by circling one of the alternative answers how
far you personally agree or disagree with the statement. There are no right or
wrong answers; just give your opinion. Please circle ONE answer only for each
question.
SECTION A
1. It is more important to have a good life now, than worry about future
health.
(a) I completely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I corrpletely disagree
2. Physical fitness is important to me.
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conrpletely disagree
3. People can't really do a lot to prevent illness.
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
4. Illness always gets me down.
5.
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
as many illnesses as everyone else.
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) 1 conpletely disagree
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I usually eat what I know is good for ne.
(a) I corrpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
Regular medical check-ups are useless unless you are ill.
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
Good health or bad health is something you just have to put up with,
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I completely disagree
I think that people are fanatical about health these days.
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
Six monthly check-ups at the dentist are a waste of time.
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
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SECTION B
1. In general I enjoy good health
(a) I completely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
2. I am unlikely to suffer from a serious illness in the future.
(a) I completely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I completely disagree
3. If I wait long enough, I will get over most illnesses by myself.
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I stroi'igly disagree
(f) I conpletely disagree
4. I am the type of person who worries a lot about their health.
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
5. I take ages to recover from illness.
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
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I go to the doctor the minute I feel unwell
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
I don't suffer from colds and flu as much as other people
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
I always have a well stocked medicine cabinet at home
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
I worry a lot about getting cancer
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
My health will probably always be below par
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
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SECTION C
1. There is nothing I can do to prevent illness from happening
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I completely disagree
2. Finding a disease early makes no difference to the success of
treatment
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
3. I am too old to worry about having health check-ups
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly'disagree
(e) I strongly disagree
(f) I conpletely disagree
4. A person can have a serious illness and not know it
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
5. Having a medical check-up usually stirs 15) trouble
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I oonpletely disagree
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I'd be frightened to have a check-up in case something was found
(a) I completely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
Certain medical tests can show up a problem you did not know about
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
I'd be prepared to give up my time if I could have a free medical
check-up with my G.P.
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
There is no point in having a check-up if you have been well all your
life.
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
Having a regular check-up for cancer is a good idea
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
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SECTION D





























. after visiting the doctor
4. I can never see
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
the doctor when I want
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
5. Doctors don't listen enough bo their patients
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
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It is irrportant do exactly what the doctor says when I'm ill
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
There's a lot doctors don't know about most connon illnesses
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
Doctors should spend more time telling their patients how to stay
healthy
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
I don't like visiting hospitals
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
I worry about having to go into hospital
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
"(f) I conpletely disagree
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SECTION E
The next sections relate specifically to cancer. Your answers to the
following statements are iirportant as they will help us to make our cancer
prevention programme more attractive to patients in our practice.
1. You can have cancer and not know about it
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
2. Finding cancer early leads to a better chance of cure
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely/disagree
3. Tests can detect cancer before you feel unwell
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
4. No matter where you find cancer there is always a poor outcome
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
-(e) I strongly disagree
.(f) I conpletely disagree
5. Cancer just about always means death
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
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The treatment for cancer is vrorse than the disease itself
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
Having cancer is the worst thing that can happen to anyone
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
Some types of cancer can be cured more effectively than others
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
If I had cancer I would want to be told
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
If I thought I had cancer I would put off going to see the doctor
about it
(a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
Ce) I strongly disagree
(f) I conpletely disagree
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This section asks in more detail about personal experience of cancer. If you have
not known anyone with cancer, please proceed to Section F below.
1. Do you know anyone who has had cancer
(If the ansver is no please proceed to the next section
2. Do you know anyone who has been cured of cancer
3. Have you heard of either cancer of the stomach or bowel?
(If no please go on to the next Section below)
4. Has a relative or friend had either of these cancers?
5. Did this greatly upset their way of life?
6. Do you think you can have either of these cancers and
not know it?
7. Do ycu think the chances of cure for either of these
cancers is
SECTION F
Soma illnesses prevent us leading our normal active lives. How nuch of an effect
would the following illnesses have on your life.
































This is the last section. Please remember all your responses are strictly
confidential and only your own doctor will see the answers. The information is
necessary to help decide priorities for further health campaigns.
Please circle the appropriate answer as before.
Please state occupation
(If retired please stage last job)
Are you currently unemployed YES/NO
At what age did you leave full tine education
Do you smoke? YES/NO
Have you ever had a previous health check-up? YES/NO
Ladies - have you ever had a cervical smear test? YES/NO
have you ever had a breast examination? YES/NO
Thank you for your co-operation. Could you now return the form in the
stairped addressed envelope to the surgery?
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Case-finding approach
The GP in this study initiated the screening process by
inviting any individual fitting the entry criteria to participate
in FOB testing, as part of a routine consultation.
Prior to the commencement of surgery, the notes were
flagged with a coloured slip of paper to indicate possible
eligibility by age. If the patient did not present with a GI
complaint the G.P. then invited the individual to see the
investigator (EM3) in a separate room to participate in the
screening programme. If the patient refused, this was recorded on
the card along with any reasons given for this so that an accurate
account of compliance and non-coitpliance could be kept.
Screening Approach
This study ran subsequent to the case-finding approach and
the individuals selected were invited by one of two standard
letters to attend their practice surgery for a general screening
check-up or a 'bowel screening' programme.
These letters, shown opposite, were typed on practice
headed note paper and signed by the senior partner of the group
practice. Only four practices, Msanwood, Street Lane, Burmantofts
and Slaid Hill were used for this study. Burmantofts and Slaid
Hill are geographically and demographically removed but share the
same GP's allowing comparisons of the effect of social class and
education on compliance without the bias of different GP's being
involved.
Selection was based on obtaining as close a match as
possible to the 'case-finding' group in terms of age, sex and
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Letter from GP to the general check-up group.
Dear
as a result of a recent survey performed in the practice
we have found there is a demand for some simple type of health
check-up. I am writing to you therefore to offer you and many
other people in your age group an invitation to take part in a
Health check-up programme. The opportunity to have your blood
pressure checked, your urine tested, and to be given a general
information sheet about a healthy diet, will be available to you
in the surgery, if you desire. At the sane time some 'do-it-
yourself' tests to check your tummy for problems will also be
available . The check-up will be quick, no examination is required
and all you have to do is make an appointment in the usual way to
see Dr Chisholm, who is helping us with this programme, on a
Thursday afternoon 4pm-7pm or on Sat 26th NOV or Sat 17th Dec from
8.30am-12am. This offer is only open for a strictly limited time,





Letter from GP for the GI check-up.
Dear
as a result of a recent survey in the practice we have
found that there is a demand for a sinple check-up. I am writing
to you therefore to offer you and many other people in your age
group an invitation to take part in a health check-up programme.
We now have available some sinple tests, which you do yourself,
which can detect problems in the stomach or bowels even though you
feel well. People at your age are at greatest risk of developing
these problems however the earlier that such problems can be found
the better and irore successful is the treatment for the patient.
The tests don't take long to do and no examination is required.
All that you need to do to take part is make an appointment in the
usual way to see Dr Chisholm, who is helping us with this
programme, on a THURSDAY 3.30-7PM or on Sat 26th Nov or Sat 17th
Dec 8.30-12noon. This offer is only open for a strictly limited
time, so please nake use of it, as it is certainly to your




Whether or not the patient had seen their GP within the past 12
months. Further selection was also dependent on no active GI
treatment or recent GI referral being found in the medical
records.
Such selection was difficult to obtain since three
practices did not have age:sex registers and over 1400 records
were reviewed in this process. However, the natch for age and sex
for the age groups 50-64 years is close.
Randomisation into the 'bowel' check-up or 'general'
check-up groups was then performed by placing all National
Insurance numbers ending with odd numbers into the bowel group and
even to the 'general' group. However, in any given household the
female spouse received the same invitation as her husband
irrespective of National Insurance number.
The design of this study is shown opposite (fig 4). As
illustrated one final division of these groups was performed.
Half of each group was randomised to receive the HBM before the
screening invitation and half was to conplete the HBM on
attendance for screening. This randomisation was siitply performed
by taking alternate names from each year of age from 50 years to
70 years.
Finally, for one week a Health Visitor was substituted for
the doctor in the screening clinic to assess whether the




Flow diagram of compliance study
Group I
(towel n = 279)
HBM questionnaire > Screening letter
Screening letter > HBM questionnaire
HBM questionnaire > Screening letter
Group II
(general n = 268)
Screening letter > HBM questionnaire
Group A = HBM questionnaire before screening
Group B = Screening invite before the questionnaire
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Statistical Methods
Simple comparisons between compliance and non-compliance
data were analysed by the Chi square test.
As the anticipated sample size was approximately 450
individuals and the type I error was set at 0.2 and the type II
error at 0.95, a 15% difference in attitudes would be required to
exhibit a significant difference between compliance and non¬
compliance for the HBM data.
The statistical package for social sciences was used on
the University of Bradford Amdahl VM 470 computer to analyse the
HBM data where the Cronbach Apha coefficient of internal
consistency,item analyses, analysis of covariance and discriminant
analysis were performed. The programmes were preset to allow for
the type I and type II errors, thus all p values attained had to
show at least a 15% difference to be truly significant.
The scales were given a numerical value based on the total
score gained for the responses to each question on the scale. The
scores ranged from 1 to 6 for each question and were weighted to
coincide with the suggested trend for the HBM. The value per




Compliance by age, sex and general practice were all
measured and are related here.
Overall Results
535 subjects were approached by their G.P. 441 (82.4%)
agreed to participate and completed at least two of the tests.
405 individuals then completed and returned the FOB test they had
been issued giving a 91.4% return for those accepting an FOB
package and 75.7% overall for the group.
Age and compliance
The itean age for those subjects who performed at least one
test was 59.3 years. The mean age for the 94 non-conpliers was
64.5 years. The following table shows the distribution of those
441 individuals by age in 5 year blocks.
Table 3.2
Conpliance for a single screening agent by age.
<55yrs 55-59 60-64 65+ Total
Conpliers 126 96 114 105 441
Non-coirpl iers 14 16 30 34 94
Total 140 112 144 139 535
Percentage 90 85.7 79.2 75.6 82..
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In the following table the return of conpleted POB's is
shown against age and the percentage return for the whole group is
calculated.
Table 3.3
FOB returns by age
<55yrs 55-59 60-64 65+ Total
FOB returns 113 91 102 99 405
Percentage 80.7 81.25 70.8 71.2 75.7
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Sex and compliance
306 women and 229 men were invited to participate in the
study: 242 (79%) feitales and 199 (86.7%) men accepted the
invitation and completed at least one test. The differences in
return of the FOB packages by sex are shown in the following
table.
Table 3.4
FOB returns in relation to patient's sex
Fenales Males Chi Test
Total number 306 229
Accept one test 242 199 5.52 p<0.02
Non-compliers 64 30
FOB returned 222 183 4.16 p<0.05
Percentage FOB 72.5 79.9
Twenty two women in the non-conplier group were on
anxiolytic agents compared to one male in the corresponding group.
Seventeen of these women specifically mentioned fear of cancer and
of finding a positive test and gave these reasons for failure to
accept the screening offer.
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Compliance by general practice
This data is summarized in the following table (Table 3.5).
Table 3.5
Conpliance by general practice
Acceptance Refusal FOB Percentage FOB
one test returned overall
Street Lane 103 18 94 77.7
Professional
Meanwood 148 25 136 78.6
Mixed class
Burmantofts 65 12 64 79
Inner city
Chapeltown 54 12 46 69.6
Inner city
Shaftesbury 69 27 65 67.7
Inner city




In the following table (Table 3.6) the number of patients
accepting an invitation to screen is shown for each offer.
Table 3.6
To show compliance by screening offer
Attendance BOB return Absolute FOB return
No. % No. % %
General check 138 51.4 136 98.5 50.75
No.= 268
GI check 135 48.6 132 97.7 47.3
No.= 278
Compliance by age
The mean age of the compliant group was 58 years and for the
non-compliers 58.4 years. There was no statistical difference by age
for compliance between the two groups as shown in the following table.
Table 3.7 Conpliance by age
<55 55-59 60-64 65+ Total
Complier 90 84 71 28 273
Non-complier 95 72 79 28 274
Percentage 48.6 53.8 47.3 50 49.9
Compliance by sex
139 of 282 females (49.3%) and 134 of 265 males (50.6%) attended
the screening appointment. No statistical difference was found between
the sexes for compliance to the FOB package.
- 143 -
Compliance by GP practice
The results are tabulated below showing attendance by offer and
by practice.
Table 3.8
Compliance per general practice
General check GI Check Total
Practice No. % No. % No. %
Street Lane 44 58.7 42 59.2 86 58.9
Meanwood 34 46.6 41 57.7 75 52.2
Burmantofts 29 44 17 26.5 46 35.7
Slaid Hill 34 54 32 50 66 52
The differences in attendance between the Burmantofts practice
and the three remaining practices are significant using the Chi squared
irethod (p<0.001, P< 0.01, P<0.01 respectively). The general
practitioners for the Burmantofts and Slaid Hill practices are the same.
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Further screening findings
40 of 41 individuals irade appointments to see the Health Visitor
when told the doctor would not be available. The renaming individual
phoned again and was seen by the investigator one week later.
There were no subjects who refused to have their blood pressure
recorded and 97% subjects brought a urine specimen for testing. Only
three individuals in the whole study refused to give a specimen of
blood, but 52 subjects refused to complete the self-administered synptom
questionnaire unaided.
21 individuals were found to be hypertensive with diastolic
pressures greater than 100 inrrHg and were subsequently reviewed by their
GP. 19 are now receiving antihypertensive therapy. 12 women who had
not previously had a cervical smear test were enrolled and 4 individuals
with microscopic haematuria had a normal midstream sanple of urine and
urinary cytology.
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Results of Health Attitude Questionnaire
Pilot Study
Forty-five of 48 (94.7%) subjects in the coirplier group from the
case-finding study completed the HBM questionnaire. By contrast only 21
of 46 (45.6%) in the non-complier group co-operated in this way.
Completion of the six health belief scales and the basic
epidemiological questions was greater than 95%. However, the completion
of the mood scale was less than 30% and the values achieved made the
inventory valueless. The mood scale was therefore dropped from the HBM
for the main study.
Reliability, as assessed by the Croribach Alpha coefficient, was
high for all scales ranging from 0.57 to 0.84 indicating acceptable
levels of internal consistency.
Validity as assessed by an item analysis of the individual
questions in the scales and their correlation with known screening
outcoire was high. Six questions in the general health scale, four in
the vulnerability scale, eight in the benefits and barriers scale, six
in the attitudes to illness scale, all ten in the knowledge scale, and
six perceived severity scale, and the scales themselves correlated
significantly with compliance outcome (range 0.02>p>0.0001).
In view of these findings the questionnaire was unchanged with




401 completed questionnaires were available for analysis at
completion of the study. 252 HBM were conpleted by conpliers to a
screening invitation and 149 by non-coirpliers. 20 individuals attending
for screening in Group B and who were seen by the Health Visitor were
not required to perform the HBM and so were excluded from the analysis.
A further 42 individuals who were non-compliers for the study were
visited at home to invite them to discuss their failure to conply and to
complete the HBM. Whilst opinions were expressed by some no further HBM
were completed. Thus 443 of 527 (83%) individuals were approached to
fill in a HBM questionnaire with 76% completion for the whole group.
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B. Item Analysis of Questions
(i) Reliability
Internal consistency of the subscales was used assessing
coefficient alpha (Cronbach, 1946).
Table 3.9















All scales showed considerable and acceptable internal consistency.
Whilst internal consistency only provides one neasure of reliability and
ideally it would have been desirable to evaluate test/retest
reliability, it was not felt possible to achieve this and proceed to
screening without producing bias or causing a major delay in the study.
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(ii) Interdependence of Scales
Table 3.10
Spearman Rank order correlations between Health Belief Scales


































Examination of the inter-health belief correlations
indicates a number of highly significant relations. This suggests
that the scales are related, interactive and seem to follow the
pattern proposed by Becker (1974) and Cummins et al (1978).
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(iii) Relationship between measures of Health Belief Scales and
Compliance (Validity)
Table 3.11










Four scales correlate significantly with known compliance
outcome to a screening offer; the general health belief scale,
vulnerability, benefits and barriers and the knowledge of cancer
scales. These four scales can be said to be predictive of
compliance, having been validated against an objective outcome
criterion.
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(iv) Item Analysis of Individual Items in Scales
(Validity)
(a) General Health Belief Items.
Table 3.12




7 Regular medical check-ups are
useless unless you are ill 0.24 <0.001
8 Good health or bad health is
something you just have to put
up with 0.166 <0.001
9 I think that people are fanatical
about health these days 0.107 =0.017
10 Six monthly check-ups at the
dentist are a waste of time 0.152 <0.002
Four questions in the general health belief section correlate
strongly with coirpliance behaviour. Non-compliers agree more readily
with the negative sentiments expressed in these statements than do
compliers.
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(b) Perceived Vulnerability Items
Table 3.13
Correlations (Spearman's Rho) between questions on
Vulnerability Scale and compliance behaviour
Question Correlation Significance P
3 If I wait long enough, I will
get over most illnesses nyself - 0.1733 <0.001
This scale has failed to determine major differences
between compilers and non-compliers with the exception of question
3. It would appear that non-compliers accept this premise, whilst
compilers do not, and that according to this scale in this HBM
there is no other difference in perceived vulnerability to
distinguish between the two behaviour patterns.
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(c) Benefits and Barriers
Table 3.14
Correlation (Spearman's Rho) between questions on benefits and
barriers and compliance behaviour
Question
1 There is nothing I can do to
prevent illness from happening
Correlation
0.13
2. Finding a disease early makes
no difference to the success
of the treatment 0.2004
3. I am too old to worry about
having health check-ups 0.264
5. Having a medical check-up
usually stirs up trouble 0.207
6. I'd be frightened to have a
check-up in case something
was found 0.25
7. I'd be prepared to give up my
tine if I could have a free
medical check up with ny GP 0.27
9. There is no point having a check-up
if you have been well all your life 0.233
10. Having a regular check-up for











The findings indicate that non-compliers perceive few benefits
to preventive health care whilst compilers see the advantage in cancer
screening. This is similar to other HBM studies. Further the non-
compliant subjects are concerned about the possible deleterious side-
effects of looking for cancer.
- 153 -
(d) Attitudes to Illness
Table 3.15
Correlation (Spearman's Rho) between questions on Attitude
to Illness scale and compliance behaviour
Question Correlation Significance
P
4 I can never see the doctor when
I want 0.1645 =0.017
6 Doctors don't listen enough
to their patients 0.147 <0.002
7 Doctors should spend more time
telling patients how to stay
healthy -0.19 <0.001
9 I don't like visiting hospitals 0.101 =0.022
10 I worry about having to go
into hospital 0.144 <0.002
It would appear that non-cornpliant individuals show resentment
towards health services compared to compliant subjects. In particular
it would seem that non-corrpliers feel that there is an excessive








1 You can have cancer and not
know about it 0.135 <0.004
2 Finding cancer early leads to
a better chance of cure 0.199 <0.001
3 Tests can detect cancer before
you feel unwell 0.197 <0.001
4 No natter where you find cancer
there is always a poor outcome 0.102 <0.02
5 Cancer just about always means
death 0.139 <0.003
6 The treatment for cancer is
worse than the disease itself 0.147 <0.002
7 Having cancer is the worst thing
that can ever happen to anyone 0.145 <0.002
8 Some types of cancer can be cured
more effectively than others 0.085 =0.046
9 If I had cancer I would want to be
told 0.031 <0.005
10 If I thought I had cancer I would
put off going to see the doctor
about it 0.145 <0.002
Examination of these correlations indicates that compliant
subjects are knowledgeable and positive in the value of early
detection of cancer whilst non-compliers appear to believe that





Correlations (Spearman's Rho) between perceived severity of




Heart attack 0.124 <0.007
Cancer 0.122 <0.008




From these results it would seem that for most non-compliers any
disease but particularly cancer, peptic ulcer and heart attack will
produce a major effect upon their life style compared to the effects
these diseases would be felt to have on the conplier group. For some
reason migraine, also appears to be seen as a more serious condition to
have conpared to a stroke.
V. Summary
Examination of these results confirms an acceptable reliability
of the scales as determined by internal consistency. Correlations
between scales and an objective ireasure of outcome suggests the
questionnaire offers valid measures. The use of an item analysis has
indicated some items of predictive value for each scale: a total of 35
of 58 items in the six HBM scales were found to be predictive for
outcome in response to a screening invitation.
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C. Univariate analysis
Examination of the findings after univariate analyses
indicates that 5 variables can independently differentiate
coitpliers from non-compliers: general health beliefs, benefits and
barriers; attitude to illness; knowledge of cancer and further
education.
Whilst the series of univariate analyses of variance
indicate differentiating variables for compliance behaviour, they
make no allowance for complex inter-relationships that nay occur
between variables. Thus, the use of a multivariate technique
rather than a set of univariate analyses should elucidate any
interaction between variables.
(b) Multivariate Analyses (Discriminant function analyses)
However, as the above analysis defines variables which
independently discriminate between conpliance groups, then making
allowance for complex inter-relationships by a multivariate
irethod, is likely to increase prediction of outcome.
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Table 3.18












An interaction of the above 9 variables significantly
discriminates between the two coitpliance groups.
F = 5.1215
p < 0.0000
Canonical correlation = 0.3714376
Used to predict group membership for the 401 individuals
in the study, the overall classification rate was 67%. The
detailed breakdown is shown in the two following tables.
- 158 -
Table 3.19






Classification of results using group discriminant functions
Actual Group No. cases Predicted Group Membership
1 2
Compilers 1 252 182 70
(72.2%) (27.8%)
Non-compliers 2 149 60 89
(40.3%) (50.7%)
The overall prediction in terms of group membership is 67%
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Discussion
Whilst there have been numerous studies to determine the
value of the faecal occult blood test in the detection of
asymptomatic colorectal neoplasia, few investigators have assessed
the factors influencing the population's compliance for FOB
testing while screening for bowel cancer. Since the cost-
effectiveness of any such screening program is dependent not only
on the validity of the test agent but also on compliance for that
test, then the low acceptance of the direct postal FOB method (36%
on average in the UK) will not permit colorectal cancer screening
to be viable. These low compliance levels were the stimulus for
the author to examine alternative approaches to the promotion of
colorectal cancer screening utilising the primary health care
facilities already available.
The results of the case finding study with a direct
approach from the GP would seem to bear out Farrand's views
(Farrands et al,1981 and 1984a) that the general practitioner
should have a greater role in promoting bowel cancer screening.
Our 75% return rate from a relatively random population would
render population screening with FOB testing a more feasible
exercise than could have hitherto been anticipated. Further as
shown in Table 3.5 the results are not heavily biased by the
inclusion of a preponderance of middle class individuals, a
criticism leveled at the original pilot study performed by
Professor Hardcastle and his colleagues (Hardcastle et al,1981) by
Million's group (Million et al,1982). A 71% return in the working
class group for this study represents a potential step forward in
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the response of this particular group for screening activity
especially as these inner city practices have serious social
problems and have a crime rate third only to Toxteth and Brixton.
Unlike previous studies (Hardcastle et al,1983; Lallemand
et al,1984; Nichols et al,1986), it was found that men had a
higher response to screening than women. Farrands et al (1984a)
also noted that the coirpliance of men for FOB testing was
increased and greater than for women following an interview. It
may be that rren are less likely to respond to a screening
invitation than women without some form of personal reinforcement.
The explanation for the very high response rates for the
direct invitation is not clear since the reasons for acceptance
were not adequately recorded at the time. However several
factors could be proposed as being relevant; the simplest would
be embarrassment at refusing the GP having just consulted him; or
the GP is seen as someone responsible for the health of the
individual and so the offer to screen must be valid; the practice
surgery is less threatening and impersonal than a screening clinic
(French et al,1982); and finally it is possible to discuss and
make a more objective decision regarding screening in general and
FOB testing in particular if direct contact is available.
It would certainly seem that the enthusiasm of the general
practioner and the screening facilitator is vitally important to
the success of this type of "opportunist" approach to screening.
Nichols et al (1986) have shown similar results to this study
using exactly the same approach from the GP to initiate screening
and found that the compliance rates varied considerably within the
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practices depending on which GP was promoting the screening. In
the current study several GP's within the practices did not wish
to be involved at all or rarely referred individuals for
counselling. In a separate study Nichols et al (1986a) showed
considerable variance in the attitudes of GP's to the merit or
demerit to colorectal cancer screening and similarly Dent et al
(1978) found poor knowledge of "risk" lesions for colorectal
cancer and negative attitudes to screening with FOB testing in the
medical profession. As suggested by Nichols and her colleagues
(1986a) this aspect of screening promotion cannot be ignored if a
GP lead screening service is to be successful.
During this study it was established that the apparent
1 normal1 referral rate to a GP for 1900 individuals aged 50-70
years was 78% patients attended the surgery at least once per
annum. This is comparable with other published GP data on
referral practice (Andersen,1977; Nichols et al,1986). The
referral patterns for the case-finding and screening group are
similar to the 'norm' and therefore it is felt that these groups
are comparable and fairly representative of this particular
population under study and are not subject to any large selection
bias. This should therefore enable valid comparisons to be made
between each group in this study and other screening studies.
It would therefore seem that the results of the current
'screening' study support the contention that the GP is seen as
someone representing health care and that the possibility of
discussing the need for screening has influenced screening uptake.
This support is in 2 parts; 50% responded to the letter of
- 162 -
invitation and attended the practice for screening conpared to 36%
complying with direct postal FOB's in other studies. Secondly,
there was no difference in compliance for either screening offer.
This would suggest that the increased compliance was due to the
letter coming from the GP and that the surgery was seen as the
appropriate setting for health activity. This finding has also
been noted for breast cancer studies and colorectal cancer
programmes (Hobbs et al,1980; Edinburgh Breast Screening Clinic,
1978; Hardcastle et al, 1983). Nichols et al (1986) have also
shown an increase in response to a specific appointment for
screening in the GP surgery with 49% compliance compared to a 38%
response to a postal method.
Once these individuals were enrolled by whatever method
the return of completed FOB's was greater than 90%. This, by
implication, suggests that the test can be completed readily in a
population sufficiently motivated. However the way FOB screening
is currently packaged that motivation is not enough to overcome a
natural distaste for stool testing. Silman and Mitchell (1984)
have also reported similar findings.
There are several inplications for the cost-effectiveness
of screening using these approaches, accepting that there are
limitations iirposed by the small numbers employed in this study.
Whilst direct postal FOB screening is siirple and easy to organise,
little account is made of the 50%-70% POB's lost from the
programme by non-return. Since the bulk of the costs are made up
by these kits, estimated to be 10 - 20 times the cost of postage,
this is clearly a severe limitation to the effectiveness of
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screening. With the 'case-finding' or 'screening' approach
employed in this study, these losses do not occur. In the 'case-
finding' approach the initial letter of invitation is not required
further reducing costs. Compliance in each study was
significantly increased compared to previous postal only screening
methods (Chi square 21.4, p< 0.001) and was achieved with little
extra input (Table 3.1). It would have been most interesting to
have repeated Lallemand et al's (1984) approach of reminder
letters to see if further encouragement from the medical promoters
would have increased the compliance rate. Unfortunately the
general practitioners were keen for their patients not to be
pressured into acceptance of screening and this avenue was not
pursued.
Table 3.8 shows a disparity in compliance by social class
for the screening approach in this study. Low compliance in the
lower socioeconomic groups for cervical and breast cancer
screening programmes has also been noted (Cardiff Cervical
Cytology Study, 1982; Wakefield and Sansom, 1966). Farrands et al
(1984) have not found that social class is a significant factor
determining coirpliance for FOB testing. The table suggests that,
despite the snail numbers, the best return for investment may be
direct postal promotion for upper social class areas with direct
input from the GP for the lower social class. This is worthy of
further investigation by cost-analysis in a large controlled
study.
The data table 3.8 is disturbing as it demonstrates 40% of
the professional group did not respond to the screening
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invitation. Such individuals should belong, theoretically, to the
most accessible and knowledgeable group for a preventive medicine
cairpaign. The health belief questionnaire nay explain why such
individuals do not comply for screening.
It was surprising that such a high response to the
questionnaire was achieved given the abstact nature of the
questions. The HBM not only recorded the attitudes of the
screening population but highlighted significant differences in
these responses for compilers and non-conpliers in 35 items from
the 6 scales. In addition differences in a further 5 demographic
items were noted. However as demonstrated by Antonovsky and Anson
(1976) and by Stillman (1977) single responses to questionnaires
indicating good awareness of the value of screening for breast
cancer do not directly correlate with screening outcome. Similarly
Farrands et al (1984a) found that 75% subjects in their study felt
check-ups were iirportant but only 50% complied for FOB testing.
The use of discriminant analysis has shown the interaction
of the 6 scales and may indicate the balance between the perceived
advantages and disadvantages of health activity held by other
factors such as resentment of medical practitioners or how
susceptible one feels to developing the disease in question (Table
3.21). Thus an individual who has exhibited high benefit and
knowledge scores nay not attend if he does not feel at risk of
harbouring cancer. These findings support Becker's proposal that
making health decisions is a dynamic process of multiple
interactive factors the sum of which decides the final action
(Becker, 1974). Silman and Mitchell (1984) also noted that their
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Table 3.21




High benefits to screening







poor respect for doctors
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non-coitplier group for FOB testing did not appreciate that they
were at risk for colorectal cancer. This was especially
disappointing for Silman and Mitchell as their study included a
high intensity educational programme to highlight the risk of the
individual for colorectal cancer.
Whilst French and her colleagues (1982) did not use the
HBM in their study of attitudes to breast cancer screening they
did find that there were several factors common to non-compliers.
These included feelings of vulnerability, pessimism towards the
value of early detection of cancer and fear of disruption to their
lives. This appears to correlate well with the current study and
may indicate some fundamental attitudinal problem to cancer
screening that will need to be overcome if such screening is to be
viable.
The approach used in this study has differed from previous
reports. Unlike Farrands et al (1984a) no input from a medical
representative was present before the HBM was completed thus
reducing any potential bias that could be introduced by an
interviewer (Collen et al, 1969). Both compilers' and non-
compliers" attitudes were recorded unlike Halper et al (1980) who
looked at healthy volunteers for sigrroidoscopy but who refused FOB
testing and from Silnan and Mitchell (1984) who failed to examine
the conpliers for their study. Thus both sets of workers were
unable to coirpare the coitpliers with non-compliers for FOB
screening in the population at large for true differences in
attitudes to screening with FOB tests. The advantages for this
approach are that the only external influence on an individual's
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responses to the questionnaire and to the screening offer could be
from immediate family or friends Who might normally help in health
decision processes. The disadvantage is that the attitudes of 25%
of the non-cornpliers are not available to the investigator.
However a considerable number of the non-compliers were approached
at home but still refused to discuss the natter indicating that
such data may never be readily available. This difficulty has also
been noted by other workers (Cummins et al,1977; Eraker et
al,1984) although Farrands et al (1984a) did not apparently
experience these difficulties.
It is quite remarkable however that 149 individuals who
failed to attend for screening should coirplete a 71-item
questionnaire with difficult abstract ideas at all. Clearly an
understanding of this groups' attitudes exhibiting compliance to
some requests from the medical profession could increase the
potential recruitment of these individuals for future screening
programmes. It is conceivable that these individuals made up the
extra 25% compliant individuals in the direct approach from the GP
during a consultation and that a mare personal approach is
required to trigger a positive screening response.
The cost in time and expense to the GP to institute his
own case-finding or screening studies would not be great. The GP's
were not burdened by any extra work or prolonged consultations to
promote the screening. In this study, whilst the patient was
requested by the GP to see a medically qualified researcher, our
Health Visitor seemed acceptable to the public. Other studies
have successfully used Health Visitors (Million et al, 1982) or
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practice nurses (Cullum and Savory, 1983; Grace, 1983) to carry
out screening, although Nichols et al (1986) felt that the use of
an ancillary worker lead to a reduced uptake of FOB screening.
Grace (1983) has also detailed how a group practice can
efficiently and cost-effectively run a screening programme without
increasing demands on the CP's time or ironey. A mere recent report
from Fullard, Fowler and Gray (1987) has emphasised the need to
utilise the practice nurses for preventive health measures and
thus maximise the return of the primary health care resources. It
is particularly gratifying for the author that the screening
clinic he initiated in one of the group practices is still on¬
going. It is thus envisaged that for urban group practices with
an attached Health Visitor or practice nurse, screening for common
diseases including colorectal cancer could be viable.
It may be concluded that the reluctance of the general
public to perform stool testing can be overcome by adequate
promotion and explanation by the medical profession. Furthermore,
the GP is ideally placed to take the lead in promoting colorectal
cancer screening in the community. Finally, there are two distinct
attitude profiles which determine conpliance to screening
measures. There is a need for continued research to understand the
factors influencing conpliance for colorectal screening in order








In chapter 2, it has been shown that there is a high
prevalence of upper and lower GI symptoms within the general
population during a given tine. The fact that 38 individuals with
symptoms were investigated and no neoplastic condition identified
serves to emphasise that syrtptoms merely reflect organ dysfunction
and not a particular pathological process.
This places the GP in a difficult position if the symptoms
he elicits from his patients are poor indicants of cancer or other
serious GI conditions. No GP will wish to miss a possible
diagnosis of cancer and he is constantly under pressure from his
hospital colleagues when he reads that there are considerable
delays in the diagnosis of cancer at the practice level (MacAdam,
1979; Holliday and Hardcastle, 1980; yhcArthur and Smith, 1984);
yet at the same time he is told that he cannot have open-access to
endoscopy as he will overwhelm the available facilities (IVhnn et
al, 1983).
In view of the findings in chapter 2, there is clearly a
need to further define 'risk' of cancer from within a symptomatic
poulation. Selective screening of epidemiologically defined high
risk groups is of course important but as pointed out by
Schottenfeld (1975) less than 10% of the cancer pool is thus
identified. However indiscriminate unselective screening is
expensive and ineffective. Thus if one suspects that new-onset
dyspepsia is a good indicator of gastric cancer risk (Gear and
Barnes, 1980) then the yield for cancer on endoscopy is 2.4%
(Allum et al, 1986). Such a yield is probably untenable in a
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screening programme. Read et al (1982) have shown that the pick-up
rate of gastric cancer is 1.4% of all gastroscopies performed and
the number of normal gastroscopies performed may be as high as 80%
(table 1.6). Similarly, Leicester et al (1983) and Farrands et al
(1985) are looking to reduce the number of unnecessary barium
enema examinations performed to exclude colorectal neoplasia.
Recently, two separate approaches to defining the risk for
specific disease processes have been investigated. These are the
analysis of symptom clusters to define the presence of peptic
disease and en passant gastric cancer and an appraisal of the
interaction of several tumour markers to detect GI cancer
preoperatively.
The statistical analysis of syirptom complexes has been
pioneered by Professor Wilfred Card (1967) to predict the relative
risk of a particular disease using likelihood ratios. His
successors have pursued this theme to produce the 'Gladys' system
to define the probability of a patient with dyspeptic symptoms
having a peptic ulcer (Spiegelhalter, 1985). In Leeds, De Dombal
has described his system of computer aided diagnosis as an aid to
the diagnosis of acute abdominal pain (De Dombal et al,1972) and
for analysis of "dyspeptic" symptoms (Horrocks and De Dombal,
1975, 1978). Recently Mann et al (1983) have reported their
experience with multivariate analysis to predict the risk of an
individual with upper GI symptoms of harbouring either peptic
ulceration, peptic stricture or gastric cancer. Using an initial
database of 235 subjects they analysed the responses to a 27-item
questionnaire and produced a scoring system which was then applied
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prospectively to a further 356 patients. The system identified
98.7% of patients with the above three conditions whilst in theory
it could have reduced the number of endoscopies by 30%.
A second approach has been a renewed interest in the use
of serum tumour nnrkers to identify cancer preoperatively.
Initially it was hoped that a serum tumour narker, such as
carcinoembryonic antigen (CEA), would have sufficient sensitivity
and specificity to detect GI cancer preoperatively in a
symptomatic individual. The recent National Institute of Health
Concensus Report (1981) declared that CEA should not be used as a
preoperative investigative tool to detect GI nalignancy and no
other individual tumour marker has been found to be of value.
However, the investigation of combinations of CEA and APRP's has
shown that they may aid in prognosis for both gastric (Rashid et
al, 1982) and colorectal cancer (Ward et al, 1977). This
observation stimulated Chu and colleagues (1982) to assess the
combination of CEA and AGP preoperatively in patients with
colorectal cancer, where the sensitivity for detection of cancer
increased significantly but was associated with a reduction in
specificity. De IVtello et al (1983) pursued this approach by using
a panel of six non-specific biochemical markers to define 'cancer
risk' preoperatively; by applying multivariate analysis they
identified 162 GI cancers (81%) with a false positive rate of 16%.
Furthermore, Walker and Gray (1983), applying discriminant
analysis to a battery of markers found that the combination of
serum protein hexose and CEA could significantly increase the
detection preoperatively of colorectal cancer.
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It was the work of IVhnn et al (1983) and De Msllo et al
(1983) that stimulated the following investigations to define the




(1) To examine the use of a panel of tumour markers to detect
GI cancer preoperatively.
(2) To determine the value of multivariate analysis to predict
risk of cancer in a symptomatic population using either
tumour markers, symptoms or a combination of both as
indicants of risk.
(3) To compare the multivariate approach to that of likelihood
ratios to determine risk of cancer.
(4) To develop a symptom scoring index of risk for gastric





86 subjects with GI cancer, 168 with benign GI disease and
720 individuals from the general public were investigated. Of the
86 GI cancers, 57 were colorectal, three of which were Dukes'
stage A, 14 Dukes' stage B, 23 Dukes' stage C and 17 Dukes' stage
D. The remaining 29 cancers were all gastric, three stage II, 13
stage III and 13 stage IV.
The benign group conprised individuals referred from one
general surgical clinic for upper and lower GI endoscopy and
enconpassed the comnon conditions of peptic ulcer disease,
gastritis, diverticular disease, irritable bowel and inflammatory
bowel disease.
The 720 "normal" individuals were recruited from the
screening study and therefore were aged between 50-70 years old
and felt to be free of overt active GI disease. These individuals
were included since it has been shown by Jones (1976) and Thomson
and Heaton (1980) that many apparently normal individuals may have
present, at any given tine, symptoms suggestive of significant
gastrointestinal disease. Thus to generate a system to determine
the risk of cancer in an individual it is necessary to take
account of the background prevalence of symptoms within an age-
matched "normal" population.
All subjects completed a self-administered questionnaire




The 41-item questionnaire as used in the previous chapter
was supplied to all synptomatic patients for conpletion. All
subjects attending for endoscopy were given the form to complete
by the endoscopy nurse and inpatients were approached by the
investigator.
Tumour markers
4 serum tumour markers, carcinoeiribryonic antigen (CEA),
alpha-l-acid glycoprotein (AGP), C-Reactive protein (CRP) and
gamna glutairyl transpeptidase (GGT) were measured.
All patients had 10 mis of blood taken from the
antecubital fossa and the sanple was placed in a plain tube and
allowed to clot. The specimen was then spun at 3,000 rpm for 10
minutes and the serum relieved. All specimens were stored at -20°C
until required for analysis.
Careinoembryonic Antigen (CEA)
CEA has been assayed by a radioimmunoassay technique. A
brief summary of this technique is now included. A direct
radioimmunoassay method is utilized using paper discs as the solid
phase. During a first incubation anti-CEA antibodies, covalently
coupled to the paper disc, react with the patient sairple. After
1 9S
washing, a fixed amount of I labelled anti-CEA antibodies is
added. During a second incubation, the added antibodies form a
specific complex with the CEA molecules which are bound to the
antibodies on the paper discs. The radioactivity of this coirplex
is then measured in a gamira counter. The greater the amount of
isotope which is bound, the more CEA is present in the sairple.
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Reagents: Supplied by Pharmacia Diagnosis AB, Uppsala, Sweden.
10 ml vials
1
1. Anti-CEA antibodies lyophilized (raised in rabbits)
contains 1 ug-7.5 uci at the date of itanufacture,
colour coded blue - 1 vial
2. CEA-free diluent, lyophilized (pig serum) - 3 vials
3. Tween solution in 5 ml vials - 1 vial
4. CEA-standards predispensed in pig serum to
2.5, 15, 50, 150, 500 ng/ml - 5 vials
5. CEA control serum, lyophilized -2x3 vials
in cassettes:
6. 3 x 30 anti-CEA antibody discs, in buffer solution
(antibodies raised in sheep) - 3 cassettes
Preparation of Reagents;
(a) CEA Control Serum
The CEA control sera were reconstituted by adding 500 ul
of redistilled water to each vial and allowed to stand for one
minute.
(b) CEA Standard Solution
CEA standards were reconstituted by adding 1000 ul of
redistilled water to each vial and left to stand for 1 minute.
(c) CEA Free diluent
Reconstituted by adding 8 ml of redistilled water to each
vial and left to stand for 1 minute.
(d) Anti-CEA 125j solution
Reconstituted by adding the entire Tween solution (5 ml)
to the vial.
(e) Anti-CEA Antibody Discs Ready for use
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Preparation of standard curve
A standard curve was automatically prepared on every test
occasion and each standard was run in duplicate and recorded using
a silent 700, Electronic Data Terminal obtained from Texas
Instruments Ltd., Bedford, England.
Test Procedure
Plastic test tubes with round bottoms and an inner
diameter of 12 mm, were used for the test procedure (obtained from
L.I.P. Equipment and Service Ltd., Shipley, W. Yorkshire).
Determinations were performed in duplicate and a standard
curve was run at each test occasion.
1. One anti-CEA antibody disc, handled by a pair of forceps, was
added to the bottom of each tube, except for tubes 1 and 2
(total activity tubes).
2. 100 ul of standard 2.5, 15, 50, 150, 500 ng/ml was pippetted
onto the discs in tubes 3-12 and a further quality control
of two previously measured speciirens, one high and one low
were also included in each CEA run.
3. Serum sanples were diluted 1:5, mixing 50 ul of the original
samples with 200 ul CEA-free diluent unless values above
250 ng/ml were expected. In such cases saitples were
diluted at least 10-fold (= 1+9), e.g. 50 ul of the
original serum mixed with 450 ul of CEA-free diluent.
4. 100 ul of unknowns were pipetted onto the discs in tubes 13
and above. The tubes were covered with plastic films and
agitated vigorously for 3 hours using a model R 100
Rotatest shaker (Luckham Ltd., Sussex, England) at room
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tenperature.
5. Each of the test tubes had all liquid removed by a vacuum
punp. 2.5 ml 0.9% saline was added to all test tubes from
number 3 onwards and the tubes allowed to stand for 10
minutes and removed as specified above. Thereafter, the
washing procedure was repeated twice.
1 75
6. 50 ul of anti-CEA. antibody solution was pipetted onto
the bottom of all tubes including 1 and 2. Tubes 1 and 2,
1 75
which contained only anti-CEA antibody I, were used to
determine the total activity added. The tubes were covered
with plastic films and left to stand overnight (16-20
hours) at room tenperature.
7. The liquid was removed and washed 3 times according to step
5.
8. The bound radioactivity was determined in all tubes using a
gamma-counter (1270 Rackgamma II counter - L.K.B.
Instruirents Ltd., Selsdom, South Croydon, England).
Calculation of Results:
1. Linear interpolation: The curve relating the counting
response (e.g. count rate, per cent bound, etc.) and the
concentration of the standards is assumed to be made up of a
series of straight lines forming the standard points. When an
unknown sairple is iteasured, the dose is obtained by linear
interpolation between the standard curve points either side of the
unknown . Between two standard points the straight line is assumed
- 180 -
to have the form:
concentration = ao + al x counting response
(ao and al are constants)
As both RlCl and R2C2 are points on one straight
line
and Cl = ao + alRl
C2 = ao + alR2




For an unknown with response Ru (lying between the values Rl and
R2) and concentrate on Cu, the concentration Cu is given by
Cu _ C1R2 - C2R1 + C2Ru - ClRu
R2 - Rl
The relationship between the count response and the concentration
of standards is expressed by:
(CPM - NSB) / (CPJy^gp - NSB)
In this instance when the reference sample is the zero
saitple (the sample having a zero concentration of unlabelled
standard), division on the unknown or standard count rate by this
value, gives fraction bound, non-specific bound (NSB) is only
subtracted When required. The form of this relationship is non¬
linear .
The calculation of the concentration of an unknown sample
is done instantaneously so that the unknown concentration is
printed on the same line after the count results.
In particular a standard curve is printed on which the
values of the actual standards are printed in the appropriate
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position; the scales for the plot are automatically set as the
basis for interpolation. The standard curve plot allows the user
to check the form of the standard curve, and if necessary, to draw
in the curve to check individual values. It also allows a check
to be made of individual duplicate or triplicate values, if for
sone reason they do not appear to follow the correct curve, the
assay can be quickly recounted omitting any which do not appear
satisfactory.
C-Reactive Protein (CRP) and Alpha-l-Acid Glycoprotein (AGP).
These agents were measured using a standard radial
immunodiffusion technique (RID). A description of the standard
technique is now presented.
The principle of RID is based on the fact that any
specific antigen (e.g. serum protein) will form a precipitin
coiiplex with its specific antiserum at a constant ratio of antigen
to antibody. An antigen when applied to a well in an agar
substrate containing specific antiserum, will diffuse radially
through the agar until the optimal rates of antigen to antibody is
achieved. Thus the quantification of the protein is obtained by
comparing the diameter produced by the serum protein with the
diameter of the precipitation rings produced by standard
commercially available serum solutions with known protein
concentrations.
There are basically 2 methods of RID:
(1) The Mancini-Heremans Technique (1965) Which is based on the
analysis of the results after the end-point of immunodiffusion has
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occurred and;
(2) The Fahey-McKelvey Technique (1965) which is designed for
early read out of results.
The first technique was used which nay provide more
accurate results at the expense of prolonged diffusion tine.
CRP and AGP
Procedure
During the preparation of the RID plates, 300 ul of the
AGP antiserum (Gehring) or 120 ul of the CRP antiserum (Behring)
was applied to the plate. Subsequently, the test sera and the
standard sera are applied to the plates. The Ad5 sera require to
be diluted to 1 in 11 whilst the standards are diluted to 1/3,
1/6, 1/12, 1/24. For CRP no dilution of the test sera is required
whilst the controls are neat, 1/2, 1/4 and 1/8.
The plate is then stored in a horizontal position at room
teiiperature in an airtight box and kept humid with danp tissues.
The antigens are then allowed to diffuse for 48-72 hrs AGP plates
may be read directly as the rings are very distinct. However,
staining of the CRP plates is required to enable accurate
delineation of the maximum extent of the precipitation rings.
Analysis
After the appropriate incubation tine, the diaireter of the
precipitating rings are measured to the nearest 0.1mm in the
I^ncini1 technique. The protein to be assayed is allowed to
diffuse until all free protein molecules have reacted with the
antiserum and no further extension of the precipitating rings
occurs. The various proteins are characterised by different
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diffusion times, at which time the end point is reached. The
diffusion time depends on the protein concentration as well as the
nolecular weight.
Reagents
1. Barbiturate Buffer pH 8.6
Sodium diethyl barbiturate (Sodium Barbitone) 20.6 g, made
up to 1 litre with distilled water (0.1M solution) and 148 ml 0.1M
HOI is then added. The pH is adjusted to exactly pH 8.6 with 0.1M
HCl or NaCH using a pi meter. The solution is then kept at 4°C for
further use.
2. Agarose for Skinning (2.5%)
1.25g of Agarose type II (Sigma Chemical Company, St.
Louis, U.S.A.) is added to 50ml of distilled water and autoclaved
to 150°c (Instrument Steriliser, Baird and Tatlock Ltd., London).
3. Agarose for Gel
1% Agarose type II in 25% dilution of the barbiturate
buffer or 1% Agarose plus 3%. PEG (polyethylene glycol 6000, BDH
Chemicals Ltd., Poole, England) in buffer was prepared as follows:
Agarose - 2g + buffer 50ml + distilled water 150ml or plus
PEG 6g were mixed together and autoclaved.
1% sodium aside was added as preservative.
The plates were skinned and left to dry at room
temperature.
For one plate 10cm x 10cm, 15ml of agarose was required,
plus the appropriate amount of antiserum, mixed thoroughly before




Forty-nine holes of 2.5mm in diameter were punched in each
plate. 5ul of serum was applied to each well using a micropipette
(5ul Micro/pettor 1055A Scientific Fhnufacturing Industries,
Emerryville, California, U.S.A.). The sera were diluted
appropriately, according to the protein being measured, using a
Clinicon Diluter (L.K.B. Instruments, South Croydon, England).
Standards and quality control sera were also applied to
the plate and diluted accordingly.
The plates were then left in a sealed container for 48-72
hours, until they had run to conpletion (AGP for 48 hours, CRP for
72 hours). The CRP plates were then dried and stained up in
Coomassie blue, until the circles were sufficiently visible to
read.
Drying and Staining Plates
1. The plates were covered with a film of distilled water and
then with a layer of filter paper and dried for 15-20 minutes
using many layers of tissue paper, which were continually
replaced. A snail amount of pressure equivalent to l-2kg was
applied on a glass plate on top of tissue paper.
2. The plates were then washed in 0.9% saline solution (20 mins
- 1 hour) and the drying procedure repeated. The plates were then
dried down completely using a hairdryer and stained.
The staining solution was prepared mixing up lg of
Coomassie blue, 90ml of ethanol, 20ml of glacial acetic acid and
90ml of distilled water. After staining for nearly 5 minutes, the
plates were allowed to destain for a variable period of tine until
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they had reached the optimal point of clearness to read, using the
following solution:
500ml of ethanol + 200ml of glacial acetic acid + 900ml of
distilled water.
Calculation of Results
The diameters were read using a graduated eyepiece (Peak
Scale LUPE 7X, Gibco Bio-Cult Ltd., Paisley, Scotland). The
concentrations of proteins in each serum saitple were calculated
with the diameters using the Hewlett-Packard calculator and
appropriate programme (Hewlett-Packard, Series 98, lVtdel 10
Calculator, Packard Instruments Ltd., Caversham, Berkshire,
England) and the results recorded using a Data Dynamics 390
Recorder (Data Dynamics Ltd., Hayes, Middlesex, England).
Gamma Glutanyl Transpeptidase
This enzyme was measured using an automated procedure as
described by Haesen et al (1972).
This method utilises the action of the enzyme in
converting amino acids or peptides into gamma glutamyl peptide
which in the living tissue can then cross cell membranes. In the
procedure any enzyme in the serum added to the system will
catalyse the reaction ->
gamma glutamyl-p-nitroanalide + glycolyglycine -GGT-> gamma
glutamyl glycylglycine and P-nitroaniline
P-nitroaniline can then be measured by colorimetry
(wavelength 410 nm). The enzyme level can then be measured as the
amount of enzyme (units/litre) that converts 1 umol of substrate




1. Amnediol buffer 0.05 M, pH 8.5. Chemical Conposition:
amnediol (2-amino-2-methyl-propanediol 1-3)
distilled water.
wetting agent Triton X-405
Preparation. Amnediol 5.26 g (B.D.H. Chemicals Ltd.,
Poole, England) is dissolved in about 700 ml distilled
water. The pH of the solution was adjusted to 8.7 + 0.1
with HCl (about 25 ml is usually required). The solution
is then diluted to 1000 ml. 3 drops of the wetting agent,
Triton X-405 (Sigma Chemical Company, St. Louis, U.S.A.)
were added and mixed.
2. GT substrate. Chemical conposition:
L-gamna-glutamyl-p-nitroanilide 2.9 mM
Glycylglycine 22.0 mM
Amnediol buffer 0.05 M pH 8.7
Preparation. L-gamna-glutamyl-p-nitroanilide, 500 mg
(Sigma Chemical Coirpany, St. Louis, U.S.A.) and
glycyglycine, 1745 mg (BDH Chemicals Ltd., Poole, England)
are dissolved with mechanical or magnetic bar stirring in
600 ml amnediol buffer at 50-60°C. The solution is stored
at - 20°C. Before use the solution is thawed in a water
bath at 37°C. It is advisable, to shake occasionally,
until the substrate is completely redissolved. The pH of
the solution is 8.2 + 0.1.
3. Stock standard p-nitroaniline, 0.735 mM 101.5 mg of p-
nitroaniline (BDH, Poole, England) was dissolved in 1000
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ml aminediol buffer solution.
4. Diluted standards. 100 ml quantities were prepared by
diluting 50, 25, 10, 5, 2 and 0.5 ml of the stock standard
with buffer solution to give p-nitroaniline standard
equivalent to 0.368, 0.184, 0.074, 0.037, 0.015 and 0.004
mM respectively.
5. Enzyme standard. A single point standardization was carried
out with an analyzed frozen (-20°c) serum pool, dispensed
in amounts sufficient for daily work.
6. Water. Distilled water, containing 5 ml 8% Brij-35 (Sigma
Chemical Conpany, St. Louis, USA) per litre, for the wash
receptable line.
PROCEDURE
The automated procedure was carried out by the Technicon
Auto-analyzer ZZII (Technicon Ltd., Basingstoke, Hampshire,
England). The incubation time is about 13 mins.
The calibration curves were constructed by introducing p-
nitroaniline standards directly into the dialyzer by a suitable
glass tube, naking use of proportioning pump suction.
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Statistical Analyses
A preliminary analysis of the relative frequency of
positive responses to each GI question was performed using a Chi
squared test to detect significantly different response rates for
cancer patients coirpared to the remaining groups. Similarly, the
cumulative frequency distribution of each biochemical variable was
plotted and, by using the 95th percentile value of the benign
group as a cut off point, the sensitivity and specificity of each
marker to detect cancer were determined.
A conparison of three approaches was next performed. The
siirple combination of tumour markers has been performed as
suggested by Chu et al (1981) and De Mallo et al (1983). The more
sophisticated approach of multivariate analysis and the use of log
likelihood ratios (Spiegelhalter 1985) are then used and coirpared.
Multivariate Analysis
A logistic discriminant analysis (Anderson, 1972; Albert,
1982) has been enployed in this study to determine which variables
are significant in discriminating between the cancer and non-
cancer subjects. A stepwise procedure was adopted in which
variables (4 tumour narkers and 18 GI questions) are added to the
model sequentially and at each step the statistical significance
for each term not already in the model is calculated. The most
significant variable at each step is added and when no variable is
significant at the 5% level the process stops. Biochemical
measurements underwent a logarithmic transfornation (log 10) and
positive responses to the questionnaire were accorded a score of
+1 and a negative response -1. Sex was coded as +1 for male and
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-1 for female. The analysis was performed using the statistical
package BMDP81, subroutine PLR, on the University of Leeds AMDAHL
470 conputer.
To fit the nodel we used 54 cancer cases and the non-
cancer group comprised 80 benign and 200 control population
(initial data set). As more cases were enrolled it was hoped that
the model could be applied prospectively, thus permitting a more
accurate impression of its validity in a clinical setting (Second
data set).
Log likelihood Ratios
A shortened description of this approach with a worked
example follows:
For a fuller description the reader is directed to Spiegelhalter
(1985). The aim of this approach is to devise a simple scoring
system which will identify risk of cancer and would require only
the use of a pocket calculator.
By using the same patient data set as utilised for the
multivariate analysis, a direct comparison of the results from the
two methods could be achieved.
(1). 'Independence' has been assumed within the diseases by
using the 'Naive Bayes' model.
Denoted as:
P(D/S1,S2, Sx) = P(S1/d) x P(S2/D) x P(Sx/d) x P(D)
P(D/S1,S2, Sx) P(S1/D) P(S2/D) P(Sx/d) P(d)
where P symptoms are shown as SI, S2, Sx.
the proportion of patients who have the symptom and the
disease are shown as P(s/D).
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the proportion of patients who have the symptom but do not
have disease are shown as P(S/D).
As it is easier to add than multiply, transform the
formula using Natural Logarithms (loge).
To derive the 'scores' the log (likelihood ratio) has been
multiplied by 5, and rounded to the nearest whole number.
Denoted as:-
51oge P(D/S1,S2,..Sx) = W(Sl/D) + w(S2/D) +.+ W(Sx/D 51ogeP(D)
P(D/S1,S2, ...Sx)
Where the loge(likelihood ratio) which is also known as the
'Weight of Evidence', is shown as W(S/D).
(2). The 'Initial odds' on CA were taken as the incidence rate of
4 per 1000 population > the age of 45.
(3). Thus the final loge (odds) is achieved by adding up the
relevant 'weights of evidence', and then adding on the
Initial loge(odds).
(4). To turn the resulting 'final score' into its theoretical
probability for disease (CA) we apply the equation
Score = 51oge(Probability / 1 - Probability)
= Probability = 1 / 1 + Exp( -score / 5).
(5). To remove the difficulty of dealing with values of infinity,
which would occur when an indicants frequency was a zero,
we add 0.5 to all numbers when working out the weights of
evidence
W(S/) = loge (AD +0.5) / (ND +0.5)
AD +0.5) / (ND +0.5)
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where AD = the number of patients with the symptom & disease
(CA)
ND = the number of patients Who have disease (CA)
AD = the number of patients with the symptom but no
disease (no CA)
ND = the number of patients who have no disease (no CA)
(Cox 1970)
(6). After working out the weights of evidence, 16 GI questions,
Age & Sex, & 3 of the tumour irarkers were decided to be of
discriminant value.
(7). These 'scores' were then applied retrospectively to the
first patient data set.
(8). By using ROC curves (Mstz,1978) a 'cut-off' point for the
probability of CA can be reached.
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EXAMPLES
To work out a weight of evidence:-








This is then rounded up to give a 1 score' of +7




This is then rounded to give a 'score' of -4
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EXAMPLE
After applying the scores to a patient's questionnaire and
tumour markers, a series of positive and negative studies will be














+62 + (-14.5) = +47.5
Then add the Initial score of -27.6 (Prior Probability)
= +19.9 (Final Score)
Then the probability of CA is:- p/l +exp(-score/5)
=1/ 1 + exp(-19.9 / 5)
=1/ 1 + exp(-3.98)
=1/ (1 + 0.018685639)
= Probability of CA = 0.981657109




The responses to the 18 GI questions for the cancer and
benign patients are shown in the table opposite (Table 4.1). As
indicated, there are six questions which elicit significantly-
different responses between those who have gastric cancer and
those with a benign upper GI condition. Similarly there are five
responses which significantly differ between colorectal cancer and
benign large bowel conditions.
The bar chart (Fig 5) indicates that patients with
colorectal cancer and gastric cancer are heavily symptomatic
having a median number of positive responses of 8 and 7
respectively. In the benign groups there is a considerable spread
of positive responses from 0-15 for benign upper GI disease and 0-
11 for benign large bowel conditions with median responses of 5
each.
The questionnaire responses to the GI symptoms for the
'nornal' group of 'screened' subjects are shown in table 4.2. In
these indivduals 73% have 2 or less positive responses to the GI
questions in contrast to those individuals with benign conditions
of the upper and lower GI tract (13.7% and 28.6%). Few patients
with cancers of the stomach and large bowel had less than 2
detectible symptoms on the questionnaire (0% and 5.9%).
The relative sensitivity and specificity of each
individual symptom shown to distinguish the cancer subjects from
the non-cancer group is further tabulated (Table 4.3). This
indicates the relative failure of these symptoms to indicate high
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Table 4.1
Percentage frequency of positive responses for question in benign and
malignant groups with P value
Q Ca Benign P Ca Benign
stomach stomach Bowel Bowel
Reduced appetite 96.6 53 0.0001* 56.67 29.76
Wt loss no diet 87 54 0.0013* 64.7 30.65
Diff swallowing 33.3 24.6 0.0001* 6.02 5.08
Food sticks 60 4 0.0031* 6.78 15.85
Heartburn 48 14.8 0.77 20 25.5
Nausea 77.4 59.46 0.078 24 42
Pain/discomf 56.6 73.13 0.1 249 52
Bowel action 14.8 5.48 0.12 35 25
Incomplete emptying 13.3 20 0.42 50 41
Alt stool frequency 32.4 13.3 0.028* 71.9 37.8
Alt stool appearance 25 12.3 0.13 62.7 36.7
Looseness 33.3 33.3 1 44 56
Constipation 58.62 18.92 0.0001* 33 31.25
Blood 10.34 10.67 0.69 46.67 32.94




















Frequency of positive responses per question in
the general practice group
No. %
Reduced Appetite 55 6.75
Wt loss, no diet 35 4.3
Difficulty swallowing 20 2.45




New pain 61 10.34
Bowel habit 32 4.03
Incoitplete emptying 66 8.12
Altered stool frequency 50 6.17







Sensitivity and Specificity of individual symptoms to indicate risk of
cancer- comparing ca v non-c groups
COLORECTAL CANCER sens % spec :
Loss appetite 56.67 82
Wt loss 64.7 82.5
Alt stool frequency 71.9 78
Alt stool appearance 62.7 78
GASTRIC CANCER sens % spec ;
Loss app 96 70
Wt loss 87 71
Diff swallow 33.3 86.5
Food sticking 60 95.5
Alt stool frequency 32.4 90
Constipation 58.6 83.5
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Fig 5 Histogram showing frequencies of symptoms













































risk of cancer on an individual basis. Since a diagnosis is
routinely made on the preence of several synptoms the analyses in




The range of values for the single agents within the
groups was large and there was considerable overlap between the
groups (Table 4.4). The 95th centile for the benign group values
were selected as the cut-off point for cancer and non-cancer
values. Thus the cut-off values for CEA, AGP, CRP and GGT were 10
ng/ml, 1.4 g/l, 12 irg/1 and 50 U/l respectively (Table 4.5). The
mean and standard deviations for the analysis by group are also
shown (Table 4.6).
The sensitivity of the markers in detecting gastric
cancer, colorectal cancer and all cancers is tabulated (Table 4.7)
using this selection criterion. Thus only 27 of 57 colorectal
cancers (47.4%) had a CEA level greater than 10 ng/l, and only 14
(48.3) gastric cancers had similarly elevated levels.
The ability to detect early stage cases by this analysis
is poor (Table 4.7), with only one third of Dukes' A & B
colorectal cancer cases being detected by AGP and CEA, and no
early (Stage II) gastric cancers being detected except in 1 case
by GGT. However, 67% Dukes' D colorectal cancers were detected by
CEA and CRP detected 53.3% of these cases. GGT and AGP were less
effective in detecting these cancers with 33% and 46% cases
identified respectively. The majority of gastric cases were
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Table 4.4
Range of marker values by group
Marker Benign Cancer GP
Range Range Range
AGP 0.4 - 3.2 0.48 - 3.4 0.4 - 1.94
(g/i)
CRP 1-66 1-134 1-51
(mg/1)
CEA 2.5 - 17 2.5 - 250 2.5 - 17
(mg/ml)




Percentage of patients with a tunour marker value
greater than the 95th centile of the benign group
Tumour marker Cut off value Cancer % Normal %
95th centile colorectal gastric
CEA >10ng ml-"'" 47.4 48.3 2.5
AGP >1.4g l-1 36.8 65 2.6
CRP >12mg l-1 44 69 2.8
GGT >50U1-1 14 10 2.1
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Table 4.6
Mean values by group of 4 tumour markers
Benign Cancer GP
Mean S.D. IVfean S.D. INfean S.D.
AGP 0.9759 0.3728 1.4412 0.5990 0.8793 0.2139
g/i
CRP 7.7544 33.9338 21.9691 29.3273 3.4604 5.6290
mg/l
CEA 4.8994 8.2752 40.0234 71.0434 3.7876 2.3578
ml/ml




Detection of Cancer (%) by Individual Tumour IVbrkers
A+B Total II Total
AGP 31 36.8 0 65 46.5
CRP 37.5 44 0 69 52.3
CEA 31 47.4 0 48.3 47.7
GGT 6.25 14 33 10.4 12.8
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advanced (26 of 29) and table (4.7) shows that the acute phase
reactant proteins are superior to CEA in the detection of gastric
cancer.
In the GP group there were a number of individuals who had
levels of a tumour marker above the relevant cut-off point. There
were 18 subjects with a CEA > lOng/ml, but less than 20 ng/ml, 20
subjects with a raised CRP, 19 with elevated AGP. 15 members of
the GP group had a GGT greater than 50 u/l with one level at 470
U/l.
The cause of these elevations could be found in some cases
for the acute phase reactant proteins AGP and CRP. An elevated
marker was found in individuals presenting to their GP with an
acute viral illness and a sore throat, colds and flu and also in
those with arthritis. Smoking accounted for the majority of
elevated CEA's with the mean for smokers being 3 ng/ml higher than
for non-smokers in the study.
Combination of Analytes
Table (4.8) shows the inpact of defining a patient as
having cancer if one of the agents in the combination is positive.
Thus using the combination of CEA + CRP, 5 additional colorectal
tumours were detected but 57 subjects in the non-cancer group were
also positive (6%). In this way one additional gastric cancer
would also be detected. By adding further analytes into the
combination whilst 2 additional colorectal and 1 gastric cancer
were detected the specificity as expected started to fall. Thus
the 4 marker combination identified 66 (65%) of the cancers at the
cost of a 10.5% false positive rate.
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Table 4.8
Combination of Analytes to detect cancer
Tuitour Marker Colorectal Gastric Total Specificity
n % n % % %
CEA 27 47.4 14 48.3 47.7 95
CEA + CEP 32 56 21 72.6 61.6 94
CEA + ARP + AGP 33 57.9 21 72.6 62.8 93
CEA + AGP + CEP
+ GGT 34 59.6 22 75.8 65.1 89
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Multivariate Analysis
The initial data set was used to fit a logistic model to
discriminate the cancer from the non-cancer group. Using only the
biochemical data, 36 (67%) of the 54 cancer patients were
correctly classified, with a false positive rate of only 5%. The
18 cancers missed by this siirple discriminant included 5 patients
with liver metastases from colorectal cancer and 2 patients with
advanced gastric cancer. A similar analysis using only the 18 GI
oriented questions on the questionnaire correctly classified 60%
cancers with a 5% false positive rate. In a logistic analysis
using both the questionnaire and biochemical data, 50 cancers
(92%) were separated from the non-cancer groups, with a similar 5%
false positive rate (Table 4.9). This is a significant
improvement on both the questionnaire and biochemical data When
used individually (p<0.02 X test). The cancers misidentified
were 2 colorectal cancers (Dukes' stage C + D) and 2 gastric
cancers (stage II + IV).
The fitted model is determined by the discriminant
function (log to base 10):
y = 0.605 (sex) + 0.112 (age)
_ 2.73 log (CRP) +5.33 log
(CEA) - 4.09 log (GGT) + 1.05 (wt. loss) + 0.968 (bowel habit) +
constant (8.4)
and the probability of cancer is then P = exp (y)/(l + exp(y)).
The "optiiral" cut off point for these values to indicate
cancer is p > 0.275 (Fig 6).
By applying this criterion to the second data set, 28 of
- 207 -
Fig 6 Histogram of predicted probability of cancer
using multivariate analysis (initial data set).








Results of Stepwise Logistic Regression
the initial data set
- analysis applied to
Biochemical markers
Predicted Sensitivity 66.7
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64 270 334 Overall accuracy 94.6
Chi square =m,- p< 0.02
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32 cancers (88%) were selected but the specificity fell to 89%
(Table 4.12). The 4 cancers misclassified as low risk for cancer
were all colorectal (Dukes' C).
The application of this type of analysis to the patients
with benign disease, lead to 26 of the 168 individuals being
identified as at "high risk" of cancer. However, included in the
26 there were 4 subjects with gastric ulceration or polyps and 4
patients with large colonic tubular polyps and villous adenomas.
Thus the system detected further "high-risk" potentially
premalignant conditions which clinicians would wish to
investigate.
Fifty-six subjects of the 720 individuals in the GP study
were classified by the analyses to be at high risk for cancer.
Only seven were investigated but no neoplasia was detected (4
diverticular, 1 haemorrhoids, 1 colonic inertia, 1 duodenal
ulcer). In the remainder, raised acute phase reactant proteins
(APRP's) due to upper respiratory tract infections (the reason for
the GP consultation) nay have caused the falsely high probability
value. To date with a follow up of 18 months no cancers have been
identified in these 56 subjects. However, within the control GP
population one wonan has presented with obstructive jaundice
secondary to carcinoma of the pancreas. She was entirely
asymptomatic at the time of initial screening.
Likelihood Ratio Analysis
Using the same initial test data set as for the
multivariate analysis the weights of evidence were calculated for
the GI questions and tumour markers. GGT was found to be of no
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Table 4.10































































11. Change in Frequency
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practical value for discriminating between the groups and has been
eliminated from further calculations. The final weights or scores
are shown opposite (Table 4.10) where the prior probability value
is noted to be -27.6.
The individual scores for each subject can then be plotted
(Fig 7) and by applying receiver operator characteristics (ROC)
curves the optimum "cut-off" point can be estimated. In this case
a value of -15 as a score or a probability of greater than 0.05
has been taken as our cut-off value (Figs 7 and 8). Using these
values, the results for the questionnaire, turrour marker data and
the combination of both are shown for the initial data set (Table
4.11).
Once again the combination of data from the questionnaire
and tumour markers is superior. The eight cancers missed by the
combination of the questionnaire and tumour rrarker data were one
stage IV gastric cancer, 3 rectal cancers (Dukes' B(2) and C) and
4 colonic cancers (2 Dukes' B and 2 Dukes' D). Three of the four
GP subjects with an 'at risk1 score were symptomatic at the time
of completion of the questionnaire. On review one was still
symptomatic as well as FOB positive and was fully investigated
with only diverticular disease of the sigmoid colon being found.
In the fourth, a smoker with an elevated CEA, presented with
bronchitis which would account for the elevation of ARP & CRP
which made him positive for the study. The false positives from
the benign group included diagnoses of peptic ulcer and gastritis
in 4 subjects, perianal conditions, 1 villous adenoma of rectum,
diverticular disease and the irritable bowel syndrome.
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Distribution of scores for three groups using
























Fig 8 probability distributions for cancer in the

























Results of Log-Likelihood Ratio Analysis applied to the initial data set
Biochemical Markers
Predicted Sensitivity 59.3
Cancer Non-cancer Specificity 92.9
Ca 32 22 54 Pos Predictive Value 61.5
Actual
Non-ca 20 260 280 Neg Predictive Value 92.2
52 282 334 Overall accuracy 87.4
Questionnaire
Predicted Sensitivity 70.4
Cancer Non-cancer Specificity 94.3
Ca 38 16 54 Pos Predictive Value 70.4
Actual
Non-ca 16 264 280 Neg Predictive Value 94.3
54 280 334 Overall accuracy 90.4
Biochemical markers plus Questionnaire -
Predicted Sensitivity r—1IT)CO
Cancer Non-cancer Specificity 94.6
Ca 46 8 54 Pos Predictive Value 75.4
Actual
Non-ca 15 265 280 Neg Predictive Value 97
51 273 334 Overall accuracy 93.1
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Table 4.12
Comparison of Results between log likelihood ratio method
and multivariate analysis for Second data set
Log likelihood ratio
Predicted Sensitivity 84.37
Cancer Non-cancer Specificity 98
Ca 27 5 32 Pos Predictive Value 69.2
Actual
Non-ca 12 596 608 Neg Predictive Value 99.16
39 601 640 Overall accuracy 97.34
Multivariate analysis
Predicted Sensitivity 87.5
Cancer Non-cancer Specificity 88.8
Ca 28 4 32 Pos Predictive Value 29.2
Actual
Non-ca 68 548 608 Neg Predictive Value 99.2
96 552 640 Overall accuracy 88.75
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To parallel the multivariate approach the second data set
was processed using the cut-off derived from the initial data set.
In contrast to the multivariate method the specificity did not
fall but iirproved to 98.5% (Table 4.12). A comparison of results
is shown in this table for the two approaches. The distribution of
scores and probability of cancer for the second data set using the
log likelihood method are shown (Figs 9 and 10).
The cancers missed by the log likelihood ratios in the
second data set were 2 gastric cancers (Stage II + IV) and 2
rectal cancers (Dukes' C + D) and one splenic flexure cancer
(Dukes' Stage C). 7 benign cases were declared as cancer. These
included 2 gastric polyps and one gastric ulcer, a colonic polyp,
2 cases of diverticular disease and one individual with the
irritable bowel syndrome. Two GP subjects were also felt to have
cancer. In one the positive responses to the GI question could be
attributed to her chronic renal failure and in the other a raised
CRP and AGP were contributory to his predicted high risk of
cancer.
Table 4.12. illustrates the high positive predictive yield
for the log likelihood ratio method (69%) which is considerably
higher than for the multivariate approach (29%).
Further Application of Log Likelihood Ratios to the
earlier diagnosis of gastric cancer.
In view of the attempts of Mann and his colleagues (1983)
to establish 'risk' for significant upper gastrointestinal disease
using discriminant analysis techniques, a further investigation of
log likelihood ratios to specify risk of gastric cancer has been
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9 Distribution of scores for three groups using Log
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Gastric Cancer v Rest (Upper GI Genign + GP)
Appetite Change Yes +8
"
No -10
Appetite Decreased Yes +1
No -10
Weight Decreased Yes +11
No -11











No -2 70-79 +8
Different Pain Yes +2 80+ +14
No -4




As in the previous analyses an initial data set and a
second data set have been assessed. The initial data set
conprised the 29 gastric cancers, 64 benign gastric duodenal and
oesophageal lesions and 200 GP cases from the main study. The
symptoms of a further 71 gastric cancers (20 early i.e. Stage I)
and 100 patients with endoscopically proven benign disorders of
the stomach (38), oesophagus (18) and duodenum (44) were recorded
in a retrospective review of their case records. This data was
then used as the second data set to give an indication of the
positive predictive value of the scoring system thus derived from
the initial data set (Table 4.13).
A prospective study was then established to coirpare a
consultant clinician's assessment of risk of gastric cancer in any
new referral to a dyspepsia clinic with the predicted risk defined
by this newly generated scoring system. The clinician was then
also asked to state the likelihood of peptic ulceration to be
present in each subject. He did this blind with the data being
collated separately for estimation of the scoring index. Three
hundred individuals were assessed in this way and the final
clinical diagnoses are shown (Table 4.16).
The values obtained from the initial data set for the
responses to the upper GI questions are shown opposite (Table
4.13). Once again the starting score was taken to be -27.6.
Applying these values the sensitivity for cancer with the
system was 79.3% for the initial data set with a specificity of
94.7% (Table 4.14). When the scoring system was applied to the
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second data set the sensitivity became 81.7% with a specificity of
94% (Table 4.14). Thirteen (65%) of 20 early gastric cancers were
detected and 45 (88%) of 51 advanced gastric cancers were also
identified as being high risk individuals (Figs 11 + 12). The
patients felt to be at risk from the benign group included 6
individuals with gastric ulcers, 2 subjects with peptic stricture
and 3 individuals with chronic duodenal ulceration. No subject in
the GP control group fell into the at risk group.
Table (4.15) shows an alternative way of handling the
probability data in which risk of gastric cancer in the second
data set is defined as P>0.05, risk of sigificant benign disease
as 0.000018 < P <0.05, and any individual with a risk lower than
0.000018 as being 'normal'.
The comparison of the predicted risk for gastric cancer in
a dyspeptic individual for the scoring system and the clinician is
shown in Table (4.17). The table shows a remarkable similarity in
the overall performance for the scoring system corrpared to the
clinician. Whilst the clinician's specificity was excellent at
95%, he only spotted as high risk four of seven early gastric
cancers coirpared to all seven being selected as high risk by the
scoring system. By adopting the high, intermediate and low risk
categories all the cancers were detected by the scoring system and
only one was missed by the clinician (Table 4.18). At the same
tine there was considerable accord as to which patients were felt
to harbour no significant disease and 20% fell into this category
for each method of assessment.
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Table 4.14
Log likelihood ratio analysis to predict risk of gastric cancer
Initial data set
Predicted Sensitivity 79.3
Cancer Non-cancer Specificity 94.7
Ca 23 6 29 Pos Predictive Value 62.2
Actual
Non-ca 14 250 264 Neg Predictive Value 97.7
37 256 293 Overall accuracy 93.2
Second data set
Predicted Sensitivity 81.7
Cancer Non-cancer Specificity 94
Ca 58 13 71 Pos Predictive Value 82.9
Actual
Non-ca 12 188 200 Neg Predictive Value 93.5
70 201 271 Overall accuracy 91
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Fig 11 Distribution of scores for dyspepsia study
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Table 4.15
Distribution of subjects according to "risk" category for
second data set
Cancer Benign disease 1 Normal'
High Risk 58 12 0 70
Intermediate 11 74 18 103
Low Risk 2 14 82 98
71 100 100 271
High risk Probability > 0.05 score > -14.5
Low risk P< 0.000018 score < -27
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Table 4.16












140 Endoscopy and ultrasound negative
- 227 -
Table 4.17
Comparison of clinicians prediction of cancer risk with log
likelihood ratio risk for 300 prospective subjects with dyspepsia
Log likelihood Ratio
Predicted Sensitivity 93.7
Cancer Non-cancer Specificity 89.4
Ca 15 1 16 Pos Predictive Value 33.3
Actual
Non-ca 30 254 284 Neg Predictive Value 99.6
45 255 300 Overall accuracy 89.6
Clinician
Predicted Sensitivity 56.2
Cancer Non-cancer Specificity 94.7
Ca 9 7 16 Pos Predictive Value 37.5
Actual
Non-ca 15 269 284 Neg Predictive Value 97.4
24 276 300 Overall accuracy 92.6



















































IVfeny authors have shown that a proportion of colorectal
and gastric cancers nay be relatively slow to both grow and
metastasise and that the longer symptoms are present prior to
diagnosis the better is the prognosis (Irvin and Greaney, 1977;
McDermott et al, 1981). It may therefore seem illogical to divert
resources to the earlier temporal detection of symptomatic cancers
if the survival for most active tumours will not be affected
(Austin, 1980). Welch and Donaldson (1974) have indeed shown that
whilst the delay to diagnosis of rectal carcinoma was reduced from
7 months to 2 months no real survival benefit accrued to these
patients. However, Holliday and Hardcastle (1981) have shown that
many individuals presenting with large bowel obstruction,
secondary to colorectal carcinoma, had presented to their GP's
within the previous 12 months with highly suggestive
symptomatology of cancer. In these patients the mortality for
surgical treatment was 38% compared to 7% for elective resection
for cancer. Similarly Waldron et al (1986) noted that 51% of
their colorectal cancer patients presented at an age of 70 years
or more and of these 58% presented as emergencies with a
subsequent 38% operative mortality. Both groups of workers feel
that earlier diagnosis would reduce the operative mortality for
colorectal cancer,possibly overall mortality, and advocate
stronger efforts to detect these cancers at a period before
obstruction is present. For gastric cancer there is some evidence
that earlier temporal detection in the symptomatic group will
increase the resection rate and confer improved palliation for
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these patients (Fielding et al, 1985).
It was the apparent success of Mann et al (1983) and De
Mello et al (1983) using sophisticated statistical methods to
define risk for significant benign gastrointestinal pathology or
cancer that stimulated this further appraisal of questionnaire and
turiDur markers to define risk of colorectal or gastric cancer in a
synptomatic individual. This in turn could be used to determine
priority for investigation in symptomatic individuals.
Consequently a reduction in the delay to diagnosis of these
cancers either at the GP or hospital level could be achieved
(NhcAdam 1979; Holliday and Hardcastle 1981; IVhcArthur and Smith
1984).
The problems of using a single tumour marker for
preoperative cancer detection are again well demonstrated in this
study. Even by taking the 95th centile value of the patients with
benign disease as the cut-off point for CEA detecting cancer,
there are still 2.5% of the normal population with elevated CEA
levels (nearly all smokers), whilst the sensitivity for cancer
overall was only 47%. Whilst the level of cut-off at 10 ng/ml is
twice that of the manufacturer's recommendation, the sensitivity
for CEA in detecting Dukes' A + B cancers at 31% and 67% for
Dukes' D cancers is consistent with many reported series (Dhar et
al, 1972; Lo Gerfo et al, 1972; Lawrence et al, 1972; Shuster et
al, 1974; Livingstone et al, 1974; Miller et al, 1974; Booth et
al, 1974; Luporini et al, 1976; Beatty et al, 1979). Similarly
for gastric cancer CEA detected less than 50% of advanced lesions
and this is similar to other reported series (Tatsuta et al 1980;
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Satake et al 1981; Staab et al 1982). Even the simple additive
effect of combinations of markers as reported by Chu et al (1982)
has done little to increase the sensitivity for cancer while
increasing the false positive rate.
Similarly the sinple analysis of symptoms (Tables
4.1,4.2,4.3) emphasises how difficult it is to interpret a single
symptom to make a diagnosis of cancer. For example, rectal
bleeding in a patient older than 50 years might normally be
considered worthy of investigation by digital rectal examination,
proctosigmoidoscopy and barium enema. Certainly 47% of colorectal
cancer subjects in this study complained of this symptom but so
did 33% of benign control subjects and 11% of GP subjects making
this symptom statistically insignificant as a risk factor for
colorectal cancer. However, in clinical practice diagnosis is
seldom dependent upon a single symptom or sign but usually as the
combination of several symptoms. But even using the multivariate
approach as proposed by Mann et al (1983) the ability to
discriminate between cancer and non-cancer was not great (60%) and
serves to emphasise the considerable overlap of symptoms between
normal subjects, symptomatic subjects with benign conditions and
those with colorectal and gastric cancer. Whilst the conditions
are different from those proposed by IVbnn et al (1983) these
findings do raise doubts concerning the validity of symptom
complex analysis alone to determine cancer risk.
It was the combination of the questionnaire and tumour
marker data however that lead to a significant increase in
prediction of cancer by the statistical methods (p < 0.02, for
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stepwise logistic regression, Table 4.9). Using the optimising
function on the BMDP package the probability cut-off was
determined. Similarly for the log likelihood ratio (LLR) method
the combination of symptoms and tumour narkers was mare accurate
overall and receiver operator characteristic curves were used to
give confidence to the cut-off scores and probability levels
(IVtetz, 1978). Using these cut-off values and the discriminant
functions derived in the initial data set encouragingly high
sensitivities were maintained for the prediction of cancer in the
2nd data set, and were equivalent to 88% and 84.4% respectively
for the SLR and LLR irethods (Table 4.12). However, Whilst the
specificity for the log likelihood ratio method was iraintained
that of the stepwise logistic regression fell to 89%. This
difference is further reflected in the positive predictive values
for the second data set. Since the positive predictive value more
accurately assesses the validity of an agent then the log
likelihood method appears superior at 75% compared to 29% for the
stepwise logistic regression analysis. It is not immediately
clear why such a difference should exist between these two
methods. One possible explanation is that whilst the logistic
regression irethod relinquishes any value that does not inprove the
discrimination of the cancer group from the non-cancer group to
the 5% level the LLR retains all values where there is any
difference between the groups. By retaining these values, their
cumulative weight may influence the outcome.
As demonstrated in Chapter 2, the general population are
frequently symptonatic with 27% having 3 positive responses to
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the GI symptoms on the questionnaire. It was therefore felt
important that any method to detect risk of cancer from within a
synptomtic population should take acount of this prevalence of
symptomatology. This has not been deemed necessary by IVhnn et al
(1983) or Davenport et al (1985) who used subjects being
endoscoped as their controls. This might nake the general
application of their systems at the primary referral level i.e.
the initial GP consultation, which was their first intention,
somewhat suspect. It is therefore gratifying to see only 56
(7.7%) of the GP subjects were felt to be at high risk for cancer
using the stepwise logistic regression analysis. Of the seven
investigated on clinical grounds no neoplastic disease was found
and neither was there any tuirour detected in the remaining 49 over
18 months follow-up. One patient has presented with obstructive
jaundice secondary to a pancreatic neoplasm 12 months after her
initial screening visit. She was entirely free of syirptoms at the
tine of screening and all her ltarkers were within normal limits.
Twenty-six of the benign disease group (15%) would have been
classified as being at high risk of cancer. Within this group,
patients with potentially premalignant conditions e.g. gastric
polyps, gastric ulcers and colorectal polyps were commonly
declared as being at high risk for GI cancer (8 of 26) and this
my represent success rather than failure of a system to determine
priority for investigation in these individuals and would fit
IVbnn's category of significant disease ( IVhnn et al, 1983).
The follow-up of these 26 "high risk" individuals from
within the benign control group has revealed one cancer already.
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This man with upper GI symptoms who had a negative barium neal and
endoscopic examination, re-presented 6 months later and was found
to have a carcinoma of the fundus of the stomach. The probability
of cancer at the first presentation was 80% using the
questionnaire and turrour marker data.
Such results in a preliminary study must always be met
with caution. Whilst the number of non-cancer subjects used in
this study is larger than previous reports, the overall study is
small and prolonged periods of prospective data collection would
be necessary to fully evaluate the potential of this approach.
Furthermore, to miss between 8 and 13 cancers (SLR and LLR
respectively), the majority of which were potentially curable is
not to be considered lightly. However, all three symptomatic
Dukes' A cancers and 13 of 14 Dukes1 B cancers were detected by
the stepwise logistic regression method but 4 Dukes' B cases were
missed by the log likelihood approach. Both systems failed to
identify the two cancers detected as part of a work-up of iron
deficiency anaemia. However, a symptom questionnaire cannot
detect asymptomatic cancers, and it is stressed that the object of
this exercise was to identify risk for cancer and therefore to
define priority for investigation when dealing with a syirptomatic
population. Any patient with persistent symptoms could easily be
referred sooner, irrespective of the probability value. An
alternative to this would be to define high risk, intermediate
risk and low risk groups for cancer. All high risk individuals
would be investigated urgently, intermediate risk reviewed and
investigated for persisting symptoms and the low group reviewed by
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the GP or at the patient's request. This has been performed in
the first study of tumour markers and syirptoms using high powered
statistical analyses and these results are available in the
.Appendix (IVhrshall and Chisholm, 1985).
The basic cost for this approach must be considered as a
balance between expenditure on the biochemical tests versus any
reduction in investigation costs by reduced referral rates. The
biochemical analyses cost £5.00 per head (including labour, but
excluding overheads) the brunt of which is the price of the CEA
tests. This could be offset by the reduction in unnecessary
investigations where the probability of cancer is extremely low.
As stated earlier the aim of this study was to investigate
a simple means of predicting the risk of cancer of colon and
stomach which would be readily acceptable to the public and not
tine consuming for the clinician. However, there is no reason why
the data could not be applied simply to one or other cancer to
study risk specifically for either one.
When applied to colorectal cancer, the SLR system
identified 44 (80%) of the cancers as being high risk and only 4%
of benign colorectal lesions as high risk. Whether this approach
would have much value is open to question, since both Leicester
and his colleagues (1983) and Farrands et al (1985) have shown
that FOB testing in patients with lower gastrointestinal symptoms
are extremely reliable. Leicester et al (1983) found 85% colonic
cancers and 50% rectal cancers were FOB positive and Farrands et
al (1985) had a 100% sensitivity for colonic cancer in their
consecutive outpatient series. In both these series a modest
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false positive rate was encountered and clearly a priority group
for full colonic assessment was defined. Clamp and Wenham (1984)
however, have shown that the combination of computer predicted
risk using a structured questionnaire plus FOB testing in a
general practice setting is mare effective than either agent used
individually. It is regretted that in this current study the
cancer and benign disease groups did not undergo FOB testing to
permit further comparison.
The potential for symptom analyses however may well be
best realised in the management of upper GI symptoms. Both Mann
et al (1983) and Davenport et al (1985) have successfully used
scoring systems to determine risk of harbouring peptic stricture,
peptic ulcer and to a lesser extent gastric cancer. Davenport et
al (1985) however tested their own patients responses using Mann's
scoring index (IVhnn et al, 1983) and found that a high percentage
of their patients with serious pathology were classed as low to
intermediate risk. They further found that one third of gastric
cancers were missed with Mann et al1s system. With the great
interest that now exists in the increased detection of early
gastric cancer (Fielding et al, 1980; Ward et al, 1985, 1986;
Allum et al, 1986) calls for increased upper GI endoscopy to
exclude the presence of early gastric cancer in new onset middle-
age dyspeptic patients (Ward et al, 1985; Allum et al, 1986) are
becoming commonplace. However, Holdstock et al (1979) and Mann et
al (1983) claim that it will be impossible to service open-access
endoscopy requirements to meet these demands. It therefore seemed
appropriate to assess whether within the broad group of patients
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with "dyspepsia" there were certain combinations of symptoms which
could readily identify cancer from non-ulcer dyspepsia, gastritis,
peptic ulcer and motility disorders.
It was surprising considering the overlap of symptoms
within these diagnoses that the log likelihood system was able to
identify over 65% of the EGC and 88% advanced gastric cancers in
the retrospective study. The fact that many of these false
negative cases had no symptoms and were found only as part of the
investigation of anaemia is not particularly a failure of the
system which relies on synptoms being present, but merely a
reflection of the spectrum of presentations of gastric cancer.
Furthermore, the false positive cases detected included 6 gastric
ulcers, 2 peptic strictures and a pyloric stenosis which all
require rather different management to the routine duodenal ulcers
and non-ulcer dyspepsia.
Once again this is only a preliminary investigation and
little weight can be attached to the findings, but the prospective
study of 300 newly referred dyspeptics to a GI clinic has given
considerable encouragement to the belief that a more rational
system to define priority for investigation in dyspeptic patients
may be available. The fact that the scoring system correctly
identified all 7 early gastric cancers and 8 of 9 advanced gastric
cancers as being high risk patients with a 9% false positive rate
is directly comparable to the performance of a consultant
gastroenterologist.
The value of this type of approach is not only in
identifying priority for investigation but it may identify those
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with so remote a chance of harbouring any serious pathology that
the need for endoscopy could be avoided. Thus Mann et al (1983)
and Davenport et al (1985) have speculated at least 30% of
endoscopies could be avoided. Using the artificial cut-off
derived in the retrospective group for low risk in the current
study 20% of the 300 clinic referral patients could also in theory
have had endoscopy withheld. Thus a scoring system has been
produced which has more potential to accurately define risk of
gastric cancer than that previously proposed by Gear and Barnes
(1980). These authors suggested that new-onset dyspepsia of two
weeks duration in middle age was sufficient evidence of risk to
warrant endoscopy. This approach has been supported by Ward and
Johnston (1986) in Leeds and by Fielding (Allum et al, 1986) in
Birmingham. Since one percent of the population over 40 years of
age fit this criterion of 'risk1 (Gear and Barnes, 1980), 110,000
endoscopies would be required to be performed in the first year of
screening if all individuals aged 40-65 years were thus considered
and accepting a steady state of 0.4% entry per year, a further
44,000 endoscopies per year would follow (Gear and Barnes 1980).
Allum et al (1986) have pursued this definition of 'risk' in a
community screening service of new-onset dyspeptic subjects and
gained a positive predictive yield for gastric cancer of 2.4%.
They also found that there were a considerable number of follow-up
endoscopies required in the further management of gastric ulcer
and "premalignant" lesions such as chronic gastritis, intestinal
metaplasia and dysplasia which wauld also accrue (Allum et al,
1986).
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By trying to further define risk through symptom analyses
the aim would be to define high risk and therefore accelerate
investigation and at the same time reduce the number of
unneccessary investigations. This would not increase the number
of early gastric cancers found per year but would increase the
yield per endoscopist should the system prove effective in a
prospective manner. Thus the positive predictive yield for gastric
cancer in the log likelihood ratio prospective study was 33%
compared to 2.4% for the Birmingham study (Allum et al, 1986).
The scoring system could perhaps render this form of selective
screening more feasible particularly if the very low risk cases
were simply observed following their first clinic visit.
For the present it would seem that there is no sinple
cheap and effective method to increase the detection of early
gastric cancer or even advanced gastric cancer. Perhaps the
British Society of Gastroenterologists1 early gastric cancer/
dysplasia study will reveal much more about the natural history
and symptomatology of these conditions that will permit their
easier detection. However for the present perhaps as Cuschieri
suggests instead of the ideal situation with endoscopy based in
group practices, selective screening of such at risk groups as
patients with Pernicious Anaemia nay be necessary (Cuschieri,
1986).
In conclusion, multivariate aalyses as suggested by De
Msllo et al (1983) and IVbnn et al (1983) can be successfully
applied to tumour markers and symptoms to identify cancer 'risk'
in a symptomatic subject. However, neither will be as successful
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alone as when both are combined.
Analyses of dyspeptic symptoms can define "risk" of
gastric cancer including a high percentage of patients with early
gastric cancer. This approach is worthy of further prospective





Haemoccult detects asymptomatic colonic cancers and
significant sized adenomatous polyps. The rate of three cancers
identified per 1,000 individuals screened is comparable with other
British studies and coupled with a predictive yield of 33%
highlights the potential of this agent in population screening for
colorectal cancer.
Fecatest has an unacceptably high positive rate (12.6%)
even with adequate dietary restriction, whilst yielding no
neoplastic disease on subsequent investigation of these cases.
This precludes its use as a screening agent for colorectal cancer.
Hema-chek seems in this limited study to be less sensitive to
occult blood in the stool than Fecatest but would appear similar
to Haemoccult and may be worth further examination in view of its
slightly lower cost.
A self-administered symptom questionnaire can be designed
to elicit gastrointestinal symptoms. However, a pilot study is
mandatory to assess the validity of the responses attained, and
should measure the acceptability of the questionnaire to the
target population, as well as the consistency, reproducibilty and
the applicability of the responses once recorded.
Screening for colorectal neoplasia with a symptom
questionnaire did not reveal any unsuspected tumour, although many
individuals with benign pathology were identified. The inclusion
of a questionnaire can only lead therefore to an increase in the
number of investigations performed and so increase the running
costs of the screening programms.
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Direct involvement of the GP in the initial screening
approach during a routine consultation resulted in a 75%
compliance rate. This rate was unaffected by age, sex or socio¬
economic factors. The response to a written invitation to attend
the practice surgery to participate in screening was significatly
less than for the direct approach at 50% (p<0.05). However, even
this response is greater than the average compliance to a postal
FOB method in the United Kingdom which is approxinately 33%. These
results would therefore seem to indicate that the way in which FOB
screening is promoted is a critical factor influencing the final
compliance rates and ultimately the viability of population
screening.
There exist two distinct attitude profiles separating
compliant and non-compliant individuals for a screening offer.
Compliant subjects have good awareness of the benefits of the
early detection and treatment of cancer, have a certain respect
for the medical profession and feel that they may be potentially
at risk from cancer. By contrast, the non-compliers are
pessimistic about the treatment of cancer, hold the medical
profession in low regard and have an unrealistic impression the
inpact illness makes on their lives. Psychologists and
educationalists may be able to manipulate these attitudes in
future studies to overcome resistance to screening and so increase
the uptake of screening facilities.
The detection of symptomatic cancers with single tumour
markers is poor even in relatively advanced cases. Similarly there
is considerable overlap in the symptoms present in benign and
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malignant GI disease. The application of multivariate analysis to
the combination of symptom and tumour marker data showed a
significant improvement in the diagnosis of GI cancer (p< 0.02),
compared to either modality assessed on its own. Similarly the
analysis of the dyspeptic patients' symptoms by the log likelihood
method has shown itself to be of value in accurately predicting
the probability of gastric cancer for a given individual. These
approaches have the merits of being cheap, non-invasive and can
rapidly identify priority for further investigation from within a
sypmtomatic population, thereby having the potential to reduce the
delays in diagnosis that can occur in general and hospital
practice.
Future requirements for the earlier detection of
colorectal and gastric cancer will depend on the development of
more suitable diagnostic tests or selection of more appropriate
'at risk' groups. Immunological tests to identify only humn
blood with no cross-reactions with animal blood or preoxidases in
food are currently being assessed and may make an impact on the
false positive rate associated with FOB testing. The E-Z test
which is a guaiac impregnated toilet paper nay render FOB testing
more acceptable to the population in future studies and so
increase the cost-effectiveness of screening.
Further controlled studies of colorectal cancer screening
with FOB's are required to determine the potential of this
approach to reduce the mortality of this cancer. Included in
these studies there should be scope to assimilate further data on
factors affecting compliance, particularly the attitudes of non-
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coirpliers to screening and the influence of any manipulations of
these factors using educational pamphlets. The GP and the practice
premises should become the pivot for any further large screening
studies in this country as it has been repeatedly shown that his
direct involvement in screening increases the coirpliance rate for
most screening offers.
The earlier detection of cancer in the symptomatic
population may be improved by the use of FOB tests in those
individuals with lower GI syirptoms to determine priority for
investigation; for gastric cancer the results of the British
Society of Gastroenterologists Early Gastric Cancer/ Dysplasia
study nay reveal certain discriminatory factors which will lead to
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THE DEPARTMENT OF SURGERY AT ST. JAMES'S HOSPITAL IN CONJUNCTION WITH
LOCAL G.P.'s IS TRYING TO COMPOSE A SIMPLE FORM OF QUESTIONNAIRE WHICH
WILL LEAD TO EARLIER DETECTION CF VARIOUS DISEASES
THE FOLLOWING QUESTIONNAIRE IS STILL ONLY A TRIAL ONE AND WE WOULD
APPRECIATE YOUR HELP IN ASSESSING IT
COULD YOU PLEASE FILL IN THE QUESTIONNAIRE AS BEST YOU CAN, TAKING YOUR
TIME AS THERE IS NO HURRY. IF YOU ARE MOT SURE OF ANYTHING OR THE
QUESTIONS ARE NOT CLEAR, DO NCI ANSWER THAT QUESTION
ON COMPLETION OF THE QUESTIONNAIRE COULD YOU PLEASE TURN OVER ONTO
THE BACK PAGE AND GIVE YOUR COMMENTS ON THE QUESTIONNAIRE, MENTIONING
ALSO ANY PARTICULAR QUESTIONS THAT DO NOT SEEM CLEAR
PLEASE FILL IN A FEW PERSONAL DETAILS. ALL ANSWERS WILL BE ENTIRELY
CONFIDENTIAL
NAME AGE SEX M/F
(FORENAME) (SURNAME)
ADDRESS OCCUPATION (If you are unemployed
or retired, please give former
occupation)
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THE FOLLOWING QUESTIONS PROVIDE USEFUL BACKGROUND KNOWLEDGE ON THE STATE OF YOUR
PAST HEALTH AND YOUR FAMILY'S HEALTH
MOST QUESTIONS REQUIRE YOU TO PLACE A TICK IN THE CORRECT BOX OPPOSITE THE QUESTION
past health yes n(
have you ever attend!:q a hospit.al outpatient clinic [ ] [ ]
have you ever been a patient in hospital? [ ] [ ]
If YES to either question, please give a few details
HAVE YOU EVER HAD AN OPERATION ON YOUR STOMACH, BOWEL OR
GALLBLADDER? [ J [ ]
DO YOU HAVE SUGAR DIABETES? [ ] [ ]
DO YOU SUFFER FROM ARTHRITIS? [ .1 C ]
DO YOU SUFFER FROM ASTHMA? [ ] L ]
ARE YOU BEING TREATED FOR RAISED BLOOD PRESSURE?
*ATMFMT
[ J [ ]
.i \ 1 nti* 1
DO YOU TAKE AMY MEDICINES/TABLETS REGULARLY? [ ] rL ]
ARE THESE FOR STOMACH OR BOWEL PROBLEMS? [ 1 [ ]
If YES, please name them
SMOKING AND DRINKING
Both smoking and drinking can affect your health. Please answer the following
questions
DO YOU SMOKE? [ ] [ ]
HAVE YOU EVER SMOKED, BUT HAVE SINCE STOPPED? [ ] [ ]
PLEASE STATE AVERAGE AMOUNT SMOKED
(If you have given up, state average amount before stopping)
PLEASE RECORD AVERAGE ALCOHOL INTAKE
(e.g. 3 pints/night, 2 glasses wine/week)
FAMILY HISTORY
Some diseases run in the Family, e.g. Asthma, sugar diabetes
ARE THERE ANY DISEASES THAT RUN IN YOUR FAMILY? [ ] [ ]
If YES, please give details
HAVE EITHER OF YOUR PARENTS OR BROTHERS OR SISTERS HAD AN OPERATION
ON THEIR STOMACH, BOWEL, BREAST [ ]
If YES, olease give details as best you can
- 300 -
THE FOLLOWING SECTIONS ARE RELATED TO YOUR HEALTH At PRESENT
PLEASE TICK THE BOX THAT SEEMS MOST SUITED TO YOU
IF YOU ARE ASKED TO GIVE DETAILS TRY TO BE BRIEF
SECTION A YES
HAS YOUR APPETITE CHANGED RECENTLY? [ ]
If YESj has it DECREASED? [ ]
HAVE YOU LOST WEIGHT RECENTLY? ■ [ ]
ARE YOU CM A DIET? [ ]
DO YOU HAVE DIFFICULTY SWALLOWING FOOD? [ ]
DO YOU FEEL THAT FOOD STICKS BEFORE REACHING YOUR STOMACH? [ ]
ARE YOU TROUBLED BY BURNING OR DISCOMFORT BEHIND THE BREAST BONE? [ ]
HAVE YOU EXPERIENCED ANY NAUSEA {feelinq sick) OR VOMITING
(being sick) RECENTLY? [ ]
DO YOU THINK YOU ARE EATING AS MUCH AS YOU WERE 6 MONTHS AGO? [ ]
DO YOU HAVE ANY PAIN OP. DISCOMFORT IN THE ABDOMEN (Tummy) WHICH
IS NEW FOR YOU? [ ]




A FEW QUESTIONS RELATED TO YOUR BOWEL HABIT NOW FOLLOW
HOW OFTEN 00 YOU OPEN YOUR BOWELS (e.g. once alternate days) • 9 • 1» o • • ••••<» 9
DO YOU FEEL YOU EMPTY YOUR BOWELS ADEQUATELY MOST TIMES? rt ] [ ]
HAS THERE BEEN A RECENT CHANGE IN THE FREQUENCY OF YOUR MOTIONS? [ ] [ ]
HAS THERE BEEN A CHANGE IN THE APPEARANCE OF YOUR MOTIONS? r ] C ]
DO YOU HAVE EPISODES OF YOUR MOTIONS BEING LOOSE THEN
BECOMING NORMAL AGAIN? [ 1J L ]
HAVE YOUR MOTIONS BECOME HARDER? [ ] [ ]
HAVE YOU NOTICED ANY BLOOD IN YOUR MOTIONS? [ ] [ J
HAVE YOU EVER NOTICED SLIME IN YOUR MOTIONS? rL ] rim 1J
- 301 -
SECTION C
THIS IS THE LAST SECTION TO 5E COMPLETED. AS BEFORE PLACE A TICK IN THE
APPROPRIATE BOX
YES NO
DO YOU HAVE A COUGH? [ 3 C 3
HAVE YOU EVER COUGHED UP BLOOD? [ ] [ 3
DO YOU SUFFER FROM PAIN OR DISCOMFORT IN YOUR CHEST? [ ] [ 3





If YES, IS THIS MORE OFTEN IN THE LAST SIX MONTHS? [ ] rL 3
DO YOU HAVE ANY DIFFICULTY PASSING WATER? C 3 [ 3
HAVE YOU EVER NOTICED BLOOD IN YOUR WATER? [ 3 c 3
HAS THERE BEEN ANY CHANGE IN COLOUR OF YOUR WATER RECENTLY? C 3 [ 3
If YES, PLEASE GIVE DETAILS
TO BE COMPLETED BY WOMEN ONLY
DO YOU STILL HAVE YOUR PERIODS
If NO, HAVE YOU NOTICED ANY BLOOD OR BROWN DISCHARGE
FROM FRONT PASSAGE?
C ] [ ]
[ ] [ ]
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Study questionnaire
THE DEPARTMENT OF SURGERY AT ST. JAMES'S HOSPITAL IN CONJUNCTION WITH LOCAL
G.P.'S IS TRYING TO COMPOSE A SIMPLE FORM OF QUESTIONNAIRE VHICH WILL LEAD TO
EARLIER DETECTION OF VARIOUS DISEASES
COULD YOU PLEASE FILL IN THE QUESTIONNAIRE AS BEST YOU CAN, TAKING YOUR TIME AS
THERE IS NO HURRY. IF YOU ARE NOT SURE OF ANYTHING OR THE QUESTIONS ARE NOT
CLEAR, DO NOT ANSWER THAT QUESTION
PLEASE FILL IN A FEW PERSONAL DETAILS. ALL ANSWERS WILL BE ENTIRELY
CONFIDENTIAL
NAME AGE SEX ty/F
(FORENAME) (SURNAME)




THE FOLLOWING QUESTIONS PROVIDE USEFUL BACKGROUND KNOWLEDGE ON THE STATE OF YOUR
PAST HEALTH AND YOUR FAMILY'S HEALTH
MOST QUESTIONS REQUIRE YOU TO PLACE A TICK IN THE CORRECT BOX OPPOSITE THE QUESTION
PAST HEALTH YES NO
HAVE YOU EVER ATTENDED A HOSPITAL OUTPATIENT CLINIC? [ ] [ ]
HAVE YOU EVER BEEN A PATIENT IN HOSPITAL? [ ] [ ]
If YES to either question, please give a few details
HAVE YOU EVER HAD AN OPERATION ON YOUR STOMACH, BOWEL OR
GALLBLADDER? [ ] [ ]
DO YOU HAVE SUGAR DIABETES? [ ] [ ]
DO YOU SUFFER FROM ARTHRITIS? [ ] [ ]
DO YOU SUFFER FROM ASTHMA? [ ] t ]
ARE YOU BEING TREATED FOR RAISED BLOOD PRESSURE? [ ] [ ]
TREATMENT
DO YOU TAKE ANY MEDICINES/TABLETS REGULARLY? [ ] [ ]
ARE THESE FOR STOMACH OR BOWEL PROBLEMS? [ ] [ ]
If YES, please name them
SMOKING AND DRINKING
Both smoking and drinking can affect your health. Please answer the following
questions
DO YOU SMOKE? [ ] [ ]
HAVE YOU EVER SMOKED, BUT HAVE SINCE STOPPED [ ] [ ]
PLEASE STATE AVERAGE AMOUNT SMOKED
(If you have given up, state average amount before stopping)
PLEASE RECORD AVERAGE ALCOHOL INTAKE
(e.g. 3 pints/night, 2 glasses wine/week)
FAMILY HISTORY
Some diseases run in the Family, e.g. Asthma, sugar diabetes
ARE THERE ANY DISEASES THAT RUN IN YOUR FAMILY? [ ] [ ]
If YES, please give details
HAVE EITHER OF YOUR PARENTS OR BROTHERS OR SISTERS HAD AN OPERATION ON THEIR
STOMACH, BOWEL, BREAST?
If YES, please give details as best you can [ ] [ ]
Please turn over
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THE FOLLOWING SECTIONS ARE RELATED TO YOUR HEALTH AT PRESENT
PLEASE TICK THE BOX THAT SEEMS MOST SUITED TO YOU
IF YOU ARE ASKED TO GIVE DETAILS, TRY TO BE BRIEF
SECTION A YES NO
HAS YOUR APPETITE CHANGED RECENTLY? [ ] [
If YES, has it DECREASED? [ ] [
HAVE YOU LOST WEIGHT RECENTLY? [ ] [
ARE YOU ON A DIET? [ ] [
DO YOU HAVE DIFFICULTY SWALLOWING FOOD? [ ] [
DO YOU FEEL THAT POOD STICKS BEFORE REACHING YOUR STOMACH? [ ] [
ARE YOU TROUBLED BY BURNING OR DISCOMFORT BEHIND THE BREAST BONE? [ ] [
HAVE YOU EXPERIENCED ANY NAUSEA (feeling sick) OR VOMITING
(being sick) RECENTLY? [ ] [
DO YOU HAVE ANY PAIN OR DISCOMFORT IN THE ABDOMEN (Tunny)? [ ] [
IF YES, IS THIS DIFFERENT FROM PREVIOUS TUMMY UPSETS? [ ] [
Please give details
SECTION B
A FEW QUESTIONS RELATED TO YOUR BOWEL HABIT NOW FOLLOW
HOW OFTEN DO YOU OPEN YOUR BOWEIS (e.g. once alternate days)
AFTER YOU HAVE EMPTIED YOUR BOWELS DO YOU FEEL YOU STILL NEED TO G0?[ ] [ ]
HAS THERE BEEN A RECENT CHANGE IN THE FREQUENCY OF YOUR MOTIONS? [ ] [ ]
HAS THERE BEEN A CHANGE IN THE APPEARANCE OF YOUR MOTIONS? t ] [ ]
DO YOU HAVE EPISODES OF YOUR MOTIONS BEING LOOSE THEN BECOMING
NORMAL AGAIN? [ ] [ ]
HAVE YOUR MOTIONS BECOME MORE CONSTIPATED? [ ] [ ]
HAVE YOU NOTICED ANY BLOOD IN YOUR MOTIONS? [ ] [ ]




THIS IS THE LAST SECTION TO BE COMPLETED. AS BEFORE PLACE A TICK IN THE
APPROPRIATE BOX
YES NO
DO YOU HAVE A COUGH MOST DAYS? [ ] [
HAVE YOU EVER COUGHED UP BLOOD? [ ] [
DO YOU SUFFER FROM PAIN OR DISCOMFORT1 IN YOUR CHEST? [ ] [
DO YOU HAVE TO GET UP AT NIGHT TO PASS WATER? [ ] [
IF YES, IS THIS MORE OFTEN IN THE LAST SIX MONTHS? [ ] [
DO YOU HAVE ANY DIFFICULTY PASSING WATER? [ ] [
HAVE YOU EVER NOTICED BLOOD IN YOUR WATER? [ ] [
HAS THERE BEEN ANY CHANGE IN COLOUR OF YOUR WATER RECENTLY? [ ] [
If YES, please give details
TO BE COMPLETED BY WOMEN ONLY
DO YOU STILL HAVE YOUR PERIODS? [ ] [ ]
IF NO, HAVE YOU NOTICED ANY BLOOD OR BROWN DISCHARGE
FROM FRONT PASSAGE? [ ] [ ]
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Health Belief Model Questionnaire
In the following sections we would like you to read some statements about
health problems, and indicate by circling one of the alternative answers how
far you personally agree or disagree with the statement. There are no right or
wrong answers; just give your opinion. Please circle ONE answer only for each
question.
SECTION A
1. It is more important to have a good life now, than worry about future
health.
4 (a) I completely agree
iT(b) I strongly agree
*f(c) I mildly agree
3(d) I mildly disagree
JL(e) I strongly disagree
| (f) I corrpletely disagree
2. Physical fitness is inportant to me.
4 (a) I completely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
1(f) I completely disagree
3. People can't really do a lot to prevent illness.
I (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
4 (f) I conpletely disagree
4. Illness always gets me down.
I (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
4(f) I conpletely disagree
5. Fit people get as many illnesses as everyone else.
j (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
4 (f) I conpletely disagree
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6. I usually eat what I know is good for ne.
& (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
I (f) I conpletely disagree
7. Regular medical check-ups cure useless unless you are ill.
I (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
i (f) I conpletely disagree
8. Good health or bad health is something you just have to put up with.
I (a) I completely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
4 (f) I conpletely disagree
9. I think that people are fanatical about health these days.
I (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
6 (f) I conpletely disagree
10. Six monthly check-ups at the dentist are a waste of tine.
I (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e). I strongly disagree
^ (f) I conpletely disagree
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SECTION B
1. In general I enjoy good health
•b (a) I completely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
! (f) I completely disagree
2. I am unlikely to suffer from a serious illness in the future.
J (a) I completely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
b (f) I completely disagree
3. If I wait long enough, I will get over most illnesses by myself.
\ (a) I completely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I stroAgly disagree
£ (f) I completely disagree
4. I am the type of person who worries a lot about their health.
| (a) I completely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(, (f) I completely disagree
5. I take ages to recover from illness.
I (a) I completely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(, (f) I conpletely disagree
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I go to the doctor the minute I feel unwell
I (a) I completely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
^ (f) I conpletely disagree
I don't suffer from colds and flu as much as other people
4> (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
((f) I conpletely disagree
I always have a well stocked medicine cabinet at home
(5 (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
((f) I conpletely disagree
I worry a lot about getting cancer
( (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
4 (f) I conpletely disagree
My health will probably always be below par
. (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(, (f) I completely disagree
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SECTION C
1. There is nothing I can do to prevent illness from happening
| (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
£ (f) I conpletely disagree
2. Finding a disease early makes no difference to the success of
treatment
I (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
k (f) I conpletely disagree
3. I am too old to viorry about having health check-ups
I (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly'disagree
(e) I strongly disagree
& (f) I conpletely disagree
4. A person can have a serious illness and not know it
^ (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
[(f) I conpletely disagree
5. Having a medical check-up visually stirs up trouble
| (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
^ (f) I completely disagree
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6. I'd be frightened to have a check-up in case something was found
1 (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(f) I conpletely disagree
7. Certain medical tests can show up a problem you did not know about
b (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
((f) I conpletely disagree
8. I'd be prepared to give up my time if I could have a free medical
check-up with ny G.P.
k (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
I (f) I completely disagree
9. There is no point in having a check-up if you have been well all your
life.
\ (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
L (f) I conpletely disagree
10. Having a regular check-up for cancer is a good idea
& (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
((f) I conpletely disagree
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SECTION D
1. I have great faith in modern medicine
4 (a) I completely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
I (f) I completely disagree
2. Nurses and doctors always do what's best for you
k (a) I completely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
I (f) I completely disagree
3. I often feel confused after visiting the doctor
| (a) I completely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
^ (f) I completely disagree
4. I can never see the doctor when I want
| (a) I completely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
f (f) I completely disagree
5. Doctors don't listen enough to their patients
I (a) I completely agree
• (b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
, (e) I strongly disagree
♦(f) I conpletely disagree
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It is inportant do exactly what the doctor says when I'm ill
4 (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
| (f) I conpletely disagree
There's a lot doctors don't know about most common illnesses
| (a) I completely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(> (f) I conpletely disagree
Doctors should spend more time telling their patients how to stay
healthy
(> (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
I (f) I conpletely disagree
I don't like visiting hospitals
| (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
i (f) I conpletely disagree
I worry about having to go into hospital
I (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
6 (f) I conpletely disagree
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SECTION E
The next sections relate specifically to cancer. Your answers to the
following statements are inportant as they will help us to make our cancer
prevention programme mare attractive to patients in our practice.
1. You can have cancer and not know about it
4 (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
I (f) I conpletely disagree
2. Finding cancer early leads to a better chance of cure
4 (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
| (f) I conpletely/disagree
3. Tests can detect cancer before you feel unwell
4 (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
I (f) I conpletely disagree
4. No matter where you find cancer there is always a poor outcome
I (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
•(e) I strongly disagree
4(f) I conpletely disagree
5. Cancer just about always means death
I (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
i (f) I conpletely disagree
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The treatment for cancer is worse than the disease itself
| (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
(> (f) I conpletely disagree
Having cancer is the vorst thing that can happen to anyone
| (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
4 (f) I conpletely disagree
Some types of cancer can be cured more effectively than others
t, (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
1 (f) I conpletely disagree
If I had cancer I would want to be told
4 (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
(e) I strongly disagree
1(f) I conpletely disagree
If I thought I had cancer I would put off going to see the doctor
about it
1 (a) I conpletely agree
(b) I strongly agree
(c) I mildly agree
(d) I mildly disagree
Ce) I strongly disagree
{) (f) I conpletely disagree
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This section asks in more detail about personal experience of cancer. If you have
not known anyone with cancer, please proceed to Section F below.
1. Do you know anyone who has had cancer (a) Yes
(If the answer is no please proceed to the next section (b) No
2. Do you know anyone who has been cured of cancer (a) Yes
(b) No
3. Have you heard of either cancer of the stomach or bowel? (a) Yes
(If no please go on to the next Section below) (b) No
4. Has a relative or friend had either of these cancers? (a) Yes
(b) No
5. Did this greatly upset their way of life? (a) Yes
(b) No
(c) Don't
6. Do you think you can have either of these cancers and (a) Yes
not know it? (b) No
(c) Don't
7. Do ycu think the chances of cure for either of these (a) Good




Sone illnesses prevent us leading our normal active lives. How nuch of an effect
vould the following illnesses have on your life.
Please tick the appropriate box for each illness












This is the last section. Please remember all your responses are strictly
confidential and only your own doctor will see the answers. The information is
necessary to help decide priorities for further health canpaigns.
Please circle the appropriate answer as before.
Please state occupation
(If retired please stage last job)
Are you currently unemployed YES/NO
At vrtiat age did you leave full time education
Do you smoke? YES/NO
Have you ever had a previous health check-up? YES/NO
Ladies - have you ever had a cervical smear test? YES/NO
have you ever had a breast examination? YES/NO
Thank you for your co-operation. Could you now return the form in the
stanped addressed envelope to the surgery?
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Mood Scale From Pilot Study
N G This is the final Section.
Each of the words in the following list describes a my people sometimes
Please use the list to describe how you have felt over the post to© teekB,
the table below.
ei
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yyynynnn nnnni ynn nn
































2ILE'. EKA8TF.R DATA A LEEDS UNIVERSITY VM/SP 2,05
:.'.:D073 0 73 1,14 :l 5,4 :i.4 YYYNYNNNNNN VyyVnNYY Y0NNNYHN?<b4nnnnnnnn
"EDO74 0 23 2,75 43 3,0 33 YYYNNNNYYNYNNjYYYNNNflY^lNNNNNNflNNNN NNN1:
cX,if, .t. ... •. ..
•! /. 1 />. (JO ■)/\ r -i
EDO 75 O O •> 4 / •> C-
jf EDO76 0 64 0,79 5 7
ED077 0 58 0,94 "X 2 •> 6
ED078 1 27 0,74 1 4 4 0
ED079 1 19 0,84 1 2 -J •../
E!)080 1 40 0,99 8 2«-.i
ED081 0 61 0,84 1 3,4
ED083 19 1 > 02 1 2,3
E.1)084 0 58 0,77 0 2. •; 7i
ED085 0 79 0,84 0 3 •> 7
ED086 1 43 0,68 1 "J At' ■> •" V
ED087 0 73 1,06 8 7,'•-./
ED088 0 56 0,858) 5 2. -J
ED089 0 76 0,65 1 2,3
ED090 0 78 0,84 6 4,1
ED091 0 Jiff 1,01 '■>. 13,7
ED092 1 56 0,97 3 2,5
E1)093 0 65 0,80 I 3,0
i... .5)094 1 52 1,38 6 ... ...•.J •> :•
< EDQ9DL. 1 41 1,22 0 6,4
•ED096 T •> 1,07 0 2,5
ED097 i 6<h 0,92 0 2,6
ED099 0 52 0,60 0 9,5
ED100 0 33 3,20 403 107,4
EDI 01 0 16 0,70 '*> •") •".«•? /•
< ED102 0 57 0,90 10,5
EDI 03 1 54 1,00 4 8,7
ED104 0 515 0,70 0 6,5
f EDI 05 1 52 0,81 10 6,5
ED106 1 40 0,81 5,4
EDI 07 1 31 0,77 "X 2,6
f ED108 1 57 0,73 ".r 4,4
EDI 12 0 >'3~ 1,09 2.. 6
EDI 13 o 62 ■> •>
( EDI 14 0 80 0,68 0 2 o •../
ED115 0 80 1,63 /. c>
EDI 16 0 74 1,30 9
.» —f
i. •> /
EDI 17 1 50 0,76 3 > 3
EDI 18 0 53 0,71 7 3,4
ED 119 1 62 1,07 4 ■) •>
i- ED120 1 60 0,81 12,3
ED 121 0 « 0,86 4 2,3
EDI 22 0 56 1,94 24 4,7
(- ED 123 0 38 0,61 0 2,5
ED124 0 64 0,83 0
,.y,
J
ED 125 31 0,83 0 4, J.
(■ ED126 0 58 1,09 0 2,5
ED 12.7 0 36 1,73 16 3 ,1
ED128 0 70 0,95 6 12, 4
c ED 129 1 70 0,86 0 2,3
ED130 1 "fx 1,06 6 2,3
ED131 1 37 1,06 "X 2,3
ED131 1 37 •» •y 2,5
324 -
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LEEDS UNIVERSITY VM/8P 2,0'.
16 YYYYYYYYYYYYt-iVYYtJt-JYYYYYOYYYYYt-Jt-i-JYYYYNHN
26 YYYYYYYYYYYYYYYYYYYYYYYOYYYYYYYYYNYNNff[
*> ■ - i«' i >l"i ' '"i >W WH
- 32
* .* J.- j. 32 j. ■> \/6
T 2,5
ED136 0 72 1 ■> 26 7 3,9 34
EDI37 1 24 0,94 6 3,5 14
ED138 0 41 ■J , •> ,
ED139 0 26 •> * •> ,
EDI 40 0 55 •? •» •> ,
EDI 41 0 30 0,65 2,5 17
ED142 0 •> 1,26 "X■..1 2,5 13
ED 143 0 64 0,82 o 2,6 20
EDI 44 1 80 1,00 9 2,5 ~.r
EDI 45 1 46 1,04 •-> —, 6 18
EDI 46 0 51 0,83 ■ 1 2 , li 11
<r
ED147 1 21 1,19 I 5,5 13
ED148 0 63 1,50 "X "X 13
ED149 1 65 1,19 "X•..I c;• t, 16
t EDI50 0 45 0,83
"X '■> 9
V
ED 151 0 40 0,90 1 •..'i , 1 7
ED152 0 19 0,83 1 6
t ED 153 0 64 1,50 b 4,3 47
ED154 0 42 0,90 »':■ 6,2 13
ED155 0 64 0 ♦ 63 5,2 17
g
EDI 56 1 46 0,83 i 2,5 9
ED156 1 46 0 ♦ 83 1 2,5 9
ED157 0 •J 0,83 "X•..! 21 10
4
ED158 0 57 1 ♦ 19 4 4,9 12
V-
ED159 0 50 0,83 i i.- 11
ED 160 0 46 1,04 •••> c:> 1 s
i
EDI 61 0 57 0,90 I 9,1 12
EDI62 0 57 0,51 "X 2,5 16
EX.i163 0 61 0,97 5 4,0 21
M ED163 0 61 0,97
("■ 4,0 21
<$Y:::di64 1 u 0,76 1 '■} v.- 30
ED 165 1 u 0,76 1 2., 5 30
L
ED166 1 81 0,97 1 6,6 30
ED 167 1 70 1 ,04 1 2,5 30
ED169 0 55 0,66 •*y 5, !.;> 28
L ED 170 I 70 1,44 6 4 ♦ 8 11
EDI71 0 50 0,78 "X•..I 2,6 17
ED172 0 0,83 1 2,5 r.
i EDI73 0 49 0,59 1 2,5 8
ED 174 0 65 0,89 1 6,4 11
ED175 1 72 1,10 21 "X o•../ ,
C ED176 I 72 1,72 51 36
EDI 77 1 50 0,89 2,5 10
ED 178 0 42 0,73 J. 2,5 6
EDI79 1 "X "X 0,89 1 2,5 53
ED 180 o 66 1,16 2.5 14
ED181 59 •i ■i , ,
i
ED182 0 78 ■f , ,
ED183 1 67 •) •J , ,
ED185 4 •> , ,































MNM MMNNYMMi-tfvYYMMNMMNOMM Y MN
YYN.N NNNNYMYYYY MNNNYYY1 Y N Nil
Y MMMNMYYMYMMYYMMMMMNYYOMMMMMMM|vMNYMMMMY




































y mmmmyymmmmftmmmn yyi yyy my]YYMMMMMMMYMMY}-4i-4MMMMMMMMOMMMMMYri4MMYMMMM
NNNMNNNMNYYNNfYYNNYYYYXINNYNNYYjYNYNNNNNX:
yymmmmmymymyy4kmmmmymmmommmymy?*4mymmmmm
f J LEX EMASTER DATA A LEEDS UMXVERSTTY VM/SP 2*05-t
T...002 0 '50 1, 77
3-003 1 57 0,98
11 YY MYMMYMMMY r^lMMMl4Mb MMMMM^TMMYMMMM:
5 MMMMMMYMMMYM^TMYYMMMMMNOMMMMYMEfTMNYYMM;






















































































































































































































































































































































































































































































































































































0 /.' > 0,64 1 2,7 18
1 4 *> ,
1 ■...11 0,76 1 2 •»!j 9
1 70 0,72 10 4,0 7
l SB 0,87 2,6 •' o.i.
i S3 1,00 8 2,5 34
i SB 0,79 4 6,4 16
0 68 0,96 16 2,5 46
0 34 0,68 1 7,1 11
0 70 0,92 1 "X•../ •? 43
0 71 1,09 10 2 4 5 20
o 70 0,68 1 2,5 67
I 67 0,72 1 2,3 13
0 SO 1,03 5 5,4 19
0 67 0,79 1 2,5 14
1 63 0,64 1 2,5 23
0 63 0,83 4 2,5 11
64 1,09 4 2,5 11
i. 60 0,72 1 2,5 13
i 60 0,72 1 '■> 15
0 60 0,92 1 2,3 11
0 69 0,86 4 4,7 8
I 59 0,47 "X 2,5 8
0 68 0,65 5,7 6
0 51 0,77 ~X *-> /.•C. 4 41
0 4 0,86 8 2. •» -J 8
i 68 0,89 "X 2,5
0 36 0,86 "X 3, 6 8
i 69 0,60 1 2,5 35
i 69 1,47 12 2,3 16
0 62 1,00 5 2,3 15
o 62 1,06 9 2., 5 18
0 64 0,82 1 3,5 13
0 60 0,71 1 2., S 5
1 70 0,82 1 L* ,2 13
o 68 0,82 "X 2,3 27
1 32 1,00 "V•../ "i 15
0 S3 1,00 1 4, 11
0 60 0,88 1 2,5 14
0 69 0,94 1 2,6 8
0 51 0,83 4 2,5 9
0 36 - 0, 97 3 3,8 9
1 68 1,11 "X 3,3 17
1 34 0,97 '•>
1 S3 1,27 "X 2., 5 13
0 48 0,57 "X•..! 2, S
4 •> 4 , ,
1 64 0,84 i V 5, 1 13
0 /. O 0,84 "X 7, 4 9
1 63 0,96 "X 4,3 11
0 64 1,09 4 V "X■..' ,
1 66 0,84 ••y 4,2 21
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YY MYMYY MMYMM MMMMMMY
YYYNMNNYNNYNNN NNMNMMN
YYMNMNMNM'YYYMYYYYMMYMYMOMMMYMMN 4MMYMMMMMM
YYMMMMMYYMMMYM MMMMNYM OMMNNMMM 4MMYYYMYMM
YYNMMNNYMMYYNN MYMMMMM OMMMMYNMNNN.YMNNN
YYMMMMMYMMYMYM MYMMYMM
YMMMMMMYMYMMMM MMMMMMM. OMMMMMMMNMMM M M
YMMMYMMMYYMMMYM MMMMMMM, M.YYYM.YYMNMM MM
YMMMYMMYYMMMYM MMMMMMM OMYYYM.YYMMMM MMM



































EMA8TEE DATA A LEEDS l!M x VERS II'Y VM/SP 2, OS
0 62 0,77
0 34 1,09 4
10 YYMMMMMMi4MMM^-4?'i-4MhMMMh;'i:>MMMYMMMMMMMMMMMivM
12 YYMMMMMMMMMYMMMMMMMMMYbOMMMMMMMMMMMMMNMM;-;









10 YYNNNNNNN^YH NNNNNNNYNNOYNNYYNNNNNYNNNNNN 60
22 YYNNNNNYYNYNNNNNNNNYNYNONNNYNNNNNNNNNNN 60
29 YYYNYNYYYNYYYNNNYNNNNY&ONNNYNNNNNNNNNNNNN 60
13 YN?14?%4N5"4NMNYNf*4r4N:NMr4NY?"4MN'4?-1 Hi-JN.MM{0;MMN.N';N?N.N.H 60
7 YYNNYNNYNYNYNNNNNNNNYYNONNNNNNNYNYYNNN.NN 60
21 YYNN.N.NNNN.YNNNNNN.NN.N.N.NN.NON.NNYNN.NNNNYN.NN.N 60
6 NNNYYN YNNYNNNNNN YNYilOYNNNNNNNNYYNNNNY 60
21 NNNNNNNNNNYNNNNNNNNNNNNONNNNNNNNNNNNNNN 60














































J. /.V. 0 33 0,83 4 ■> 20
<•'
EL313 I 64 1,04 5 '7 x.•? '.j 25
EL..314 0 63 0,64 ') 12
EL313 I 32 0,69 1 2,5 27
'
EL316 0 30 0,70 '•} 2,5 7
Ei.,.317 1 30 0 •> 70 1 2,3 10
71 o 0 30 0,89 1 2,5 6
ELS19 1 33 0,84 •i. 7,6 12
EL.320 0 33 0,84 5,7
0 , EL321 38 0,60 3,3 10
EL.322 o 36 0,79 3,1 13
EL..323 1 34 0,70 '} 4,6 45
£
EL.324 0 34 0,70 1 2,5 14
* -Xlry.j 1 54 0,39 4 ■> 15
EL328 0 61 0,99 1 •y 7
EL..329 1. 50 1., 04 4 2,5 14
c
EL..330 0 48 0,74 1 2,5 "X
EL332 0 63 0,91 '*> •» 6
EL.341 1 64 0,88 1 * 20
t
EL343 1 49 0,35 1 •) 11
EL.344 0 53 0,64 •~y 12
EL..342 1 53 0,33 1 2,5 58
(L
L.L.344 0 48 0,69 1. 2,5 11
EL.353 A 60 •> •i •> •y
EL.334 o />9 ■> •J *> -y
C
L1..357 1 54 0,33 1 •y 18
EL358 0 37 0,73 1 •y 10
EL.361 1. 69 1., 35 1.6 14
C
EL36S A 69 •y •y -> ■y
ENOO1 1. 69 0,92 "X 2 ? 5 C5
EH002 1 33 0,80 "V 3,0 300
A
EM003 1 /. "X 1., 18 4 "X '*> 44
EM004 0 6 1 0,80 '*> 3,0 16
EN005 0 68 1., 05 '? 2,5 38
i~
EH006< 0 62 1,03 'X 2,7 53
EH007 I 61 0,74 "X O "Ji.\. -y 14
i
EH008 1. /. •'"J 1,32 /. rv,L. -J ..j 8
u»
171009 0 30 0,92 2,5
E1K)10 0 /. -"5 1., 30 J. 2,5 30
/
EHO I 1 0 31 0,30 '} 2, •...' 4
EHO12 o 53 0,51 ■"> 2,5 8
LINO13 o 33 0,62 2,5 8
i
2.M01.4 1. 67 0,67 •j. t:: "J •.?'
I—
EHO13 o 33 0,67 1 2,5 16
L.MO'.i 6 1 63 0,73 2,3 11
I
EN017 I 59 0,92 2., 5 7
U-
EHO18 0 63 0,79 2,3 8
EMO19 •J. 0,73 I 2,5 38
/
EN020 o 70 0,73 "X 2,3 10
L
EHO21 0 62 0,92 "X 2,5 20
EN022 0 70 0,92 9 2,3
u
L:H023 0 56 1., 05 i 4,5 /
329 -
Y YNNNNWIMN V N T ■<
YYNNNNNNNNNNr
■:N; ■: N. ■; ■ '<NN
iJN!?^N(hj>4h4NNN()NNh4r4NNRW4NYNNiN.vYNir
























































r 5 ehaster data a leeds university vh/sp 2,on
• 1 j
.1)024 O 56 1,19 1 3,4 10 YYNNYNNNNNYNYK'^^4NVYki^.)NYNYNNN?4NYNNNNNNY:i
:1K)25 0 66 1,49 2,3 7 YYNNYNYYNYNYY|fNNNNNYYNNOYNNYNNNNYNYNNNNNNI
""" ' ' sH
0 32 1,09 1 2,3 11
0 32 1,00 1 2,3 11
0 32 0,87 1 2,3 82
0 69 0,78 1 2,3 9
0 30 1,03 12 7
0 36 1,24 1.3 2 4 ■. . ) IS
o 63 0,91. 1 3,7 5
1 31 0,67 1 2,3 7
0 33 0,67 1 6,3 37
1 63 0,87 1 2., 3 '*>''>
0 69 1., 03 1 3,8 13
0 66 0,74 1 > •../ «•••
0 32 1,09 1 17,1 12
o 32 0,96 1 2,3 \r-.J
0 60 1., 12 1 2,7 6
1 66 0,86 1 2,3 11
0 33 0,77 1 2,3 6
•J. 67 1,02 1 2., 5 8
0 33 0,91 1 3,2 8
1 32 1,12 1 7,8 17
1 67 1,24 4 2,3 43
1 61 0,97 1 2,3 •".5 '.J
0 70 1,07 1 2,3 43
1 69 1,12 6 6,3 405
0 34 1,19 5 3,1 24
1 30 1,02 1 11,4 12
0 69 0,86 1 2,3 11
•f 60 0,63 1 2., 3 9
1 62 •* 4 4 4
0 37 0,93 1 7,0 18
1 60 0,77 1 4,1? 16
1 33 0,92. C>- .... ,.y 68
0 61 0,92 4 4,3 r
0 62 0,70 "X 3,3 11
:i 63 0,70 ".7 2,5
i 60 0,70 o "X "■>•../ 4 4 18
0 60 1,48 37 3,9 46
o 39 0,84 ..y 4,3 11
o 61 1,13 13 8,6 18
0 64 1,04 4 •6,1 6
o 37 0,70 0 •-> r.::4 6
0 62 0,77 0 '•> <:»4 13
0 /. "X 1., 07 "X 2., 3 9
0 uz 0,70 "X 4,7 8
0 67 J. •> J.Z'i 21 2,3 10
0 39 4 4 4 4
0 63 4 4 4 4
1 64 1,31 31 2,6 20
1 69 0,77 3 4,6 30
0 66 0,77 4 2, 18
0 66 0,99 3 8, 0 11
0 33 0,84 0 2., 3 8
- 330 -
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0 39 0,70 :
0 61 0,92 i: 4,0
LENDS UNIVERSITY Vn/SP 2,03




NYNNNNN 0NNNNNNN '4YN.N.YNNN 60
1062
.





1083 0 67 0,88 4 6 •> 10
1084 0 68 0,65 1 3,8 12
1085 0 61 0,68 2,5 17
1086 1 52 0,84 1 2,5 19
1087 0 52 0,88 1 ■-} 7
1088 1 58 0,84 1 7,3
■1089 1 53 ■? *> , ,
•1090 1 59 0,65 1
1091 0 *t •> , ,
1092 0 67 0,74 0 2,5
1093 1 66 0,78 6 2,5 15
1094 0 56 1,07 4 16,6
1095 0 66 *> ,
1096 0 66 0,70 7,0 15
1097 0 59 0 •> 90 0 13,0 18
1098 0 52 :i, 10 41 "7 '•;» 19
1099 1 51 0 > 90 4 8,4 :i. 1
1100 1 48 :l, 20 12 4,5 14
1101 1 63 0,90 Yi, 1 31
1102 1 63 0,60 0 5,7
1103
1
a 0,60 o 6,4 11
1104 0,80 "X 3,7 7P.
1105 0 68 0,77 '? 3,9 ii
1106 0 66 1 ,34 5,9 8
1107 1 70 0,89 17 4,4 185
1108 0 69 0,60 27 3,8 11
1109 0 67 0,81 1 5,2 13
1110 0 32 0, A/8 •{J. 6,8 6
1111 0 57 0,76 '*> 13,5 8
1112 0 52 1,30 i 6 25
1113 0 54 1,37 4 6,0 13
1114 0 66 0,57 '■> 2,5 11
1115 0 /. "X 1,05 7 O <2 30
1116 0 0,64 10 5 •> 12
1117 1 65 1,53_. 8 3, 4 ...j ..j.
1118 o 56 0,96 4 2 •> i x
1119 0 52 0,72 0 "X "X■..t, 8
1120 0 52 1«18 4 2,5 7
1121 0 58 •) •> •> ,
1122 0 51 0,79 5 2 •> 5 i 4
1123 0 56 0,96 o 2:1
1124 0 ft A •> , •>
1125 1 VO 0,92 7 2,5 35
1126 0 64 1,05 :l *7 O 8
1127 0 52 0,86 4 6,4- 13
1128 1 59 0,95 4 j -6 19
1129 1 64 1,09 16 2,5 11
1130 0 56 1,09 i 2,5 O
1131 1 /. /. 0,95 1 2,5 9
1132 1 55 1,79 2 *! 20
1133 1 65 •> •> , ,
1134 0 67 ■J •? •!
- 331 -
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0 YE.; 0,86 1
0 A:.;; 0, A? 1
LEEDS UNIVERSITY VH/S : 105
6,0 11 YYMMMMMM MMMM
2 ,5 IS YYMMMMMYMYYYM:
<;"v ; >. \'\"\ \\ Vv'v-AV V.V VvY1
••4 V4Y^'4MMM^4 bYMMYMMM 1NNYYNNNNK 60
•4 MNNYYMM OMMMMYMM 4MNYMMMNMN 60;
.. ;.s\v> i\. 'v\'v '•» rx ' o.' v.t'. VVci\ '•>
.<. O, .... •> •..< .i. .i.
0:31.58 0 60 0,82 1 •..) •> / 16
EH139 1 66 0,81 '3 •. •t J '"i
EM 140 0 /. '•> 0,77 "X•..t 2,5 15
EMl 41 0 60 0,53 1 2,5 13
EMI 42 1 58 1,14 •fJ. 2,3 11
EM143 0 33 0,77 1 2,3 10
EM144 0 50 0,57 1 7,2 11
EMI 45 0 37 0,57 1 2,5 16
EM146 0 60 0,99 1 2,5 20
EM148 o 52 1,19 '"J 11,8 21
EM149 0 /. o 1,94 26 3,1 11
EM150 1 58 0,90 i 5,1 20
EM202 0 "66 0,78 "X..} 11,3 37
EM207 1 66 1,00 1 2,5 'yx
e:m2j.o 0 ■> 0 > 83 1 2,5 11
EM211 1 64 1,05 8 2, Op 21
EM212 0 60 0,84 1 3,7 8
EH216 0 63 1,25 1 2,5 38
EM217 1 « .0,705 1 3,9 14
EM219 1 62 1,00 V.Y 4,8 8
EM220 0 52 •» •: •> *3*>
EM221 1 66 0,78 3 2 « 3 20
EM222 0 57 0,93 "X 2 -i •.;» 6
EM223 1 64 1,22 O "X 18
EM224 0 63 ■> •> •> ,3<
EM223 1 61 0,76 '} 2,6 13
EM226 0 58 1,11 /•j 2,5 11
EM227 1 60 0,63 5 3,4 21
EM228 o 50 0,70 3 2,'...» 8
EM229 0 60 0,90 6,0 16
EM233 1 57 1,16 6 4,7 16
EM234 0 59 1,08 f 3,5 26
EM235 1 37 0, £53 "X 3,0 11
EM236 o 58 0,78 r.v 2,3 •../
EM239 59 1,00 "X •! 11
EM240 0 61 1,00 ■? 18
EM241 1 58 0,79 1 "X "X 20
EM243 1 57 0,63 3 '"•O
EM244 0 59 1,08 5 •} 16
6M245 1 53 1,16 4 -J ':>c?
EM2.46 0 53 •> •> ,>
EM247 1 52 0,94 I 2 -3 30
EM248 0 52 0,65 1 2 •: 3 8
EM231 1 57 1,08 7 * 12
EM252 o 53 0,93 "X•.J •> 7
EM254 0 33 /\ <:>"x 4 3,6 10 '
EM257 1 ■} •! *? , I
EM2-38 0 50 0,93 4 •s 12
EM260 o 67 0,93 4 ■J 9
iv..Rl.'4Y6L 1 50 0,74 1 ■> \j 13
ZM2o2 ~0 45 0 , 79 1 '*> /. 8
EM263 1 66 1,08 X
4NNYYNNNNN
- 332 -
< j'v i '.i\l \ I tM\i\ I \i \ t \1 v. IVtMWi'lMMM'.l4,


































































































rI EES EHASTEE DATA
EH264 0 66 0,93 3
EM266 0 62 1,03
A LEEDS UNIVERSITY VM/8P 2,05
14 Y NNNNNNNYNNNN^^NYN^?^/NNNNf>!NNlMNNNNlp!^;;
.0, 4 11 iNYYN.YN.NY YNNNNNNYNNNNNNONNYNYN^NNNNHHe
■ v-f: "m
CLl'l,:'v.Xi 0 t, X •» V4 1 •../ •> V .t. e
EM270 0 65 0,78 4 * 12
EM273 1 51 0,89 rr 2 •> •.:> 7
EM2.74 0 56 0,89 1 2,9 8
EM277 1 50 0,84 1 6 •> 6 11
EM278 0 52 1,11 8 2,5 25
7027? 1 67 0,65 1 2,5 12
EM280 0 55 0,74 1 2,5 10
E02415 i 59 0,79 1 2,5 15
E0286 0 57 0,69 1 2,5 10
EM289 1 56 0,60 1 3, 1 11
EM291 1 63 0,53 1 4,1 69
E02?2 0 65 0,84 "X•..! 2,5 8
EM293 1. 60 1,22 1 4,1 31
E0305 1 56 0,74 1 "X '•> 8
E0306 0 52 0,55 1 3,6 8
EM307 1 58 0,79 1 3,0 21
E0308 0 54 0,94 1 2 •> 5 10
EM309 1 54 1 ■> 00 1 2,5 19
E0310 0 53 0,60 1 4,7 11
E0311 1 52 1,00 1 2,9 20
E0312 0 51 •> 4 *
E0313 1 50 0,94 1 3,1 14
E0314 0 48 0,79 1 2,9 8
E031? 1 50 0,69 1 2,9 34
70320 0 50 0,72 '*> •> 13
E0323 53 0,89 1 2 * 5 18
E0329 '.t. 06 0,94 1 '"> V.-i ■...' 12
E0330 0 54 1,05 1 4,3 11
E0333 1 55 0,72 1 3,5 16
E0334 0 57 0,77 1 2,5 <:>
E0335 1 59 1,00 7 •> 6
EM336 0 37 0,53 '•) * 10
E0344 0 1;3 0,63 1 2,5 9
EM346 0 53 0,58 1 6 ■> 4 5
E0347 1 54 0,82 1 "X <::•••../ *> 15
E0348 0 /. -X 0,87 4 "J /.*> K.J 13
EM349 1 50 0,72 "X •> 41
E0356 0 60 0,77 3. 2,5 12
30357 1 55 0,95 '*>/-. •> 9
EM369 1 46 1,00 "X 3,4 16
EM370 0 40 0,85 5 2,5 8
,10375 1 53 0,87 1 0 1-; 13
EM379 •! 49 i ,Lo a Uf< -Is*





E0385 •fJ. 48 0,77 I 2. ■» 9
E0386 0 50 0,82 i 2,5 r>
70387 1. 56 0,87 2,5 20
E0388 0 49 1,09 1 7,2 8
E0389 1 37 0,98 1 4,1 13
E03? 1 50 0,68 1 3,4 37
E0393 1. /./■} 1,00 "X 4 24
E0001 0 59 0,62 4 2. 4 \.i 8
- 333 -





Y' ?^-4 Y4Y r-4 fM ;"4 4^4 Y4N.M r4 rJ f~4N.Nf^41^4 f^4 <>N ^--4 Y f^4 Y Y" f-4 ?~4 r4 f'y ?^4 fV










Y"«YNr-4 Y' t*4 f'4 N4N.N. Y' h4Yt"4N. ?*4 ?~4N.N.Y Y ?"4N- <> 1 *4N:N N. f"4i">iN.N.N.N. r41~4 fY *
YYYNNN.N.YNNYYYixNNNNN.Nr6N.N0Y r6xNNN?vr«!NNYNNNN
YNNNNNYYNNNN^viNNNNNNNNONYNNYNf^NYYNNNNNt-*
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LEEDS UNIVERSITY Vn/SP 2,08
17 YYN Y YYYN H'v4-4 !'4Niov(;•-:<)Y NNN YN Y N.N IN
Y"Hr4iv4N?7N.N.NY'MP4Y YNNNN-?'4T4{'4 »NNNNNNNVNNYNNNh2,3 12 r4P4 r4 M ?- y Y NN?^4 N?
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ilf.j emaster data A leeds university vn/sp 2,05
•*
PI70 0 59 0,93 1 5,6 5 YYNNNNNNNN?%INNN^^NNNh?4)NNNNNNNNNNNNN»J-5^ 6
5.71 1 57 0,51 4 , 11 YYNNNNNNNNYNYNNNNNNNNNN()NNNNNNNNNNYNNN1 3
C..i"" A / V/ •..//.CI
EP175 1 33 1,09 6
LP 176 0 52 0,77 1
EP177 1 32 1,03 1
LP178 0 49 0,64:) 1
LP179 1 60 •> <
LP180 0 59 0,432 1
LP 181 j. 54 0,31 '■)
LP182 0 52 0,66
LP183 1 51 0,72 1
LP 1434 o 49 0,82 1
L.P135 1 50 0,86 5
lp 1.435 1 50 0,36 5
E:PJ.89 1 60 0 , 68 1
EP192 0 56 0,32 7
EP193 1 53 0,72 "X
LP194 0 52 0,55
LP J. 95 1. 53 0,77 1
LP196 0 49 0,432 1
LP201 1 64 0,82 1
EP202 0 60 1,03 1
EP207 1 66 •y ,
Lr'217 1 63 1,05
EP218 0 53 0,77 '}
LP223 1 60 0,438 4
EP224 0 58 •> ,
EP225 1 62 0,66 '■>
EP227 1 56 1., 05 3
EP229 1 60 0,436 '?
EP232 0 66 0,66 r~>
EP260 0 •> A , ... 4
ESOOl 0 52 0,31 •A
ES002 1 60 1,04 10
L3003 1 65 0,79 ~x
<18004 0 32 0,62 5
L3005 1 56 0,92 ■■■>
LP/006 0 66 0,79 ">
LS007 1 70 0,73 1
L3008 1 53 0,433 12
LS009 0 51 1,42
ES010 1 56 1,14 9
ES01 1 0 62 0,96 1
ES012 0 53 1,09 1
L3013 0 69 1,19 1
E8014 0 36 0,63 1
.18015 0 59 0,437 1
r.:.80 j.6 1 53 0,96 1
ES017 o 51 0,96 1
ES013 1 67 0,437 1
iL8019 0 62 1,05 1
E3020 0 56 1,19 1
ES021 1 56 1,09 A
E8022 1 60 0,743 1
ILE; EMASTER DAT A
- 335 -
2,5 12 YYNNNYNNNNYYYNNNNNNNNNNONNNNNNNNNNYNNNN 26
2,5 10 N NNNNNNNNNNYNNNNNNNNNNONNNNNNNNNNNNNNNY 26
2,5 72 YYNNNNNNNNNNNNNNNNNNNNNOYNYY YYNNNYNNNN 6
2,7 11 YYNNNNNNNNNYNNNNNNYYNNNONNNNNNNNNNYNNNNY 6
, YNNNN.NN.NNNYNNNNNNNNYNNNONNNYN.NNNNNYN.NNN. 6




2.5 11 YYNNNNNNNNNYNNNNNNNNNNNONNNNNNNNNNYNNNNY 26
15 NYNNNNNNNYNNNNNNNNNNNNNONNNNNNNNNNNNNNN 26
15 YNNNNNNNNYNNNNNNNNNNNNNONNNNNNNYNNNNNNN 26
2,5 9 NYNNYNNNNNYYNNNYfcJNNNNNNONNNYNNNNNNYYNNN 26
2,5 6 YYNNYNNYNNN?mNNNNNNNNNNNONNNYNNNNNNNNNNNNN 6
17 YYNNNNNNNNYNN.NNN.NNNNNYYONNNNNN.NNNYYNYNN. 26
6 YYNNYNNNNNYNNNNNNNNNN?^0NNNYNNNNNYYNNNNNN26
2,5 26 YYNNNNNNNNYYNNNNNNNNNNNONNNNNNNNNNYNNNN 26
2,5 11 YNNYNNNNNNYNNNNYNNNNNNONNNNYNNYNNYNNNNNN26










9 YYNNYNNYYN YNNNNNNYYYYYOYNNNNNNNYNYYYYNNY 6
4.3 1 \
2,5 8 YYYNYNNN NYYYN N.NN.NNNN 1NNNNYNYNNNN NNNNN 6
2,5 16 YYNNNNNN NYNNN NNNNNNN ONNNNNNNNNNNNNNN f
4.7 24 YYYNNNNY NYNNN 0NNNYN?#4NNNN NNN k
2,5 6 YNNNYNNYYY YNN NNNNYNN ONNNNNNNYYYYNNNNNN %
3.4 8 NYYNNNYYNY NNN NNNNNNN ONNNNNNNYNNYNNNN i
2.5 7 YYNNYNYY NNYNN NNYYYNN ONNNYNNNNYNYNNNNNN'f
2,5 14 Y YNYNNYYNNYNYYYXlxNNNNN 1 NYNNYNNNNNYYNNN
2,5 44 YYYNYNYYNNYNNYNYNNNNNN ONNYNNYNNNNN NNN I
2,5 33 YYNNYNYYNY NNN YNN YYY OYYNYYYNNNYN YNNNY |
2,5 13 YYYN NYYNNYYYN NNNNNYY ONNNNNNNNNYYNNNN 1
3,0 8 YYNNNNNYNNNYNYY NNN YY INYYYYNflNN YYNNYNyI
2.5 5 YY NNNYYNNNNYYYNNYYY N 1NYY YNYYNYYYNNYNYif
5.8 55 YYNNYNNYNNYNYN NNNYYYY ON NYYYYYNYYNNNNNN j
2.6 11 YYNNYNNYNNNYNN NNNNYNY 1NNNNNYN f.
6.3 13 YYNNNNNYNY YNN NNNNNYN ONNNYNNNNNNN NNYNN |
3.7 11 NNNNNNYN NNNNN YNNNNNN , NNNNNNNNNNYNNNN f?
3.4 25 YYYNNNNYNY NNN YNNNNNY OYNNYNNNYNYYNNNNNN -
4,0 28 YYNNNYYY Y NNN NNNYYYN OYNYYNYYYYYNNNNN j.
3.7 7 YYNNYNNY NYNYN YYNNYNN ONNNNYNNNNNYNYN NNl'
4.8 14 NYNNNNNYNY NYN NNNNNNN ONNNNNNNNNNYNNNNNN
2,6 26 YYNNYNNYNY NYN NNNNNNN ONNNYNNNNNNYNNNN I
6,8 11 YYNNYNNN Y NYYNNNN YYY 0YNNYYNNYNYYYNNN §







15 YYNYNNY NYNYYYNYNNYNN ONNNNYNNNNNYNNNN




,j4 1,01/ 1 •> 0 <T t < vw < x t v (y t x x ix i y«y i y; oty ;y. y
E8026 1 61 0,98 20 3,1 37 YYNNNNNN Y NNN NNN N.N.N ONNNNNNNNNNYNNNN
ES027 1 57 0,87 1 3,0 31 YYYNNNNYYNYNNN NNNNNYY 0YYYYNNYNNNN NNN
ES028 0 35 0,82 1 2,5 2.0 YYNNNNNN NYYYN NYNNNYN ONN.NYNN.N.NN.YYNNNNNN
ESC/29 0 50 0,93 1 10,1 7 YYYNYNNY Y YYN YYNNYNY 0NNNYNNNYNYN NNNNY
ES030 1 69 0,77 1 3,4 8 Y NNYNNYNY NNN N NNNNN ONYNNNYNYNNYN NN
ES031 1 55 0,87 1 5,3 10 Y YYNYNNYNNYNNYYNNNNNNN ONNNYNNNNNYYNNNN
ES032 0 47 1,44 1 7,3
....
YYNYN YYNY YNY YYNNNYN ONNNNNNNYNNYYNNNNY
ES033 1 52 1,08 1 6, 1 19 YYNN NNN Y NNN YYNNNNN ONNNNNNNNNNN NNY
E8034 0 53 0,77 1 2., 5 16 YNNNNNYY N.NNNN NNNNNNN ONNNNNNNNNYN NNNY
E803S 0 31 0,87 1 2,5 "? Y N NNYNNN NNNNYNN ONNNNNNNNNNY YNNNNN
E8036 1 66 0,77 1 3,1 8 YYNNYNNY Y YNN NNNNNNN ONNYNNNNNNNYNNNN
ES037 1 68 0,77 •\r•../ 2,9 14 NYNNNYNYNNNNNN NNNNNNN ONNNNNNNYNNN NNN 1
ES038 0 60 1, IS 3 4,7 9 YNYNYNNYNY NNN NNNNNNN ONNNN.NNNYN.YYNN.NNNN i
ES039 0 53 0,92 3 3,1 10 YYNY N YNNYYNYYNY N NN ONNNYNN.YYNNYNYN.YNN
ES040 1 63 0,84 *">fS.. 3,4 8 YYNNNNNN NYN.NN NNNNNNN ONNNYNNNNNNYNNNN 1
ES041 0 60 0,89 '•j "X YYNNYNYYNNNNYN YNNNYNN ONNNNNNNNNYYNNNN 1
ES042 0 30 0,84 1 6,7 14 YNNNNYNNNNYNYNNNNNNNNN ONNNNNNNNNNYNNNNNN'l
ES043 0 51 0,92 "X X /•../ -> 33 YNNNNNN NNNNN NNNNYNN ONNNN?4NNNN!4YN.NN.NY
ES044 0 57 S> ■> 77 "X •7r... •> •..! 11 YYNNYNNY NYYNN NNNNNYY ONY YNNNYNNYYNNNNN
E8048 Q sV •» •» •> *> YYYNNNNYYNNNNNNYYNNYNN 0YYYYNNNNNNY'YNNNNN
ES049 1 33 0,87 1 •j e:;•> 19 YYNNYNNN NYN.NN NNNY NN ONNNNNNNNNNYNNNN I
ES050 0 50 0,70 1 2,6 7 YYNNNYNYNY NNN NYNNNNY ONNNNNYYYYNN NNNY 1
ES051 0 50 0,80 4 2,5 •:v>•../A-.. YYNNYNNN YYNYN N.NNNNNYYONNNYYNNNNN.YNNNNNN 1
ES053 0 67 0,90 7 3,0 18 NNNNYNNNNNNNYN NNNNNNN ONNNNNNNNNNYNNNNN /
ES034 0 70 0,70 4 3,1 10 YYNNNNNN YYNNN. NNNNNNN ONNNNNNNYNNYNNNNNN,
E8055 0 57 1, 40 11 6,6 1.8 YYNNYNNYNYYNNYNINNNYNN 1NNNNYNNNNNN NNNNY.
ES036 1 69 0,80 y 951L 13 YYNNYNNYNNYYNN NNNNYNN on.nn.nnnnti'YNYYNNN
ES037 0 59 0,80 '? 10,4 16 NNNNYNNYYYYNNN NNNNNNN ONNNNYYNYNNN NNNNN
esoss 0 53 0,69 6 2,5 YYNYYNNYYNNNYN NYNNNNY ONNNNYYNNNYYYNNNNN2
ES05? 1 66 0,62 1 2,5 12 YYNNNNNNNNNNYN NNNNNN ONYYNNNNNNNYNNNN 2
E8060 1 70 0,68 "X 2,5 13 NNNNYNYYNNYYYN NNNNNNN ONNNYNNNNNNYNNNN 2
ES061 1 55 0,64 6 2,5 '•v*.r YYNNYNNNNNYNNNNNNNNNNNNONNNYNNNNNNYNNNN 2
ES062 0 62 0,94 4 3,1 13 YYNNNNYYNNYNNNNNNNNNNN ,NNNNNNNN YYNNNNNN2
ES063 1 58 0,76 2,3 47 YYYNNNNYNYNY Y N NNNNNNN 0NNNYNNNNNNN NYN
ES064 1 55 0,94 1 13,7 46 YYNNNNNN YYNNNNNNNNNNN ONNNYNNNNNNYNNNN
ES065 0 55 1,30 12 8,3 « \y YYNNNYNYNYYNYN NNNNNYYNONNNYNYNYNYYNNNYNN2:
ES066 0 61 1,07 0 3,9 20 YYNYNNNYNYNNNN XYNNNNNNONNNNNNNNNNNNNN NN2
ES067 1 51 0,91 5 16,3 37 YYNNYNNYNYYNNN NNNNNN.Y ONNNNNN.NNN.YYYNYY 2
E8068 1 61 1,13 9 4,0 17 YYYNYNN.YN.YYN.YN N NNNNN ONNNNNNNYNYN NNN 2
ES969 0 £3-21,05 Cf 5,1 •: /j.{. "V YNNNYYNYNYYNNN NNNNNNN ONNNYNNNYNNN NNNNN:
ETOOir j. oo 1,77 C> 3,6 o YYNNNNNYYNYNNY YNNNNNN 0YYYYYNYNNNNN.NNN
ET002 I 73 0,98 "X 5,7 9 YYNNNNNY NYNNYYYNNNYNNY0YYYYNNNNNYNNYYN
ET003 0 78 1,11 ■y 4,7 13 yynnynnnnnyynyyynnnnnyyoyyyynnynnnyynnnnn
ET004 1 77 0,98 5 25,0 33 YYYNNNNYNY YNYYYNNNNNY ONYNNYNNYNYYNNNN.
ET003 0 80 2,18 2.9 4,1 9 YYNNYNNYNNNYNYYYNNYNYYYONNNYNNNNNNYNNNNNN
El 006 1 57 2,18 87 2,8 27 YNNNNNNNNNNYYYYNNNNNY ONNNNNNNYNYYNNNN
ET007 0 55 3,40 134 2.50,0 44 Y YN YN.YYNNNNYYYY YYYY 1YNYNYNNNNNY NNNNY
ET007 0 55 3,40 134 250,0 4.4 YNNNNNNNYNNNNNYNNNNNYYYOYYNNNYYYNNYYNNN
ET008 1 56 1,32 4 9,9 10 YNNNNNNNNNNYNNNNNNNNNNON YNYYNNNNYNNNN
ET009 0 68 2,70 98 6,8 NNNNNNNNNN NYYYNYY YN , N N NNNNNNNNNYNN.
ET010 0 54 1,39 17 237,0 17 YYNNNNNNNYNNNYYYNNNNNN ONNNNNNNYYYYNN.NNNN
ETO'.i.l 0 68 1,02 '*> 9,1 15 YY YYYYY YYY YY YY 0 YYYY YYY Y
FILE? ENASTEE DATA A LEEDS UNIVERSITY VM/8P 2,OS
ET012 "1 78 'i.«80 76 168,0 16 YYYNNN YYNYNNYYYNNYYYN ,Y NYYNNYNYNNNNN
TT013 1 67 1,82 15 280,0 27 NYNNNNNNNYNNNYYYNNNNNN 0NNNNYNNN.NNYN.NNN;
• ■




'66TW TT llf, 4
013 1 70 1, 82 26 14,9 19 YNNNNNYr r fNNYYYNYYNNN 0YNNNNNNYNNYNNNN
016 1 50 0,82 '•:» 4,1 11 YYNNNNNNNNYNYN YNNNNNN ONYNNNYNNN YNNNN
017 0 82 1,02 o 42,0 6 YYYNYNNY NN NYYNYNYYYYNOYYYYYYYNNNYYYNNNN
018 0 83 0,76 '■> 3,8 7 YY Y YYNN N N NNNN NN ONN NN NNYNNNN
019 0 33 3,10 86 4,0 13 YYYNN.N. YYYNNNYYYNNNNN.Y 0NNNN.NNNNNNYYN.NNNN
020 0 83 1,51 19 6, 7 12 YY Y YYNNYYY1'YNNYYYY 0NNNNYYNNNYYYNNYNN
021 o 71 0,59 6,3 13 *
022 •J •> •? -y •J •? YYNNNNNYY Y NNYNYNNNNNYYONYNNYN.NNNNN NNY
023 •; 67 0,82 ■"> 65,6 92 YYN.NYN.NYYN.YN.NN NN.YYYNN ONNNNNNNNN YNNNY
024 0 83 0,70 A. 4,9 17 YNNNNN NNNNN NNNNN. ONN NNNNNNNNNNNNNN
025 <0 85 1,51 12 5 •> 6 6 NNNN NNYYNNNNYYYNNNNNN '.i.NYNYNNNNNNYYNNNNN
026 0 79 0,82 1 "7 ■} 160 YYYNNNYYNNNNNNNNNNNYNNN1YYNNNYNNNNYNNNNNN
027 0 77 0 , 48 1 7,6 20 YYNNYNNNNNNNNYYNNNNNNNNOYNYNNYYNNNYNNNNNN
028 0 70 1,44 11 40,8 7 YNNNNN YNNNNYYYN YY N1NYYYYNNYNYN NNYNN
029 1 66 1,82 95 250,0 165 •>
'.>30 1 62 2,27 78 21,6 19 YYNN NNNNNN NYYYNNYNN YONNNYNNNNNNYNNNY
031 0 77 2,71 108 10,9 50 NYNNNNNNNNYYYYYYYNNYYNNONNNNNNNYNNYNNNNNN
032 o 71 1,24 6 234,0 42 YYNN.N.N YYNYY YNNNN , YY NY NN NN
033 1 66 2,54 105 19,7 48 YYYYYYYYYYNYYNNYNY YYY OYYYYYN YYYYYYYY
034 0 80 0,83 10 6,5 19 YYNNNNNYYNYNNN NNNNN N , YNNYYNNNNN NNNNN
>35 1 69 1., 42 14 36,0 57 YYNNYNNNNNY NNNNNNNNN 1NNNNNNNNNNYYNNN
036 0 69 1,83 17 9,6 14 YNYNNNYYNYNNNYYYNNNNYYYONNYYNNNNN.NNNNNN
037 1 85 1,33 12 24,2 12 YYNNYNNYNY NYN YNYYYYN 1NNYN.YNNNNNYNN.NN
038 1 54 2,18 26 17,4 10 YYYNNNNYYYYNYYYYYYYNNY , NYYYYNNNNYNNNNN
frv-A^ , •> -> * *> YYYNNNNYNYYNNNNNNN YYYONYY YNYNNYYNN.NY
04(0 0 m 0,81 1 3, 0 O YYNNYNNYYNYNNYYNNNNYNN ONNYNYNNNNNYNNNYNN
041 1 65 1,30 21 27,2 17 YYNNNNNNN YNNN NNNNNNN ONY NYNNNNNYNNNN
042" 1JT>"
0,74
•> •} •> NNNNNNNNNYYNNYYYNNYYYY 1NNYNNYYYNYNNNNN
>43 1 •J 1 14,2 CI
>44 0 71 0,89 1 11,1 "'}f NNNNNNNN NNNYYYYNYYYYN. ON NNNNNNNNNN
>43 0 76 0,94 4 6,3 6 YYNNYNNYNNYNYYYYNNNNNY 1YYYNYYYNNYYNNNNNN
>47 0 66 1,30 "Y 4,3 12 NYNNNNNN NNNYYNNNNNNNY 1YYNYNNNNNNYYNNYNN
>48 1 1,68 13 2,5 16 YYNNYNNNNNYNNN. YNNNNNY INYYYNYYNNNYYNNN
>49 1. 77 2,87 42 12,8 8 YYYNNNNNNYNNNNNYNNNNNNNOYNYNYYYYNNYYNNN
>30 1 73 1, 44 11 12,8 9 YYNNNNNYNYNNNYYYNNNNNNNOYYNNNYNYNNYYNNN
>52 o 65 1,88 13 10,7 12 YYNNNNNYNYNYNYYYNNNNYY 1YYYNNNNYNNYYNNNNN
>53 ■J. 81 1,04 4 2,9 8 YYNNYNN YNYNNNNNNNNNNN ,NYNNYNNNNNYYNNN
>54 1 61 1,50 -.YO 5,6 53 YYNNYNNNNYNNNYYYNNYNYYYONNNNYNNNNNYNNNN
>55 1 81 1,15 27 7,8 17 NNNNNNN YYNNNNYNNNNNY OYYYNYNYYNNYYNNN
>55 1 81 1,15 27 7,8 17 NNNNNNNYNYNNNYYYNNNNNNNONYYNNYNYNNYNNNN
'56 •> •> 4 * YYNNNNNYNNNNNN NNNNN , YY YN.YNN.N NNN.
>57 0 ■} 1,50 40 10,0 •>
'58 1 71 1,31 4 8,0 9 YYYNNNNNNNYNNN NNNNNNN 1YYYYNNNNNNYYNNN
'59 1 80 1,31 8 15,3 6 YYNNNNNNNYYNNN YNNNNNY 1NYYYNNYNNNYNNNN
1 <- 2,43 98 16, 4 47 *>
-61 0 71 0,99 V 4,0 16 YYYNYNYYNNYYYN YYNNYNY 1YYYYNYNNNYYNNNNNN
'62 0 •> 1,10 46,0 400 ❖
>63 - 0 •i 0,76 11 24 5 330 •?
64 0 54 1,04 8 .)• /.•../ •> "X•..J YYNNYNNYNNYNYN NNNNNYY 1YYYY Y_XNNNNN.NNN.NN
'65 :i. 74 0,68 1 / -J 13 YYYNNNNN Y NNN YNNNNYYY1NYNYNNNYNNYYYNN
66 1 72 1 > 06 4 "X X. 11 YYNNYNNYNYNN YYYNNNNNNNONNNYNNNNNNYYNNN
67 1 59 1,99 11 '*> "J 15 NNNYYNNNNNYNYYY YNNNNYY1NN NYNNNNNYNNNN
EHASTER DA : A A LEEDS UNIVERSITY vN/SP 2,05
68 1 60 1 -61 8 7,3 16 YNNNNNNN NNNYjN NNNNNYNN1.YNNYYYYNNNNNNNNNN
69 0 60 1,40 18 42,4 10 YYNNNNNYYNYYY|YYYNNNNYYYONYNNYN^!NN.YYNNN.NN
- 338 -
; <■..> / J. V /■ CAJ .1. Ci .i. , / •../O
ET072 0 71 1,87 28 91,1 9
ET073 0 57 1,39 45 9,1 31
,11074 i 66 1,20 19 3,8 9
ET075 1 72 0,85 0 3,9 52
E s 077 1 69 2,09 5,2 61
ET078 1 52 1,1.8 "7 250', 0 7
ET079 0 62 1,23 20 2,5 7
ET080 0 76 1,50 19 9,1 15
t'.'.. i 08 1 74 1,61 53 4,1 34
ET082 0 76 2,00 49 54,5 16
ET083 0 80 2,21 73 5,3 17
EI 084 1 53 0,76 1 5,6 18
ET085 i 80 1,94 '•yx 7,6 34
ET086 0 74 2,31 35 5,0 11
ET087 0 48 1,50 23 a2,0 •>
ET088 1 62 1,04 4 10,3 31
EI 089 0 58 1,11 3 8,6 14
ET090 1 63 1,04 5 3,1 16
ET091 1 68 0,96 "X 14,2 12
ET092 1 66 2,07 13 50,0 26
ET093 0 61 0,72 1 2,5 21
ET094 0 66 1,29 13 250,0 94
E7095 1 74 1,82 16 173,0 16
ET096 1 74 1,16 '■} ~X 250,0 350
1.1097 1 60 1,39 "X•../ 97,5
ET098 ]. 72 1", o-.r :r 12,8 15
EI099 1 66 1 - 17 74,0 8
EI 100 0 68 1,46 '} "J 5
ET 101 1 73 0,83 ..y •> 11
ET102 1 68 1,34 8 •> 30
ET103 1, 70 0,83 4 14




ET 105 0 /. O 1 0 1 '•> 13,7 5
ET106 0 53 3,20 403 107, 4 170
El' 107 j. * 0,76 1 2,5 30
E9001 1 56 0,74 1 2 , :J 19
E9002 0 51 0,74 1 2,5 7
E9003 0 49 0,78 1 2,5 6
E9004 0 64 0,59 1 2,5 5
E9005 0 57 1,22 13 2,6 6
E9006 0 58 0,70 1 2,7 13
E9007 0 53 0,82 1 2,5 6
E9008 1 60 0,48 1 2,7 13
E9Q09 1 64 0,66 :i. •» •../ 15
E'v'010 0 0,66 1 2,5 6
EV011 0 55 0,86 l 2,5 24
E9012 1 51 0,86 1 2,5 15
E9013 1 45 0,90 1 4,2 34
E9014 1 50 0,70 l •> -.J 42
2.9015 0 50 0,55 •j. 2,5 7
29016 0 53 0,55 1 2,5 5




































yyvnnnnn wm nt munimimmmypmYHmr




YNNNNNNYNYNNN N NNNNYNN ONNNNNNN -.NNYNNNN

















nynnnnnnnnnnyln nnnnnnn onnnnnnnnn ynnnnnn
"iles emaster data a leeds university vm/sp 2,05
•9017 0 59 0,66 1 3,5 8 yyynnnnnnnnyi^nnnnnnnn ,nnnnn^i^nnynnnnnn
o 35 0,66 3,5 12 yynnnnnnnnn yn nnnnnnnnonnnyynn^nnynnnnnk
5)20 0 43 1, 22 o
5)21 0 68 0,70 o
5)22 0 30 0,70 J.
5.)23 0 58 0,94 i
5)24 -J 68 1,12 i
5)25 0 68 1,03 i
5)26 0 53 0,78 •7
5)27 1 6? 1,12 '•j
5)28 0 48 0,90
6)29 1 65 0, ?0 ')
5)30 o 56 0,86 "X
5)31 1 65 1,62 19
5)32 o 51 1,12 4
5)33 1 52 1,03 1
5)34 0 60 0,99 1
5)35 1 51 0,78 "X
5)36 0 64 0,90 "X
5)37 1 56 1,12 4
5)38 1 33 0,78 1
5)3? 0 55 1,22 1
5)40 0 58 0,92 1
5)41 0 8? 0,86 19
5)42 1 54 0 , 92 "X•_/
5)43 0 35 0,98 4
5)44 1 48 0,74 "X
5)45 0 48 0,86 5
5)46 0 43 0,68 1
'047 1 46 1, 46 4
5)48 1 58 0,80 "}
5)4? 0 58 1,05 "X
5)50 •J. 52 0,86 "X
5)54 o 27 •> •»
5)33 0 60 ■j *
5)56 67 ->
057 0 51 •f *
5)61 1 36 r. <:y\i\f •> / •../ 1
062 *> *> (\ /. "X 3
5)63 1 48 0,93 1
064 0 40 0,67 J.
5)65 1 45 0,83 4
066 0 47 0,72 1
5)67 o 51 0,63 4
068 0 40 r. o "x\f 4 / •f
5)6? 0 4? 0,83 1
070 1 64 1,10 1
5)71 0 41 0,77 1
072 0 69 0,67 1
5)73 o 73 0,72 1
074 0 /. "X 1,14 1
075 0 72 1,00 1
076 1 78 0,72 1
077 0 71 0,78 1
Li;::; emaster data
07? 0 74 0,?4


































































NYNNNNNN N NYjN NNNNYNN




NYNNNNNN NNN N NNNNNNN
NNNNNNNNNNNNi'-fNNNNNNNNN
YYNNNNNNNNNN^NNNNNNNN
NYNNNNNN Y NNN NNNNYNN
YNNNNNNNNY N^.NNNNNNNN.






































N YNNNY YNONNNYNNNNNNN NNNNN
YYNNNNNYNNNNYN NNNNNNN ONNNYNNNj^NNYNNNN
















YYYN NNN N N
4NNNNNNNN ONNNNNNN viNNNNNNNNN
-i NNNNNNN , NNNNNNNNNNN NNNY




































LLLDS UNIVERSITY VM/SP 2,05
4,5 28 YNNNNNNYN NY 0 NNNYNNNNNN
3,3 27 N. YNYNNY N Y^YYYNNNNNN OYNNNNNNNNNYNNNNNN
- 340 -
















i r—- r— r—
r-~ i— -
x >""3 X X X X X_L' * x X X X X X X X X XX * x x X X X X X XH * x x X X X X X X* x x X X X X XJU * x x X X X 3o K x "3
X X* x x




X X* x X
X X3 * X X X XX K
*
* X> X X X X X X X X X X X'3 * X) X) X X X X X X X X X X X X X XK "oU X X X X3 K X) X) X X X XX * x 'X X X X X3 K X X X X X X-L. X X X X X X >7.3 X X X X X X X< X X) X X X X XX X) X X X X Xx X 33 X o X) X X X X X X ID X X X X A7X
X
X X X X X X X X X X X X
X
X X X X X X X X X X>- X 73 X X X X X X X /3 X X4 X 73 X X X X XX •73 X X X X XX X 73 X X X X XX X 73 X X X X XX X 73 X X X X X:* X 73 X X X X X—i X 73 X X X X XX 73 X X X X X3 X 73 X X X X X X X X X XX X X X X X X X X
X X X X X X X X XX X X X X X X X X X XX X X X X XX X X X X XX X X X X XX X X X X XX X 33 X X XX X X X X XX X X X X XX X X X X XX X X X X X X X X X XX X X X X X X X X
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The role of a questionnaire and four biochemical markers to
detect cancer risk in a symptomatic population
E.M. Chisholm1, R.J. Marshall2, D. Brown2, E.H. Cooper2 & G.R. Giles1
1 Department of Surgery, St. James's University Hospital; and 2 Unit for Cancer Research, University of Leeds,
Leeds, UK.
Summary The roles of a self-completed symptom questionnaire and four biochemical markers of disease were
assessed to determine risk for gastric and colorectal cancer from within a hospital population and a random
population. Eight-six patients with cancer, 168 subjects with benign conditions of the stomach and large
bowel and 720 individuals from the community at large were investigated. Multivariate analyses of the
questionnaire and biochemical data were performed individually and in combination using a data set
comprising 54 cancer subjects, 80 patients with benign disease and 200 random individuals. The most
favourable predictive equation derived was then applied to the remaining data set to determine its efficacy. In
the primary analyses the questionnaire data identified 32 (60%) cancers successfully and using the biochemical
markers alone 36 (67%) patients were also correctly classified as cancer bearing. However, the combination of
the questionnaire and marker data improved the sensitivity for cancer to 50 cancers detected (92%) (P<0.02).
Using the predictive equation from this combination of data to identify risk in the second data set 28/32
(88%) cancers were correctly identified with only an 11% false positive rate. An 18 month follow-up for the
non-cancer group has to date revealed only one cancer (ca. pancreas).
In this limited study, multivariate analysis of questionnaire and biochemical marker data does successfully
identify individuals at 'high risk' of harbouring gastric or colorectal cancer within a symptomatic population
and may have a role in determining priority for investigation for a symptomatic individual.
There can often be considerable delay in the
diagnosis of gastrointestinal (GI) cancer in a
symptomatic population presenting to a clinician,
despite the availability of sophisticated methods
of investigation (MacAdam, 1979; Holliday &
Hardcastle, 1980). While it is desirable to investi¬
gate all symptomatic patients to exclude neoplasia,
there has been a call to rationalise the way patients
are referred for investigation, particularly to
endoscopy units (Mann et al., 1983). Clearly some
simple method to select 'high risk' groups is
required so that priorities for investigation of
patients can be made and so reduce delay in the
diagnosis of GI cancer.
Unfortunately no such simple method exists.
Initially it was hoped that a serum tumour marker,
such as carcinoembryonic antigen (CEA), would
have sufficient sensitivity and specificity to detect
GI cancer preoperatively in a symptomatic
individual. The recent National Institute of Health
Concensus Report (1981) declared that CEA should
not be used as a preoperative investigative tool to
detect GI malignancy and no other individual
tumour marker has been found to be of value.
However, the investigation of combinations of CEA
and acute phase reactant proteins (APRPs) has
Correspondence: G.R. Giles
Received 18 July 1985.
shown that they may aid in prognosis for both
gastric (Rashid et al., 1982) and colorectal cancer
(Ward et al., 1977). This observation stimulated
Chu and colleagues (1982) to assess the com¬
bination of CEA and alpha-l-acid glycoprotein
pre-operatively in patients with colorectal cancer,
where the sensitivity for detection of cancer
increased significantly but was associated with a
reduction in specificity. De Mello et al. (1983)
pursued this approach by using a panel of six non¬
specific biochemical markers to define 'cancer risk'
preoperatively; by applying multivariate analysis
they identified 162 GI cancers (81%) with a false
positive rate of 16%. Further, Walker and Gray
(1983), applying discriminant analysis to a battery
of markers found that the combination of serum
protein hexose and CEA could significantly increase
the preoperative detection of colorectal cancer. In
addition Mann et al. (1983) have recently reported
the use of multivariate analysis of the symptom
complexes of patients presenting for endoscopy to
develop a scoring index which identifies priority for
investigation and 'risk' of upper GI disease.
We have incorporated both these approaches into
a study to assess: (a) the use of multivariate
analysis applied to four biochemical indicators of
disease: CEA, gamma glutamyl transpeptidase
(GGT), C-reactive protein (CRP) and alpha-l-acid
glycoprotein (AGP) to identify cancer risk; and (b)
© The Macmillan Press Ltd., 1986
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the role of symptom analysis with or without the
addition of potential tumour markers to define risk
for GI cancer.
Patients and methods
Eighty-six subjects with GI cancer, 168 with benign
GI disease and 720 individuals from the general
public were investigated (Table I). The group from
the population at large was included since it has
been shown by Jones (1976) and Thomson and
Heaton (1979) that many apparently normal
individuals may have present at any given time
symptoms suggestive of significant gastrointestinal
disease. Thus to produce a system to reduce over-
investigation of individuals it is necessary to take
account of the background prevalence of symptoms
within an age-matched population. Entry into this
group was determined by age, 50-70 years, and by
enrolment by the general parctitioner of individuals
felt to be free of active gastrointestinal disease.
Each individual was required to complete a
symptom questionnaire and give a 10ml sample of
blood. The blood was allowed to clot, centrifuged
at 3000 r.p.m. and the serum stored at — 25°C for
subsequent analysis.
Table I Details of study groups
Group No. Mean age Site of disease
Cancer 86 68 y 57 Colorectal
29 Gastric
Benign 168 53.7y 88 Colorectal disease
80 Gastroduodenal disease
'Normal' 720 58.1 y No active GI disease
Questionnaire
The questionnaire comprised 41 questions, 18
relating to GI symptoms and 23 further questions
pertaining to previous health, social history and
pertinent epidemiological data. The format was
simple, requiring a tick in a box to represent a
positive or negative response. The questionnaire
had previously been validated on 144 individuals
and has been reported elsewhere (Chisholm et al.,
1985). In this survey only the 18 GI questions have
been used in the subsequent analyses.
Analytical methods
CEA was determined using Phadebas CEA Prist
kits supplied by Pharmacia Diagnostics AB
(Upsala, Sweden). Gamma glutamyl transpeptidase
(GGT) was measured at 37°C by the method of
Haesen et al. (1972) using a Technicon II Auto-
analyser. C-reactive protein (CRP) and alpha-l-acid
glycoprotein (AGP) were measured by single radial
immunodiffusion Mancini et al., 1965) using anti-
sera and standards obtained from Behringwerke,
Marburg, Koln, Germany.
Statistical analysis
A preliminary analysis of the relative frequency of
positive responses to each GI question was
performed using a x1 test t0 detect significantly
different response rates for cancer patients
compared to the remaining groups. Similarly, the
cumulative frequency distribution of each bio¬
chemical variable was plotted and, by using the
95th percentile value of the benign group as a cut¬
off point, the sensitivity and specificity of each
marker to detect cancer were determined.
A logistic discriminant analysis (Anderson, 1972;
Albert, 1982) has also been employed in this study
to determine which variables are significant in
discriminating between the cancer and non-cancer
subjects. A stepwise procedure was adopted in
which variables (4 tumour markers and 18 GI
questions) are added to the model sequentially and
at each step the statistical significance for each term
not already in the model is calculated. The most
significant variable at each step is added and when
no variable is significant at the 5% level the process
stops. Biochemical measurements underwent a
logarithmic transformation (log 10) and positive
responses to the questionnaire were accorded a
score of +1 and a negative response — 1. Sex was
coded as +1 for male and — 1 for female. The
analysis was performed using the statistical package
BMDP81, subroutine PLR, on the University of
Leeds AMDAHL 470 computer.
To fit the model we used 54 cancer cases and the
non-cancer group comprised 80 benign and 200
control population (first set data). As more cases
were enrolled it was hoped that the model could be
applied prospectively, thus permitting a more
accurate impression of the validity of the model in
a clinical setting (second set data).
Results
The sensitivity and specificity for the individual
biochemical markers using an arbitrary cut-off
point equal to the 95th centile of the benign group
are shown in Table II. Thus the single most
sensitive agent was CRP with an overall detection
for cancer of 52%.
X2 analysis of the 18 GI questions revealed 6
questions which significantly distinguished between
cancer and non-cancer subjects (Table III).
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Table II Percentage of patients with a tumour marker value greater than the 95th
centile of the benign group
Cut off value Cancer (%)
Tumour marker (95th centile benign) Colorectal Gastric Normal (%)
CEA > lOngmD1 47.4 48.3 2.5
AGP >1.4gr1 36.8 65 2.6
CRP > 12mgl_I 4.4 69 2.8
GGT > 50 U U1 14 10 2.1
Table III Percentage frequency of positive responses per question for
cancer and non-cancer groups
Cancer Non-cancer* P value (x2 test)
Reduced appetite 56.7 29.78 0.0012
Weight loss 64.7 30.7 0.0001
Food sticking 33.3 24.6 0.0001
Nausea 24.0 42.0 0.02
Altered bowel frequency 71.9 37.8 0.0001
Altered stool appearance 62.7 36.7 0.0025
"Non-cancer = Patients with benign disease and normal individuals.
However 35% non-cancer bearing subjects had 3 or
more positive responses present.
We used the first set of data to fit a logistic
model to discriminate the cancer from the non-
cancer group. Using only the biochemical data, 36
(67%) of the 54 cancer patients were correctly
classified, with a false positive rate of only 5%. The
18 cancers missed by this simple discriminant
included 5 patients with liver metastases from
colorectal cancer and 2 patients with advanced
gastric cancer. A similar analysis of the 18 GI
questions correctly classified 60% cancers with a
5% false positive rate. In a logistic analysis using
both the questionnaire and biochemical data, 50
cancers (92%) were separated from the non-cancer
groups, with a similar 5% false positive rate (Table
IV). This is a significant improvement on both the
questionnaire and biochemical data when used
individually (P<0.02, x2 test)- The cancers mis-




Biochemical markers 36 (67)" 95
Questionnaire 33 (60) 95
Markers plus questionnaire 50 (92) 95
"Percentage in parenthesis.
identified were 2 colorectal cancers (Dukes' stage
C + D) and 2 gastric cancers (stage 11 +IV).
The fitted model is determined by the
discriminant function (log to base 10): y= 0.605
(sex) +0.112 (age) +2.73 log (CRP) +5.33 log
(CEA) -4.09 log (GGT) +1.05 (wt loss) +0.968
(bowel habit) + constant (8.4) and the probability
of cancer is then />= exp(y)/(l +exp(y)).
The 'optimal' cut-off point for these values to
indicate cancer is Pit0.275.
By applying this criterion to the second set data,
28 of 32 cancers (88%) were selected but the
specificity fell to 89%. The 4 cancers misclassified
as low risk for cancer were all colorectal (Dukes' C).
Application of this type of analysis to the
patients with benign disease, lead to 26 of the 168
individuals being identified as at 'high risk' of
cancer. However, included in the 26 there were 4
subjects with gastric ulcer or polyps and 4 patients
with large colonic adenomata and villous polyps.
Thus the system detected further 'high-risk'
potentially premalignant conditions which clinicians
would wish to investigate.
Fifty-six subjects of the 720 individuals in the GP
study were classified by the analyses to be at high-
risk for cancer. Only seven were investigated but no
neoplasia was detected. In the remainder, raised
acute phase reactant proteins (APRPs) due to
upper respiratory tract infections (the reason for the
GP consultation) may have caused the high
probability value. To date, with a follow up of 18
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months, no cancers have been identified in these 56
subjects.
Discussion
The problems of using a single tumour marker for
cancer detection are again well demonstrated in this
study. Even by taking the 95th percentile value of
the patients with benign disease as the cut-off point
for CEA detecting cancer, there is still 2.5% of the
normal population with elevated CEA levels, whilst
the. sensitivity for cancer was only 47%. However,
with a logistic analysis using the combination of
four biochemical markers, we have confirmed the
approach of de Mello et al. (1983) in that 36 (67%)
cancers were detected in the first analysis, with a
5% false positive rate.
The analysis of the symptoms showed that 35%
of the general population had at least three positive
GI responses in the questionnaire. Eleven per cent
had noticed rectal bleeding at some time (6%
within a year) and 27% had experienced episodes
of diarrhoea which somewhat dilutes these
symptoms as potential markers for GI malignancy.
Using the multivariate approach, only 60% cancers
were correctly classified, thus showing the
considerable overlap of symptoms between benign
disease and cancer bearing subjects. This raises
doubts concerning the validity of symptom complex
analysis to determine cancer risk.
Combining the questionnaire data and the
biochemical values, however, a significant improve¬
ment in the diagnosis of cancer has been achieved
(/>< 0.02, x2 test). By demanding a cut-off point
which assured a high level of specificity in the first
data set, we feel that we have managed to reduce
the degree of false positivity that would normally
be expected in a second phase study. Thus the
recognition of 88% cancers with an 11% false
positive rate in the second data set using this
method is encouraging. It could be argued that by
accepting a low level of probability of cancer
(P<0.275) we have ensured a high sensitivity.
However, by utilising a large number of controls we
have shown that few 'normal' individuals would be
selected for investigation despite the presence of
multiple symptoms in 30% of the population.
Furthermore, few of the benign disease group (15%)
would be selected for investigation, implying that
the cut off is satisfactory. The classification of
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SUMMARY
We discuss the use of the trichotomous logistic model to discriminate between patients with
gastrointestinal(GI) cancer, patients with benign GI disease and 'normal' subjects, using symptoms and the
concentrations of some serum proteins that are potentially indicative of malignancy as covariates. A
parsimonious model can be obtained by invoking an indistinguishability hypothesis which is appropriate
when a covariate is considered to have no predictive value between categories. It is shown that the
polychotomous model can be re-parameterised under the null hypothesis to give a 'reduced form', which can
be fitted by maximum likelihood. The validity of the use of the same methods for retrospective sampling is
discussed. The approach is illustrated by the development of a logistic model to identify symptomatic and
asymptomatic subjects with a high risk of GI cancer.
key words Logistic model Indistinguishability hypothesis Gastrointestinal cancer Maximum
likelihood
INTRODUCTION
The dichotomous logistic regression model is now widely employed in medical research but there
are only a few cited examples1 where the polychotomous logistic regression model has been used,
even though it has advantages over normal theory discriminant analysis2. In this paper we describe
an application of the use of a trichotomous logistic model to identify subjects with a high risk of
gastrointestinal (GI) cancer using the concentrations of certain serum proteins and GI symptoms
as covariates. The number of parameters to be estimated, (p+ l)(k — 1) for p covariates and k
categories, may be excessive for a parsimonious representation and methods of achieving a more
economical model are desirable. One approach is to consider formulating hypotheses concerning
the predictive value ofcovariates in the model. Anderson3 has used the term 'indistinguishability' to
describe a hypothesis of this sort, a terminology that we shall also adopt. Under the null hypothesis
the polychotomous model can be written in a 'reduced form'. By fitting the reduced model it is
possible to test the null hypothesis with either a score test or a Lagrange multiplier test4, or if the
full model is also fitted, with the likelihood ratio test. It has recently been shown that it is possible to
carry out a polychotomous logistic analysis by fitting a number of separate dichotomous models
0277—6715/85/030337—08S01.00
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with little loss of efficiency1'5. However, this approach is not generally appropriate for the reduced
form of the logistic model that we consider in this paper. Software for fitting the reduced model is
also not readily available and we have accordingly developed a suitable program ourselves. We now
outline the background to the study that stimulated this work.
THE GASTROINTESTINAL CANCER STUDY
There is often a considerable delay between the onset of symptoms and the diagnosis ofGI cancer.
Many patients are diagnosed with advanced disease and the tumour stage at diagnosis is sometimes
associated with the duration of this delay6. A number of factors may contribute to a delay; initially
immediate action might not be taken because many of the early symptoms are also indicative of
benign or relatively minor conditions. Persistent symptoms usually lead to referral for specialist
treatment, which might necessitate exploratory tests such as endoscopy, and possibly also surgery.
These procedures are time consuming and expensive and often prove to be negative for cancer.
Consequently there is a need to determine a system of priorities to select symptomatic patients for
investigation. Similarly, there are obvious benefits if subjects with a high risk ofGI cancer could be
isolated prior to the onset of symptoms. Clearly some simple methods to isolate high risk subjects
are desirable.
The role of biochemical markers in screening, diagnosis and monitoring ofcancer of the GI tract
has been discussed widely in the literature'. In particular the serum protein carcinoembryonic
antigen (CEA) has been considered a promising marker ofmalignancy but its lack of specificity has
precluded its widespread use8. The combination of a number of serum proteins has been suggested
for detecting GI cancer pre-operatively in symptomatic patients (De Mello et al.9). These authors
claimed an 84 per cent sensitivity and an 81 per cent specificity with a dichotomous logistic
regression model to discriminate between patients with GI cancer and patients with non-malignant
GI disease, but they did not consider including symptoms in their model. One stimulus for the
present study, therefore, was to investigate whether serum proteins together with symptoms might
provide a better model. We also felt that the inclusion of'normal' subjects in the study would be
useful in that it would give an indication of the background prevalence of symptoms and of
'normal' concentrations of the serum proteins. Three groups were therefore considered for the
study: patients with GI cancer, patients with benign GI disease requiring endoscopic investigation,
and apparently 'normal' subjects aged over 45. Separate samples of the cancer and benign GI
groups were taken from patients referred to the Department of Surgery, St James's University
Hospital, Leeds. The benign group included symptomatic patients undergoing therapy for a non-
malignant condition, and the cancer group consisted of a consecutive sample of patients with a
confirmed diagnosis of cancer of the oesophagus, the stomach or the large bowel. The normal
sample was collected over a period of eighteen months from six general practice clinics in the Leeds
area. Patients attending with a GI complaint or with a history ofGI disorders were excluded. Each
patient supplied a blood sample from which CEA and three other tumour associated serum
proteins were measured immunochemically: gamma-glutamyl transpeptidase (GGT), alphaj-acid
glycoprotein (AGP) and C-reactive protein (CRP). In addition patients completed a questionnaire,
from which 14 binary responses relating to key GI symptoms were derived (Table I). Complete
data for a total of 96 cancer patients, 163 benign patients and 804 normal patients were obtained.
Only 100 normal patients and 99 benign patients were used for model development, the remaining
patients were set aside for model validation. Further details relating to the clinical aspects and the
motivation for the study are discussed by Chisholm et al.10.
The objective was twofold: first to consider whether symptoms and protein concentrations could
be used to distinguish between benign and cancer patients in a symptomatic population, and,
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Table I. A list of the 14 gastrointestinal symptoms in the
questionnaire
Symptom Description
1 Recent weight loss
2 Recent appetite loss
3 Food sticking before reaching stomach
4 Burning or discomfort behind breastbone
5 Nausea or vomiting
6 Pain or discomfort in abdomen
7 Abnormal frequency of motions*
8 Need to go after emptying bowels
9 Altered bowel habit
10 Change in motion appearance
11 Periods of loose motions
12 Motions becoming more constipated
13 Blood in motions
14 Slime in motions
* More than 3 per day or fewer than 3 per week.
second, to determine the usefulness of these factors for a cancer 'case finding' role in an
asymptomatic population. Separate dichotomous logistic regression models between the benign and
cancer groups and between the asymptomatic and cancer groups can be contemplated, however, we
considered that a more satisfactory analysis, in view of the three distinct categories, might be
obtained by fitting a trichotomous logistic regression model between all three groups. From such a
model the individual logistic models between each of the three pairs of categories can be derived,
and the trichotomous form allows classification to a benign, possibly pre-malignant, state. Readers
not interested in the mathematical details of the polychotomous logistic model should omit the
next section.
THE REDUCED LOGISTIC MODEL
Suppose that Y is a multinomial variable with a sample space of k possible categories {>T, • ■ ■, yk}
and that x = (jt1)... , xp) is a vector of covariates. The logistic model specifies a conditional




where X = (l,x) and <xs = (as0, . . . , asp)T is a vector of model parameters, as0 being a constant
term. For uniqueness it is assumed that ak = 0. Often it may be of interest whether a particular
covariate, say Xj, has any potential for discriminating between categories y, and ys. To be specific we
can consider categories and y, to be 'indistinguishable' with respect to a covariate Xj when
asj = a,j or, equivalently, when the relative risk of against y„ for a given x, does not depend
on Xj. More than two categories may be indistinguishable so that, defining a set of categories Sj
for Xj, a null hypothesis is
H0j: asj = oi,j = Cj for >'s and y, belonging to the set Sj.
Here c, is not specified unless yk is included in Sj and then c} = 0, since ak = 0. A null hypothesis H0j
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can be defined for any number of covariates and a compound null hypothesis, H0, can be
constructed from the separate hypotheses for each such j. The term exp (cjXj) can be factored from
the numerator and denominator of (1) and the model reparameterised with a.sj — Cj replaced by a*.
Under H0j, a*- = 0 for ys belonging to the set Sj so the model under H0 can be written as
exp (Xs/?s)
Psx = ~k (2)
Z exP (X, ft)
r= 1
where Xs is a vector of length qs consisting of the elements of X that correspond to the non-zero ocsj,
and /?s is a vector of corresponding model parameters. Henceforth (2) is referred to as the 'reduced
logistic model' under H0. If Qs denotes the index set ofcovariates referenced in Xs then (2) is unique
in its parameters if the intersection of Qs over s = 1,. . ., k is null. The approach to fitting the
logistic model by fitting separate dichotomous models4 is not appropriate unless one of the Qs sets
is empty, so that there is a pivotal category. The simple case k = 3, Xj = X2 = (1, Xj) and X3 = x2
illustrates this: the parameter fi3 appears in the individual regressions between categories 1 and 3,
and between categories 2 and 3.
An advantage of the parameterisation in (2) is that it has the same structure as the unrestricted
model (1) so that any program that is used to fit (2) can be used to fit both the restricted and
unrestricted models. The maximum likelihood equations for fitting (2) when sampling is
prospective, that is when observations of Ygiven x are made, are similar to those given for example
by Anderson2 and are omitted. A solution can be obtained by a Newton-Raphson procedure and
this is the method that we have adopted in our program. Possibly other accelerated convergence
algorithms would be faster but we have found Newton-Raphson quite efficient and the estimated
information matrix is obtained directly. With minimal extra programming the Lagrange multiplier
test statistic4 can also be computed. This test asks whether the restricted estimates are sufficiently
near to the absolute maximum of the likelihood. (It is computed as a quadratic form 1q L010 where
10 is the first derivative vector and L0 is the second derivative matrix of the likelihood with respect
to the parameters in the unrestricted model, but computed with the restricted estimates.) Copies of
the computer program are available on request.
When sampling is retrospective, that is, when separate samples are taken from each of the k
categories and x is the observed variable, the inference problem is less straightforward2,11~13. For
model (1) it is, however, legitimate to treat the sample as if it were obtained prospectively and to
make adjustments to the constant term estimates according to the prior probability, ps, and sample
size, ns, associated with each category. Specifically this means adding log (nkpjnspk) to the
estimated constant terms. This theory carries over to the reduced model (2) if the model includes
precisely k — 1 free constant terms.
RESULTS FOR THE GI CANCER STUDY
As outlined above the GI study data consisted of separate samples from three populations: cancer,
benign and 'normal' patients. It is therefore necessary to invoke the retrospective theory mentioned
above. Since the serum protein values are continuous variables the resulting estimates are not
maximum likelihood in the strict sense2,1'. In practice however, they may be treated as such and the
usual likelihood theory for testing the model, treating the retrospective sample as if it were a
prospective one, can be utilised. We require, however, a prior probability for each category to
'adjust' each constant term. To classify an apparently normal individual, a prior probability should
reflect the prevalence of pre-clinical cancer and benign disease in the population. Prevalence rates
are not easily obtained but the incidence of cancer is well recorded14, as is the incidence of benign
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disease requiring in-patient treatment15. Simple calculations show an incidence of GI cancer of
about 4 per 1000 for the population aged 45 and over14, and the in-patient treatment rate for
benign disorders is 3 8 per 1000 for the same age group15. The majority of benign disorders are,
however, treated as out-patients. Experience at endoscopy units in Leeds suggest that about 1 of
every 10 cases in the elderly age group that is diagnosed with a GI disorder has cancer. If the
incidence rate for cancer is also adopted as a measure of prevalence, prior probabilities of 0 004 and
0 036 are suggested for cancer and benign disease respectively. These are the figures that we have
adopted for subsequent analysis. It is, however, legitimate to use subjectively chosen prior
probabilities for the classification of an individual.
The four serum proteins and the 14 questionnaire responses, together with sex and age, give a
total of 20 covariates and 42 parameters for the unrestricted trichotomous logistic model. A model
with fewer parameters was felt to be desirable and two hypotheses were thought to be feasible: first,
that the benign and cancer patients are indistinguishable with respect to the questionnaire
responses and, second, that the benign and normal groups are indistinguishable with respect to the
serum proteins. These two hypotheses will be referred to as HQ and Hs respectively and H0 is used
to denote both HQ and Hs. Various authors5,16,17 have given evidence to support HQ, at least for
early stages of GI disease, and the potential role of the serum proteins as markers of malignancy
justifies consideration of Hs.
It is instructive to demonstrate the construction of the appropriate reduced model to test H0. If
the covariate vector x is partitioned as follows
x = (x0,xe,xs),
where x0 is the vector of age and sex, \Q is the questionnaire vector, and xs is the serum protein
vector, then under H0 the reduced form (2), with s = 1, 2 and 3 referring to the cancer, benign and
normal groups respectively, can be written with
Xi = (l,x0,xs); X2 = (l,x0); X3 = x^.
Table II gives the likelihoods attached to each of the fitted models with the associated likelihood
ratio and Lagrangemultiplier test statistics. The test for Hs is not significant, whilst the tests for HQ
and H0 are inconclusive. Consequently we considered it wise to adopt Hs but to test an alternative
hypothesis concerning the questionnaire data in which only certain questions were considered
indistinguishable between the cancer and benign categories. Chi-square tests for differences in
response rates were used to indicate which questions might be indistinguishable, and an
appropriate reduced model was fitted in which the non-significant responses were made
indistinguishable. This reduction was not significant (P = 0 53). A further reduction in the model
was obtained by a 'manual' stepwise procedure in which estimates were compared with their
estimated standard errors and those not significant were removed. The effect of the reduction at
each step was judged by the likelihood ratio test. This led to a model with 15 parameters (Table III).
No further reduction seems feasible though a number of possibilities have been tried. The serum
proteins CRP and GGT do not add anything to the model and only 6 questions are useful, 3 of
these, Q3, Q5 and Q14, being indistinguishable between the cancer and benign groups.
The model can be used in two ways: first to identify cancer patients in a symptomatic population
and, second, to pick up subjects with GI disease prior to the onset of symptoms. For the former a
dichotomous logistic model, between cancer and benign patients, can be derived directly from
Table III. To use the model for 'case finding' one can calculate the probability of both cancer and
benign disease using the trichotomous form, and isolate likely cancer cases as well as likely benign
cases, since these may be indicative of a pre-malignant condition. We now briefly give some results
on the predictive accuracy of the model.
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Table II. The log-likelihoods associated with the unrestricted model and with alternative
reduced models
No.
of Maximum Likelihood Lagrange
Model parameters log-likelihood ratio test test D.F. p-value
Unrestricted 42 — 135 90
hQ 28 — 150 15 28-50 25-17 14 002
"s 38 - 137-54 3-64 3-10 4 0-50
H0 24 -151-68 31-56 28-26 18 0-03
Final model 15 —150-26 28-72 26.27 27 0-60
(Table III)
Hq = indistinguishability of cancer and benign groups with respect to questionnaire data;
Hs = indistinguishability of benign and normal groups with respect to serum proteins; H0 = both
Hq and Hs. P-values are obtained using the chi-square approximation for the likelihood ratio test.
Table III. The covariates and their associated estimated values for the 15 parameter reduced
model
Cancer (n, = 96) Benign (n2 = 99) Normal (n} = 100)
Age 0-092 (0-02) Qi 1-407 (0-59) Q3 - 1-173 (0-53)
Sex 1-817 (0-52) Q2 2-343 (0-82) Q5 - 1-607 (0-44)
AGP 1-846 (0 55) Q9 2-047 (0-57) Q14 -2-504 (0-58)
CEA 0-325 (0-07) Constant -1-581 (0-26)
Q1 2-186 (0-77) Constant* -4-854




* 'Adjusted' for separate sampling using prior probabilities 0 004 and 0 036 for cancer and benign disease
respectively.
Figures in parentheses are estimated as asymptotic standard errors. All covariates are binary (1 = yes)
with the exception of AGP (g/1), CEA (/xg/1) and Age (years).
Q1 = weight loss; Q2 = appetite loss; Q3 = food sticking; Q5 = nausea or vomiting; Q9 = altered bowel
habit; Q14 = slime in motion; Sex = 1 for male.
Consider first using the model for 'case finding'. High risk individuals can be isolated if their
estimated cancer probability exceeds cq or, when this criterion fails, if their benign probability
exceeds c2. A system of utilities might be used to optimise the choice of rr and c2; here we discuss
only the sensitivity for some arbitrarily chosen values. One possibility is to take cq and c2 equal to
the prior cancer and benign probabilities, 0 004 and 0-036. In this case, for the 295 patients that were
used to fit the model, 93 % (89/96) of cancer patients, 45 °/0 (45/99) of benign and 79 % (79/100) of
asymptomatic patients were correctly classified. However, the probability of actually having cancer
given classification to the cancer group, which can be computed from these empirical classification
rates and the prior probabilities by using Bayes Theorem, is only 0-15 and the corresponding figure
for benign disease is 0 08. The low predictive accuracy results from the low prevalence of cancer
together with an estimated 0-01(1/100) misclassification rate from normal to cancer and a
0 02(2/100)misclassification rate from normal to benign. This problem with predictive accuracies is
well known18. If cq and c2 are both increased to 0-5 there are no misclassifications of the normal
group to cancer and the estimated probability of having cancer, when being assigned to cancer, is
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now more acceptable at 0-86. The corresponding figure for benign disease is still low at 0-43.
However, only 54% (52/96) of cancer patients and 21 % (21/99) of benign patients are correctly
classified although 99% (99/100) of the normal cases are correctly classified. It is instructive to
consider how the model fares on the group of 704 asyptomatic patients set aside for model
validation. Follow up studies of these patients, using faecal occult blood (FOB) tests and
exploratory tests for the patients with a positive FOB response, have identified one case of sigmoid
cancer and three cases of benign polyps. Unfortunately none of these cases gave an abnormally
high probability of either cancer or benign disease. Using the Cj = c2 = 0-5 rule there were no
classifications to cancer and 16 classifications to the benign category. Only 4 of these cases
have, to date, been diagnosed with a GI disorder. These results raise doubts as to the use of the
model to identify disease in an asymptomatic population. Consider, however, classification for a
symptomatic population. If the dichotomous model between the cancer and benign states is
derived from Table III and is used to classify symptomatic patients, then 59 % (57/96) of cancer
patients and 98 % (97/99) ofbenign patients are correctly classified, adopting a cutoffprobability of
c = 0-5, that is, assign to cancer if the estimated probability ofcancer exceeds c. The probability that
a patient who is assigned to the cancer group actually has cancer is 076. The corresponding figure
for benign disease is 096. Alternatively for c = 01 these probabilities are 047 and 0 99 whilst for
c = 0-9 they become 1-0 and 0-94. The value 1-0 arises with c = 0-9. because there are no
misclassifications from benign to cancer, but only 41 % (39/96) of the cancer patients are correctly
classified. With the c = 0-5 rule, 63 of the 64 benign patients that were set aside for validation were
correctly classified to the benign state.
CONCLUSION
These results demonstrate that it is feasible to use the model for detecting malignancy among
symptomatic subjects, but it will require further testing to establish its usefulness for routine work
for an asymptomatic population. It was always doubtful whether the model would perform well for
asymptomatic cases, since symptomatic patients were used for its development and it is being
required to detect patients at a preclinical stage. Nevertheless, the concept of using both symptoms
and a set of biochemical tests to define high risk subjects seems worth persuing, possibly with
alternative 'tumour markers' and a more comprehensive description of symptoms. The framework
of the logistic model is suitable for work of this sort and the 'reduced form' is particularly useful for
constructing tests concerning the predictive value of covariates.
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Validation of a self administered questionnaire to elicit
gastrointestinal symptoms
i M CHISHOLM, F T DE DOMBAL, G R GILES
abstract
elf administered questionnaires are becoming popular investi¬
gative tools in medical research, yet few reports state the extent
■f methods used to validate these questionnaires before their
eneral use. A pilot study was therefore carried out to validate a
■1 item questionnaire for use in a population screening study for
■astrointestinal disease.
Participants in the study comprised 69 population controls, 40
■atientswith benign disease, and 35 patients with gastrointestinal
ancer. Acceptability, ease of completion, reliability, and repro¬
ducibility of the questionnaire were all assessed. Only one
lbject refused to complete the questionnaire. Ninety six per
:nt of the questions were completed by each subject and only
«ie response in 1440 was altered in the reproducibility study,
"he questionnaire disclosed symptoms similar to those elicited
f a clinician and highlighted unreported gastrointestinal symptoms
the control group. Three questions were found to be unreliable
-id were altered before the questionnaire was put into general
se.
It is concluded that a pilot study to validate a new questionnaire is
-mpie to perform and necessary to identify unreliable questions.
*troduction
:lfadminstered health questionnaires have been used as an adjunct
medical history taking for many years,' but more recently
testionnaires have been seen as investigative tools to identify risk
oups for cardiac disease,2 colorectal neoplasia,34 and upper
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gastrointestinal disease.5 Few questionnaires, however, have been
subjected to critical statistical analysis to determine their validity
before being used clinically.6 To be valid a questionnaire needs to
meet five criteria: (a) to be acceptable to the population under study;
(b) to be easily completed; (c) to be consistent—that is, to elicit
responses similar to those gained in a conventional doctor-patient
interview; (d) to be reproducible when administered on two separate
occasions; (e) to be of value or use when complete.
We report the steps taken to validate a questionnaire to elicit
gastrointestinal symptoms in a screening programme for bowel
cancer.
Questionnaire
The questionnaire contained 41 questions. Eighteen were specifically
related to gastrointestinal symptoms—oesophagus (3), stomach (3), bowel
habit (8), weight and appetite (4)—and the remainder covered epidemio¬
logical data (4), previousmedical history (6), family history (2), and a general
systems inquiry (11)—respiratory system, genitourinary system, and drug
usage. The questions were closed in nature and it was possible to omit five
responses if negative answers were given to the preceding question. To
answer a question a tick was placed in the appropriate yes or no box.
Patients and methods
A total of 144 subjects were enrolled and were divided into three groups:
69 "normal" subjects who were not attending hospital; 40 patients with
proved benign gastrointestinal conditions; and 35 patients with proved
gastrointestinal cancer. All 144 subjects were required to complete the form
unaided in order to assess the acceptability and feasibility of completing the
questionnaire. A test-retest system was used to assess the reproducibility of
the responses, 20 subjects being required to complete a second questionnaire
after a two week interval.
Twenty three patients with symptoms referred to hospital by their
general practitioner completed a questionnaire before being interviewed in
the routine manner by a consultant. To determine the consistency of the
responses on the patient's questionnaire the clinician then completed an
identical questionnaire on the basis of the interview and without reference to
the patient's form. The two forms were then compared using kappa
statistics.
'MJ/1140/85 copyright © 1985 all rights of reproduction of this reprint are reserved in all countries of the world
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Statistical method—Since the possibility of chance agreement between two
series of replies to the same set of questions varies according to the incidence
of positive and negative replies to the individual questions, the kappa
statistic was calculated to adjust for the contribution of chance agreements.
Kappa (k) is calculated according to the formula, K=(Po—Pe)/(1-Pe),
where Po is the observed proportion ofagreement and Pe is the proportion of
expected agreement from chance and calculated from the marginals in a two
bv two table. The values for kappa vary from 10 where there is total
agreement to -1 where there is total disagreement. A value of zero
corresponds to chance agreement alone.
Results
Acceptability—One subject refused to complete the questionnaire.
Feasibility—Three subjects failed to complete the questionnaire owing to
poor eyesight or dyslexia. The average time for completion was seven
minutes (range four to 10 minutes). The completion rate for the questionnaire
was 96% of all questions.
Reproducibility—In all three groups the test-retest study showed that only
one answer was altered in one questionnaire, and this related to family
history. Thus only one response was changed out of a possible 1440
answers.
Consistency—In the study which compared responses obtained on the
questionnaire with those obtained by the consultant clinician kappa statistics
were applied to the 18 gastrointestinal symptoms. In 15 questions there was a
close correlation of answers and all the kappa values exceeded 0 85. With
three questions, however—namely, those designed to elicit responses
concerning tenesmus, early satiety for food, and new episodes of abdominal
pain—the kappa values were 0 2, 0125, and 0 3 respectively. The
remaining general questions all had kappa values of 1.
Applicability—When the responses to the gastrointestinal questions were
compared among the three groups of subjects the number of positive
responses was naturally greater in the hospital referred groups. Of 65
subjects in the normal group, 54 (83%) had zero or one positive response,
seven having three or more positive responses. In the group with cancer 33 of
35 (94%) had three or more positive responses, as did 33 of the 40 subjects
(83%) in the benign disease group (table). Follow up assessment of the seven
Distribution ofpositive gastrointestinal responses
in three groups
No of positive Normal Benign Cancer
responses (n^65) (n = 40) (n=35)
0 39 0 0
1 15 3 0
2 4 4 2
>3 7 33 33
"normal" patients showed that one had a confirmed diagnosis of ulcerative
colitis, two were treated for dyspeptic symptoms on follow up, and three
were referred for investigation of rectal bleeding and were found to have
haemorrhoids. The remaining subject, who had right sided abdominal pain,
loose altered stool, and altered urine colour, was found to have stones in the
common bile duct on investigation.
Discussion
The format and content of the questionnaire were clearly
acceptable to the population sampled. The high degree of compliance
recorded, however, may have been biased by small sample size.
Problems in completing the questionnaire would probably occur
commonly if the questionnaire were applied to the population at
large, owing to embarrassment, lack of reading glasses, and
illiteracy.
The benefit of the realiability section of the pilot study was to
identify those questions that were unreliable before general use.
The phraseology of these questions was identical with that used in
previous questionnaires and structured interviews,"s 8 and their
apparent failure in our specific study reinforces the view put
forward by Oppenheim that merely using questions from other
questionnaires without testing them in the context of their eventual-
use cannot be justified."
By using the test-retest assessments and the correlation study we
were able to observe the ability of the questionnaire to elicit
symptoms successfully both in the known symptomatic groups and-
also in the supposedly normal population group, leading to the
detection of previously unsuspected gastrointestinal disease.
Furthermore, and equally important in the screening setting, a-
negative response to gastrointestinal questions was found to be a-
true negative response in all 15 reliable questions, and on retestin^
no negative gastrointestinal response became positive. These
findings are consistent with other data on reproducibility studies ol
health questionnaires.1'
The questionnaire accurately elicited symptoms of gastrointestinal
disease in the hospital group, and on subsequent follow up of the
heavily symptomatic "normal" group further disease was identified, se
the potential value of the questionnaire can be seen. This is shown ir
the table below where the distribution of positive responses ii
analysed by group. Here the risk of gastrointestinal disease ant
therefore the potential need for investigation can be defined. In the
case of this particular questionnaire the risk is defined by three oi
more positive responses.
We conclude that a pilot study of any questionnaire is mandator}
to identify any faults in its format or content; that it takes little
time or effort to perform; that simply using questions fron
established health questionnaires does not imply reliability; anc
that statistical methods should be applied to the correlation studie:
to ensure the validity of the questionnaire.
By performing our pilot study we have devised a questionnairi
that can reliably elicit symptoms of gastrointestinal disease con
sistent with the ability of a clinician but can also accurately identif;
people with established gastrointestinal disease and can highligh
normal subjects with symptoms, as yet unreported to a doctor, tha
merit further investigation.
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ABSTRACT
The faecal occult blood test (FOB) has several limitations
including high false positive rates, high false negative rates and lev?
ccnpliance, which reduce its validity as a screening agent for
colorectal cancer. We have investigated the use of a self-administered
general health questionnaire in oonjunction with FOB testing in 1082
subjects to assess the value of the questionnaire to screen for
colorectal neoplasia and compared its acceptability and yield of
neoplasia with that of the FOB test. 720 (66.6%) individuals completed
the questionnaire whilst 689 (63.7%) carpleted the FOB test. 20 FOB
tests were positive and upon investigation 5 subjects were found to have
neoplastic lesions -2 cancers and 3 large polyps. This represents a
predictive yield for a positive FOB as 25%. 29 subjects were
investigated for symptoms alone but none were found to have evidence of
large bcwel neoplasia (0% yield). The questionnaire significantly
increased the false negative investigation rate and precludes its
routine use in colorectal cancer screening.
HSroODUCTIQN
For the past 2 decades, the crude 5 year survival rate for
colorectal cancer, the second cannonest cancer in the UK, has remained
at 21%^. Since the reported survival of early stage cancer may be 65%
-88% a great deal of research has been directed into the use of
screening agents to detect these early lesions. The screening agent
most camronly used is the faecal occult blood test (FOB), Haonoccult
(Eaton laboratories), but the agent has certain severe limitations of
its use. These include a high false positive rate^, a high false
- 3 -
negative rate for symptomatic cancer^, polyps^ and asyrrptcmatic
cancer ^7' and an extremely low acceptability to the population of the
Alternative methods for screening to aid the FOB's validity
have been sought and recently the use of a symptom questionnaire was
advocated by Schewe^^ to identify the symptomatic cancer patient with
a false negative FOB. Silman et al^^ have reported a study which
combined the FOB with a 9 item questionnaire, and noted that "all
significant neoplastic lesions detected on screening were symptomatic"
and were thus detected by the questionnaire. Further they stated that
the predictive yield for a positive questionnaire was statistically
indistinguishable to that of the FOB test. Crespi^^ has reported
similar findings using a 4 item questionnaire where a positive
neoplastic yield of 16% on investigation of a positive response was
noted. Since a questionnaire is simple and easy to complete it would
overcome the natural reluctance of the population to perform FOB testing
and may therefore be a more viable form of population screening.
We have therefore investigates the use of a questionnaire in a
colorectal cancer screening study where the yield of neoplastic disease
discovered by the questionnaire was to be determined and compared with
conventional FOB testing.
PATIENTS AND METHODS
1082 subjects, frcm 6 group practices, were invited either
directly by their general practitioner during a consultation or by a
letter to participate in the study. Each individual was in the age
range 50-70 years and had to have no active gastrointestinal (GI)
complaints or be on active GI therapy at the time of entry to the study.
A 41 itan questionnaire (Table 1), specially designed for the
- 4 -
study and previously validated^was completed by the subject. The
questionnaire contained 18 specific GI questions and the format was a
simple one requiring a tick in a box for yes or no. Any individual with
3 or more positive symptoms (as determined by the previous pilot study)
was reviewed and investigated where indicated. Counselling on FOB
testing was then given and a completed 3 day package was then returned
by post for testing by the sane individual (EMC). A positive FOB was
investigated by fibreoptic sigmoidoscopy and either double contrast
barium enema or colonoscopy.
RESULTS
720 individuals completed the questionnaire, whilst 689 subjects
completed the FOB test. 20 individuals (2.9%) had one or more FX®
slides positive, none of whcm had a positive response to the GI
symptoms. Investigation of these subjects lead to the discovery of 2
colonic cancers (1 Dukes' A descending colon; 1 Dukes' B sigmoid colon)
and 3 adenomatous polyps greater than 1 cm diameter in 5 individuals.
This represents a predictive yield for neoplasia for a positive FOB of
25%.
240 subjects (35%) had three or more positive responses to the
questionnaire. In the analysis, it became clear that many apparently
normal individuals suffered from symptoms attributable to the upper
gastrointestinal tract e.g. heartburn 24%, nausea 13%. As our principle
concern was directed to a study of large bowel disorders, these
individuals are excluded from this analysis which concentrates on
symptoms normally associated with colonic disorders. Table II shows the
distribution of positive responses for the total group bo the questions
concerning the GI tract. Whilst 77 (11%) had noticed fresh blood per
- 5 -
rectum only 42 (6%) had noticed this in the previous 6 months and only 5
(0.8%) had not already reported the symptom to their general
practitioner. Similarly, 26% reported periodic diarrhoea and 14%
reported constipation. In view of the widespread prevalence of these
general symptoms it proved necessary to re-examine the questionnaire
data. Consequently, after further consultation only 29 individuals
(4.2%) underwent definitive investigation of the large bowel. In this
group, no neoplastic conditions were identified, although disease was
recognised in 25 (diverticular disease, haemorrhoids and irritable bowel
syndrome) and in 4 no obvious reason for the symptoms was found. This
represents a predictive yield for neoplasia for a positive questionnaire
of 0%. Thus, the number of investigations performed by including the
questionnaire increased by 29 for no additional identification of either
cancer or polyp. This represents a significant rise in investigational
procedures for the programme (p < 0.001 test). Of the 211
individuals with 3 positive responses who ware not investigated, no
colonic cancer has been diagnosed after 18 months of follcw-up but one
patient has been identified as suffering with pancreatic cancer and has
undergone surgical treatment.
DISCUSSION
Despite the high prevalence of symptoms in the population, no
significant neoplastic disease in the study could be identified by the
questionnaire. This may be due to the fact that the incidence of dark
red blocd in the stool was reported once in the 683 subjects compared
with 17 in 900 for Silman's studydO. in a similar study in
Nottingham, Farrands and Hardcastle^ ^ have reported the use of a 5
item self-completed questionnaire in conjunction with FOB testing and
- 6 -
found a yield for their questionnaire of 1 polyp (P.Y = 0.8%). However,
in the same individuals, RDB's detected 4 cancers and 6 polyps,
constituting a false negative rate for the questionnaire of 83% (Table
III).
The current more detailed questionnaire was acceptable to the
public and was readily ccnpleted thus the issue of carpiianae as
reported by Crespi^~^ is not a problem corpared with FOB testing.
However the inclusion of the questionnaire as an adjunct to FOB testing
aiming to reduce the false negative rate and false positive rates
associated with FOB's, has significantly increased the number of people
requiring additional investigation . This increased the running costs
of the study and would further reduce the cost-effectiveness of
screening ccrrpared to using FOB'S alone. The yield for the
questionnaire could be considered to be low because we did not
investigate all individuals with only one syrrptcm. To date no new
colonic neoplasia with an 18 month follow-up has beer recorded although
one individual has developed obstructive jaundice secondary to cancer of
the pancreas. Further the prevalence of symptoms in the current study
reflects the prevalence of symptoms found in other randan populations
examined by Jones^) Thompson and Heaton^) thus reinforcing the
belief that symptom questionnaires will elicit considerable symptoms of
benign disease precluding its value in the detection of symptomatic
polyps or cancer.
We conclude therefore that despite the severe limitations
associated with the faecal, occult blood test, the addition of a symptom
questionnaire to colorectal cancer screening is not viable and could
seriously reduce the cnst-effectiveness of such a programme.
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Composition of the Questionnaire









Frequency of individual symptoms
Symptcms No. %
Reduced appetite 55 6.75
Wt loss, no diet 35 4.3
Difficulty swallowing 20 2.45




Now pain 61 10.34
Bowel habit 32 4.03
Incomplete emptying 66 8.12
Altered frequency 50 6.17






Comparison of Questionnaires for Bowel Cancer Screening
Criteria for No +ve % Finding Predictive
Investigation Yield %
Silman (10) 1 +ve response 114 12 7 polyps 16.1
Farrands (14) 1 +ve response 128 23.5 1 polyp 0.78
Chisholm 3 +ve responses 29 4.2 0 0
